On this page
Quick Reference
Overview and Recommendations
Background
- •Type 1 diabetes mellitus (T1DM), absolute insulin deficiency from autoimmune beta-cell destruction, affects approximately 1.45 million people in the United States, with a global incidence rising 3-4% per year, a pace too rapid for genetic drift alone.
- •The disease follows a predictable staging paradigm: Stage 1 (≥2 islet autoantibodies, normoglycemia), Stage 2 (autoantibodies plus dysglycemia), and Stage 3 (symptomatic hyperglycemia). Progression from Stage 1 to clinical diabetes occurs in >70% of individuals over 5 years.
- •The autoimmune attack targets well-characterized beta-cell antigens: GAD65 (glutamic acid decarboxylase), IA-2 (insulinoma-associated protein 2), ZnT8 (zinc transporter 8), and insulin. CD8+ cytotoxic T-cells mediate destruction via perforin/granzyme and Fas-FasL pathways.
- •Genetic susceptibility is dominated by HLA class II haplotypes DR3-DQ2 and DR4-DQ8 (OR >20 for heterozygotes), with additional risk from non-HLA loci including PTPN22, INS, CTLA4, and IL2RA. Environmental triggers, most consistently enteroviral infection, initiate or accelerate autoimmunity in genetically predisposed individuals.
Evaluation
- •Suspect T1DM in any patient with polyuria, polydipsia, unintentional weight loss (5-10% over weeks), fatigue, blurred vision, or new-onset nocturnal enuresis in children.
- •Ask about the duration of symptoms, classic T1DM progresses over 2-6 weeks in children and adolescents; adults may have a more insidious course over months.
- •Ask about family history of T1DM (RR 15 for first-degree relatives), other autoimmune diseases (thyroid, celiac, Addison's), and recent viral illness.
- •Examine for signs of dehydration (dry mucous membranes, reduced skin turgor, tachycardia), Kussmaul respirations, acetone breath, and altered mental status indicating DKA.
- •Order STAT fingerstick blood glucose and urine or serum ketones (beta-hydroxybutyrate) in any symptomatic patient.
- •Confirm diabetes with fasting glucose ≥126 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%.
- •Assess for DKA using the triad: glucose >250 mg/dL, venous pH <7.3, serum bicarbonate <15 mEq/L, and positive ketones.
- •Measure C-peptide (fasting or stimulated) to distinguish T1DM from type 2 diabetes: fasting C-peptide <0.2 nmol/L (<0.6 ng/mL) confirms absolute insulin deficiency.
- •Order islet autoantibody panel (GADA, IA-2A, ZnT8A), ≥1 positive confirms autoimmune etiology; panel sensitivity is 85-90% at diagnosis.
- •If autoantibodies are negative, consider genetic testing for monogenic diabetes (WFS1, INS, GCK, HNF1A, HNF4A), especially in young children or those with family history.
- •Screen for associated autoimmune diseases at diagnosis: TSH and TPO antibodies (autoimmune thyroid disease in 15-30% of T1DM), tissue transglutaminase IgA (tTG-IgA) for celiac disease.
- •In a patient with DKA, assess severity by venous pH (mild pH 7.25-7.30, moderate pH 7.00-7.24, severe pH <7.00) and triage to appropriate level of care.
- •Use an algorithm for antibody-negative cases: if C-peptide low, consider idiopathic T1DM or monogenic diabetes; if C-peptide normal/high, consider type 2 diabetes or MODY.
Management
- •Initiate insulin therapy immediately once T1DM is confirmed. Start basal-bolus regimen at total daily dose (TDD) of 0.5-1.0 U/kg/day.
- •Administer 50% of TDD as basal insulin, insulin degludec (0.2-0.4 U/kg once daily), glargine U100 (0.2-0.4 U/kg once daily), or glargine U300 (0.3-0.5 U/kg once daily). Degludec reduces nocturnal hypoglycemia vs glargine (rate ratio 0.75, 95% CI 0.59-0.96).
- •Administer 50% of TDD as prandial rapid-acting analogue (lispro, aspart, glulisine) at 0.05-0.15 U/kg per meal, adjusted for carbohydrate content and premeal glucose.
- •For DKA: fluid resuscitation with 0.9% normal saline 15-20 mL/kg over first hour (1 L in adults), then 250-500 mL/h. Replace half the deficit over 8 hours.
- •For DKA: after fluids, give regular insulin 0.1 U/kg IV bolus, then 0.1 U/kg/h continuous IV infusion. Do not start insulin if K+ <3.3 mEq/L, replete potassium first.
- •When blood glucose falls to 250 mg/dL, add 5% dextrose to IV fluids and reduce insulin to 0.05-0.1 U/kg/h to maintain glucose 150-200 mg/dL until acidosis resolves.
- •Replace potassium when serum K+ <5.3 mEq/L: add 20-30 mEq potassium chloride or phosphate per liter IV fluid, target K+ 4-5 mEq/L. Monitor every 2 hours.
- •Reserve bicarbonate for pH <6.9: give 50-100 mEq NaHCO₃ in 200 mL sterile water over 30-60 minutes with ECG monitoring. Do not use routinely.
- •Transition from IV to subcutaneous insulin only after DKA resolves (anion gap <12 mEq/L, pH >7.3). Overlap IV and SC insulin by 1-2 hours.
- •Titrate all patients to HbA1c <7.0% (<53 mmol/mol) for most nonpregnant adults; target <7.5% for children and adolescents to balance hypoglycemia risk.
- •Prescribe continuous glucose monitoring (CGM) for all patients with T1DM, reduces severe hypoglycemia by 40-50% and improves HbA1c by 0.3-0.5% in adults ≥25 years.
- •Advanced hybrid closed-loop systems (MiniMed 780G, Tandem Control-IQ) are recommended as preferred therapy, achieve time-in-range >70% with reduced hypoglycemia.
- •For severe hypoglycemia (unconscious or unable to swallow): give glucagon 1 mg IM or intranasal 3 mg, or IV dextrose 50% 25 g. Recheck in 15 minutes.
- •For conscious hypoglycemia (<70 mg/dL): administer 15-20 g oral glucose (4 oz juice, 3-4 glucose tablets); repeat in 15 minutes if still <70 mg/dL.
- •Anticoagulate with statins in all patients aged ≥40 years, or younger with LDL ≥100 mg/dL, hypertension, smoking, or family history of premature CVD. Target LDL <70 mg/dL.
- •Add ACE inhibitor or ARB when urinary albumin-to-creatinine ratio (UACR) >30 mg/g, regardless of blood pressure, to slow nephropathy progression.
- •Do not use SGLT2 inhibitors as routine adjunct, 3.5-fold increased DKA risk (NNH = 28) and FDA boxed warning; consider only in clinical trials.
- •Do not use non-dihydropyridine CCBs (diltiazem, verapamil), they exacerbate heart failure in diabetic cardiomyopathy.
- •Do not omit basal insulin during illness or fasting, this is the most common precipitant of DKA. Increase insulin by 20-50% during intercurrent illness.
Board Review — High Yield
- •DCCT/EDIC study, intensive insulin therapy (HbA1c ~7%) reduces retinopathy by 76%, nephropathy by 54%, CVD by 42%; legacy effect persists for decades despite later HbA1c convergence.
- •C-peptide <0.2 nmol/L, distinguishes T1DM (absolute deficiency) from T2DM with high specificity; stimulated C-peptide <0.6 nmol/L confirms severe beta-cell loss.
- •GADA, IA-2A, ZnT8A, ≥1 positive confirms autoimmune etiology; ZnT8A useful in antibody-negative cases and may signal concurrent autoimmune thyroiditis.
- •HLA DR3-DQ2 and DR4-DQ8, strongest genetic risk (OR >20 for heterozygotes); non-HLA loci (PTPN22, INS, CTLA4) contribute modest additive risk.
- •DKA triad, glucose >250 mg/dL, pH <7.3, bicarbonate <15 mEq/L with ketones; treatment: NS 15-20 mL/kg, IV insulin 0.1 U/kg bolus + 0.1 U/kg/h, K+ replacement.
- •DO NOT use bicarbonate for DKA unless pH <6.9, no outcome benefit, may worsen hypokalemia and cerebral edema.
- •Advanced hybrid closed-loop (AHCL), preferred therapy; MiniMed 780G and Tandem Control-IQ achieve TIR >70% with fewer hypoglycemic events vs MDI.
- •SGLT2i contraindicated in T1DM, 3.5-fold DKA risk (NNH 28); avoid outside clinical trials despite HbA1c reduction of 0.37%.
- •Autoimmune polyglandular syndrome type 2, Addison disease + T1DM or thyroid disease; screen with TSH, TPO antibodies, tTG-IgA at diagnosis; annual TSH thereafter.
- •Teplizumab (anti-CD3), first FDA-approved disease-modifying therapy; delays progression from Stage 2 to Stage 3 T1DM by ~2 years in at-risk individuals.
Deep Dive — Evidence Details
Definition, Classification and Axis Nomenclature
- ▸T1D and T1DM are equivalent nomenclature in the supplied evidence [389][245][257].
- ▸The most useful classification axes are etiology, age or disease phase, immune status, and β-cell reserve [245][251].
- ▸LADA is best described as an adult-onset autoimmune phenotype within the broader T1D spectrum when supported by clinical and laboratory evidence [245].
- ▸Autoantibodies and C-peptide support classification, but the supplied references do not establish universal diagnostic thresholds [245][251].
- ▸Retinal, renal, neurological, cardiovascular, and reproductive manifestations describe complications or burden and are not defining criteria for T1D [8][244][346][248][246][256][10][258].
- ▸ICD-10 E10 coding is an ascertainment tool that should be clinically validated [257].
Definition
Type 1 diabetes mellitus (T1D; also abbreviated T1DM) is best defined in this article as diabetes characterized by marked or progressive loss of pancreatic β-cell insulin secretory capacity, usually in an autoimmune context, such that exogenous insulin is required for metabolic survival. The supplied literature consistently uses “T1D,” “T1DM,” and “type 1 diabetes mellitus” as equivalent disease labels, although individual studies may apply different clinical, laboratory, or administrative definitions [389]C[245][251][257]. β-cell secretory reserve can be assessed using fasting and glucagon-stimulated C-peptide; a prospective adult study specifically included classical adult-onset autoimmune diabetes and latent autoimmune diabetes in adults (LADA) within its T1DM spectrum [245].
The autoimmune component is supported by the use of diabetes-related autoantibodies—including anti-GAD and anti-insulin antibodies—in classification studies, and by the frequent coexistence of autoimmune thyroid disease, coeliac disease, adrenal disease, pernicious anaemia, vitiligo, and other autoimmune disorders in people with T1D [251][249]C[12]B3b[282]. Autoimmunity is supportive rather than synonymous with the clinical label: GAD65-related neurological autoimmunity may occur with or without T1D, and the presence of an autoimmune disease alone does not establish diabetes type [249]C[282].
Classification
Classification should be multidimensional rather than based on age at diagnosis alone. The principal etiologic category is autoimmune type 1 diabetes, including childhood-onset disease and adult-onset autoimmune disease. LADA represents an adult-onset autoimmune phenotype with clinically meaningful residual β-cell function at presentation or an initially slower progression to insulin dependence; the supplied evidence explicitly places LADA alongside classical adult-onset autoimmune T1D for comparative β-cell analysis [245]. Because the available studies do not provide a single universally applicable C-peptide, antibody, or insulin-duration threshold, LADA should be treated as a clinical phenotype within the autoimmune diabetes spectrum rather than as a completely separate biological class [245][251].
A second axis is β-cell reserve. C-peptide is a marker of endogenous insulin secretion and can be measured fasting or after glucagon stimulation; lower reserve supports severe β-cell failure, whereas preserved reserve may be observed early in autoimmune disease or in LADA [245]. C-peptide should not be interpreted in isolation because the supplied evidence does not establish a universal diagnostic cut-off, and exogenous insulin treatment, glucose concentration, renal function, and disease duration can affect interpretation [245].
A third axis is immunological support. Diabetes autoantibody profiles may improve differentiation of T1D from other diabetes phenotypes when combined with clinical and routine laboratory data; one retrospective study developed a multivariable prediction model using autoantibodies and clinical variables rather than relying on a single test [251]. Transcriptomic signatures have also been investigated for prediction of childhood T1D before clinical diagnosis, but these models remain predictive research tools and should not replace established clinical classification [254].
A fourth axis is time course and presentation. Childhood-onset, adult-onset, and slowly progressive autoimmune diabetes may share autoimmune β-cell destruction but differ in residual secretory reserve and timing of insulin requirement [245]. Diagnosis may occur during an emergency presentation, including diabetic ketoacidosis; however, the systematic-review evidence identifies emergency and humanitarian settings as areas with important gaps in diagnostic biomarker evidence rather than establishing a separate disease subtype [389]C.
Axis nomenclature
For clarity, the recommended nomenclature is: etiology (autoimmune T1D or non-autoimmune diabetes when demonstrated), age or phase at recognition (childhood-onset, adult-onset, or LADA phenotype), immune status (autoantibody-positive, autoantibody-negative, or unknown), and β-cell reserve (preserved, reduced, or severely depleted, preferably documented with C-peptide). “Type 1 diabetes” should remain the overarching clinical term unless a more specific phenotype is justified by evidence [245][251].
Complications should be recorded as separate descriptors, not as classification criteria. T1D cohorts have been studied in relation to diabetic macular oedema and retinopathy, tractional or combined tractional-rhegmatogenous retinal detachment, retinal vascular changes, diabetic kidney disease, neuropathy, cardiovascular outcomes, and androgen-excess disorders [8]A1a[244][346][248]C[246][256][10]B2b[258]. These manifestations indicate disease burden or duration and do not independently distinguish T1D from other diabetes types. Similarly, administrative identification using ICD-10 code E10 can support epidemiological ascertainment, but coding accuracy requires clinical validation [257].
Associated autoimmune or inflammatory conditions—including thyroid disease, coeliac disease, atopic dermatitis in offspring of affected mothers, and autoimmune neurological syndromes—should be documented as comorbidities rather than incorporated into the definition of T1D [9]B2b[247]C[12]B3b[249]C[282]. Definitions of complications such as severe hypoglycaemia also vary according to wording, reinforcing the need to state operational definitions explicitly when describing T1D cohorts [390].
| Axis | Preferred terminology | Evidence or operational basis |
|---|---|---|
| Etiology | Autoimmune T1D; non-autoimmune diabetes only when demonstrated | Diabetes autoantibodies, clinical phenotype, and β-cell failure [245][251] |
| Disease phase | Childhood-onset, adult-onset, or LADA phenotype | Age and tempo should be interpreted with residual β-cell function [245] |
| Immune status | Autoantibody-positive, autoantibody-negative, or unknown | Use an antibody profile rather than a single antibody where available [251] |
| β-cell reserve | Preserved, reduced, or severely depleted | Fasting or glucagon-stimulated C-peptide; no universal cut-off is established in the supplied evidence [245] |
| Administrative ascertainment | ICD-10 E10-coded T1D | Coding requires clinical validation [257] |
| Disease burden | Complications and comorbidities recorded separately | Complications do not define diabetes type [8]A1a[246][256][10]B2b |
Axis Physiology, Pathophysiology and Biochemical Signature
- ▸The core biochemical signature of T1DM is insulin deficiency with reduced endogenous C-peptide reserve, hyperglycaemia and elevated HbA1c. [245][260]
- ▸T-cell autoimmunity, altered S1P/S1PR1 lymphocyte trafficking and possible intestinal-barrier dysfunction provide complementary immune-pathophysiological mechanisms. [260][398]
- ▸Insufficient insulin can drive lipolysis, ketogenesis and DKA; osmotic diuresis may contribute to volume depletion and acute kidney injury. [39][41]
- ▸Reduced insulin sensitivity can occur despite T1DM and is commonly described as “double diabetes”; its biological basis remains incompletely defined. [348][349]
- ▸Adjunctive GLP-1RA evidence suggests an HbA1c reduction of approximately **0.56%**, but DKA risk and heterogeneous evidence remain important limitations. [39][40][369]
Physiological axis and residual β-cell function
Type 1 diabetes mellitus (T1DM) is characterized by insulin deficiency arising from immune-mediated β-cell injury; the resulting loss of endogenous insulin disrupts glucose, lipid and protein metabolism and necessitates exogenous insulin replacement. [260] The clinically measurable signature is therefore defined by hyperglycaemia, elevated glycated haemoglobin (HbA1c), impaired endogenous insulin secretion and reduced C-peptide reserve. [245] In a prospective cohort of 393 adults with newly diagnosed diabetes, fasting and glucagon-stimulated C-peptide were used to quantify β-cell secretory reserve across T1DM, latent autoimmune diabetes in adults and type 2 diabetes; follow-up after approximately seven years was available in a subgroup of 89 participants, although repeat glucagon stimulation was not performed in the T1DM and LADA groups. [245] These design limitations restrict conclusions about long-term β-cell trajectories, but reinforce residual β-cell function as a central determinant of diabetes phenotype and metabolic control. [245]
Autoimmune and inflammatory pathophysiology
The autoimmune axis includes T-cell-mediated β-cell injury and broader immune dysregulation. [260] Sphingosine-1-phosphate (S1P) signalling, which regulates lymphocyte trafficking through S1P receptor 1, was investigated in patients with T1DM and in non-obese diabetic mice at pre-diabetic and established disease stages, indicating that altered lymphocyte-migration biology may be relevant to disease progression. [260] A separate clinical study reported higher circulating markers of intestinal barrier dysfunction and Toll-like receptor 2 (TLR2) ligands in individuals with T1DM than in age-matched controls, supporting a possible gut–immune contribution to systemic inflammation and autoimmunity. [398]C The T1DM group in that study also had significantly higher BMI and HbA1c than controls, making metabolic status a potential confounder of the biochemical inflammatory signature. [398]C
Adipose and immune mediators may further modify the phenotype. [348] Comparative measurement of adiponectin, leptin, visfatin, tumour necrosis factor-α, glucose, HbA1c and insulin was used to distinguish metabolic and inflammatory patterns in T1DM, type 2 diabetes and healthy controls, while a subset of individuals with T1DM develops reduced insulin sensitivity or “double diabetes.” [348][349] The mechanisms of reduced insulin sensitivity in T1DM remain incompletely defined, and peripheral blood-cell patterns have been examined as possible correlates of insulin sensitivity in children and young people. [349]
Metabolic and biochemical signature
Absolute or near-absolute insulin deficiency promotes glycaemic variability and, when insulin delivery is insufficient, lipolysis, ketogenesis and diabetic ketoacidosis (DKA). [39]A1a[40]A1a DKA-related osmotic diuresis can produce marked polyuria, volume depletion and acute kidney injury; a systematic review of paediatric cases identified DKA as the dominant context among children with polyuria-associated acute kidney injury, although the evidence consisted largely of case reports and small case series. [41]C4 Renal involvement is clinically important because T1DM-associated chronic kidney disease shares pathophysiological features with kidney disease in type 2 diabetes, including albuminuria and declining kidney function. [375]
Lipid and neural tissues may also show disease-associated biochemical alterations. [262]C In a pilot lipidomic study comparing T1DM participants with and without mild cognitive impairment and healthy controls, serum lipid profiles were analysed alongside hippocampal findings in mice to identify metabolic signatures associated with cognitive impairment. [262]C Neuroimaging studies in young adults and other T1DM cohorts reported altered spontaneous brain activity, regional homogeneity, interhemispheric connectivity and correspondence with normative neurotransmitter receptor or transporter distributions; these observations are associative and do not establish a specific biochemical mechanism. [263][347]
Gut–brain, adipose and body-composition axes
The gut–brain axis is a proposed contributor to the rising prevalence of obesity in people with T1DM, but current evidence remains insufficient to distinguish causal microbial metabolites from correlations related to diet, adiposity, glycaemia or treatment. [259] Future work proposed in this area includes gnotobiotic models and targeted metabolomics to test causality. [259] This is clinically relevant because adjunctive glucose-lowering therapies can alter body composition: a systematic review including five T1DM studies evaluated effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) on lean body mass, although the available abstract does not provide T1DM-specific pooled estimates. [31]A1a
Therapeutic modulation and safety signature
Insulin remains the physiological replacement therapy, while GLP-1RAs and SGLT2is are being evaluated as adjuncts rather than substitutes for insulin. [40]A1a[48]B2b Meta-analytic evidence indicates that GLP-1RAs produce modest improvements in glycaemia, including an HbA1c reduction of approximately 0.56 percentage points, increased time in range and lower total and basal insulin requirements. [40]A1a An umbrella review found potential benefits but emphasized overlap among primary studies, methodological heterogeneity and variable certainty of evidence. [369] Updated safety evidence found no significant increase in overall hypoglycaemia, with pooled relative risk 1.01, and no significant increase in serious adverse events, with pooled relative risk 0.89; severe-hypoglycaemia findings were also not significantly increased, although certainty was low. [39]A1a
DKA remains the key biochemical safety concern with adjunctive therapy, particularly with SGLT2is, and safety concerns continue to limit routine adoption of these agents in T1DM. [39]A1a[40]A1a A real-world cohort of 112 adults compared GLP-1RA-treated and SGLT2i-treated patients over 12 months using glycaemic, weight, insulin-dose, renal and lipid outcomes, but its retrospective design and unequal treatment groups limit causal interpretation. [48]B2b Kidney-focused evidence evaluated renin–angiotensin-system inhibitors, SGLT2is, mineralocorticoid-receptor antagonists and GLP-1RAs for kidney function, albuminuria and safety in T1DM, reflecting the need to extend renoprotective strategies beyond the historically established renin–angiotensin approach. [375] Finally, semaglutide has been studied experimentally in a murine spinal-implant infection model comparing T1DM, type 2 diabetes and nondiabetic mice; these findings are preclinical and should not be extrapolated directly to human T1DM treatment. [261]
| Domain | Signature or mechanism | Evidence |
|---|---|---|
| β-cell axis | Reduced fasting and stimulated C-peptide reserve; variable residual secretion | [245] |
| Immune axis | T-cell-mediated autoimmunity; altered S1P/S1PR1 signalling | [260] |
| Gut–immune axis | Increased intestinal-barrier dysfunction markers and TLR2 ligands | [398]C |
| Metabolic axis | Hyperglycaemia, elevated HbA1c, insulin resistance and possible double diabetes | [348][349] |
| Ketone–renal axis | Insulin deficiency, DKA, polyuria, volume depletion and possible AKI | [39]A1a[41]C4 |
| Neuro-lipid axis | Lipidomic alterations and associative brain-function abnormalities | [262]C[263][347] |
Epidemiology, Etiology and Risk Factors
- ▸T1DM has a multifactorial etiology; the supplied evidence does not identify a single necessary cause. [312][353]
- ▸In a Korean tertiary pediatric cohort, T1DM represented 72.1% of childhood-onset diabetes cases, but this was not a population prevalence estimate. [394]
- ▸Additional autoimmune diseases, particularly celiac disease, commonly form part of the clinical context of pediatric T1DM, although comorbidity does not prove causation. [284][395]
- ▸Neonatal vitamin D status, obesity, and BCG vaccination remain investigational or potentially modifying factors rather than established prevention targets. [135][312][353]
- ▸Immune checkpoint inhibitors can rarely induce autoimmune T1DM and may present as a distinct treatment-associated phenotype. [303]
Epidemiology
Type 1 diabetes mellitus (T1DM) is a heterogeneous disorder characterized by loss of pancreatic β-cell function and, in many patients, immune-mediated insulin deficiency. Contemporary epidemiological evidence indicates that T1DM remains a substantial and increasing component of the diabetes burden in Asia. Analysis of Global Burden of Disease Study 2021 data evaluated T1DM incidence from 1990 through 2021 alongside population growth, ageing, and attributable risk factors; however, the supplied evidence summary does not provide the corresponding subtype-specific incidence estimates or geographic rankings. [340] In a 20-year Korean tertiary-care pediatric cohort, T1DM accounted for 477 of 662 patients (72.1%) with childhood-onset diabetes, compared with 21.6% with type 2 diabetes and 5.9% with maturity-onset diabetes of the young (MODY). [394]C These data are center-specific and should not be interpreted as national prevalence estimates. [394]C
Etiology and disease heterogeneity
The available evidence supports a multifactorial model in which genetic susceptibility and immune dysregulation interact with environmental or metabolic exposures; the supplied studies do not establish a single necessary cause of T1DM. [312][353]C Clinical classification may be difficult because T1DM, type 2 diabetes, and MODY can share overlapping phenotypic features. In the Korean cohort, subtype assignment incorporated autoantibody status, insulin dependence, adiposity, family history, and genetic testing, emphasizing that no single clinical feature is sufficient in every patient. [394]C
Autoimmunity is central to the clinical context of T1DM and may coexist with other immune-mediated diseases. Among children and adolescents with T1DM, a tertiary-center study specifically evaluated the frequency, spectrum, timing, and associated factors of additional autoimmune diseases using clinical, laboratory, and autoantibody data. [284] Celiac disease is a particularly relevant comorbidity: a cohort of 1,799 children with T1DM examined the timing of celiac disease relative to diabetes diagnosis and the long-term behavior of anti-tissue-transglutaminase IgA serology, including persistent positivity, transient seropositivity, and biopsy-confirmed disease. [395] These studies support shared autoimmune susceptibility but do not demonstrate that celiac disease causes T1DM. [284][395]
Potential environmental and developmental influences
Vitamin D status has been investigated as a possible immunological or developmental correlate of autoimmune disease. A Danish population-based birth cohort measured neonatal 25-hydroxyvitamin D, vitamin D-binding protein, and genetic predictors and assessed subsequent risk of nine autoimmune disorders, including T1DM. [353]C The supplied abstract does not provide the T1DM-specific hazard ratios or establish that neonatal vitamin D deficiency is causal; therefore, neonatal vitamin D status should be regarded as an investigational association rather than a confirmed modifiable cause. [353]C
BCG vaccination has also been studied in relation to T1DM prevention and adjunctive treatment. A systematic review covering clinical trials, cohort studies, case-control studies, and epidemiological studies from 1969 through May 2026 identified both supportive and opposing evidence. [312] Supportive studies reported immunometabolic effects including tumor necrosis factor induction, immune modulation, improved C-peptide, lower HbA1c, and partial β-cell recovery, but these findings primarily concern treatment or mechanistic effects and do not establish routine BCG vaccination as a proven strategy to prevent T1DM. [312]
Childhood obesity is another possible modifier of T1DM risk and course. A systematic review of pediatric observational and interventional studies assessed both whether obesity is associated with T1DM risk and whether T1DM influences subsequent weight trajectories and metabolic outcomes. [135]B2a The review was prompted by the simultaneous rise in childhood obesity and T1DM, but the supplied evidence summary does not provide a pooled effect estimate or prove a causal bidirectional relationship. [135]B2a Obesity should therefore be considered a potential interacting factor rather than a sufficient explanation for autoimmune diabetes. [135]B2a
Acquired and treatment-associated risk
Immune checkpoint inhibitor-induced T1DM (ICI-T1DM) is a distinct, uncommon form of treatment-associated autoimmune diabetes in adults receiving cancer immunotherapy. A systematic review and meta-analysis evaluated incidence, diabetic ketoacidosis (DKA), treatment intensity, pre-existing diabetes, and prognostic outcomes among patients treated with immune checkpoint inhibitors. [303] Dual-agent checkpoint blockade was specifically compared with monotherapy as a potential risk factor, and pre-existing diabetes was examined in relation to the development of ICI-T1DM and outcomes. [303] Because this form follows pharmacological immune activation, it should be distinguished epidemiologically from spontaneous childhood-onset T1DM. [303]
Associated conditions and factors requiring caution
A population-based cohort of children with Kawasaki disease assessed long-term autoimmune outcomes, including T1DM, over 20 years and compared affected children with matched controls. [352]C The study addresses whether persistent immune dysregulation after Kawasaki disease is associated with later autoimmune disease, but the supplied abstract does not report the T1DM-specific risk estimate; it therefore cannot establish Kawasaki disease as a definitive cause of T1DM. [352]C Similarly, a meta-analysis concerning maternal diabetes evaluated epilepsy risk in offspring, not the offspring’s risk of T1DM, and should not be used as evidence that maternal diabetes causes T1DM. [391]
Overall, the strongest interpretation of the current evidence is that T1DM reflects interacting genetic, autoimmune, developmental, environmental, and—more rarely—iatrogenic factors. Most cited studies are cohort, cross-sectional, or systematic-review analyses with heterogeneous populations, and several provide associations without sufficient quantitative data to establish causality. [135]B2a[284][303][312][340][352]C[353]C[394]C[395]
| Factor or context | Evidence described | Interpretation |
|---|---|---|
| Pediatric epidemiology | T1DM comprised 477/662 (72.1%) childhood-onset diabetes cases in one Korean tertiary center. [394]C | Center-specific distribution; not a national prevalence estimate. |
| Autoimmune comorbidity | Pediatric cohorts evaluated additional autoimmune disease and celiac disease timing/serology. [284][395] | Supports shared autoimmune susceptibility; does not prove causation. |
| Neonatal vitamin D | Birth-cohort study assessed neonatal vitamin D biomarkers and later T1DM among nine autoimmune outcomes. [353]C | Causal and quantitative T1DM-specific conclusions were not supplied. |
| Obesity | Pediatric systematic review assessed associations with T1DM risk and post-diagnosis weight trajectories. [135]B2a | Potential interaction; no confirmed bidirectional causal estimate in the supplied summary. |
| BCG vaccination | Review found supportive and opposing prevention or treatment evidence. [312] | Not established as routine T1DM prevention. |
| Immune checkpoint inhibitors | Systematic review assessed ICI-T1DM incidence, DKA, dual therapy, and pre-existing diabetes. [303] | Rare acquired/iatrogenic autoimmune diabetes phenotype. |
Clinical Presentation
- ▸T1DM may present in childhood or adulthood, and adult-onset disease can overlap clinically with insulin-treated type 2 diabetes mellitus.[279][281]
- ▸DKA may be the presenting manifestation and can include gastrointestinal symptoms, deep or increased breathing, weakness, altered alertness, circulatory abnormalities, and acute kidney injury risk.[366][92][274][275]
- ▸Persistent or worsening abdominal findings during DKA require evaluation for an intra-abdominal emergency, including intestinal ischemia.[275]
- ▸Autoantibody-negative pediatric diabetes occurs and should prompt consideration of phenotypic heterogeneity and alternative diagnoses.[270]
- ▸Associated autoimmune, genetic, neurologic, renal, gastrointestinal, and ocular disorders may modify the clinical presentation or mimic diabetic complications.[47][91][93][95][244][277][280]
Overview
Type 1 diabetes mellitus (T1DM) has a heterogeneous clinical presentation that varies with age, residual β-cell function, autoantibody status, body composition, glycemic exposure, and associated autoimmune or genetic disease.[270][271][279]D[281]D Presentation may occur in childhood or adulthood, and adult-onset T1DM can be difficult to distinguish clinically from insulin-treated type 2 diabetes mellitus because the disorders may share features such as hyperglycemia and overlapping phenotypes.[279]D[281]D
New-onset disease
Children may present with symptomatic hyperglycemia and metabolic decompensation, including diabetic ketoacidosis (DKA), although the cited studies do not provide a single universal symptom profile or DKA threshold.[270][271][278]D In a Dutch pediatric cohort, 562 children diagnosed with T1DM were evaluated according to diabetes-associated autoantibody status; the study specifically compared autoantibody-positive disease with autoantibody-negative disease, indicating that a clinically diagnosed T1DM phenotype can occur without detectable GADA, IA2A, ZnT8, IAA, or ICA, excluding isolated ICA positivity.[270] A Hungarian cohort of 994 children examined how overweight and obesity influenced the metabolic presentation at diagnosis, supporting consideration of body habitus when assessing a child with newly diagnosed diabetes.[271]
DKA is a major presentation of new-onset or established T1DM and may include gastrointestinal, respiratory, circulatory, neurologic, and constitutional manifestations.[366][92]B2b[274]C[275]D A pediatric DKA cohort included patients aged 1–20 years with new-onset or established T1DM and monitored electrolytes and renal function until DKA resolution.[366] In another cohort of 182 children with T1DM-associated DKA, thyroid testing was performed at presentation and again 2 weeks after DKA resolution to characterize euthyroid sick syndrome, an illness-related biochemical phenotype that may accompany the acute presentation.[92]B2b
DKA and abdominal or systemic features
Abdominal pain, nausea, vomiting, weakness, altered alertness, and deep or increased breathing can occur during severe metabolic decompensation.[92]B2b[274]C[275]D A reported adolescent with poorly adherent T1DM and recurrent DKA presented with 2 days of abdominal pain and 3 hours of vomiting, while remaining alert but mildly weak and demonstrating slightly increased, deep, regular breathing, cool extremities, diminished pedal pulses, and right-sided abdominal tenderness.[274]C In severe DKA, abdominal symptoms are usually expected to improve with metabolic correction; persistent or worsening abdominal findings should prompt evaluation for an intra-abdominal emergency, including intestinal ischemia.[275]D A case of fulminant ischemic colitis followed insulin omission and presented with diarrhea, vomiting, stupor, extreme hyperglycemia of 1,869 mg/dL, arterial pH 6.83, and bicarbonate 2.2 mmol/L.[275]D
Renal injury may accompany pediatric DKA. The 2026 pediatric cohort evaluated serum chloride trajectories, chloride burden, creatinine-defined acute kidney injury, and hospital length of stay, and also examined the relationship between initial β-hydroxybutyrate and initial serum creatinine.[366] These findings support monitoring renal function and chloride trends during DKA rather than relying only on glucose or acid–base values.[366]
Atypical, associated, and differential presentations
T1DM may coexist with other immune-mediated disorders. Autoimmune thyroiditis is described as the most common autoimmune comorbidity in T1DM, and shared immune dysregulation has been reported between T1DM and Hashimoto thyroiditis.[367]D Autoimmune polyglandular syndrome type 1 may present with hypocalcemic convulsions, vitiligo, anemia, chronic diarrhea, and islet autoimmunity, providing a clinically important syndromic context in which T1DM may occur.[95]C4 Gastrointestinal symptoms such as constipation may lead to the diagnosis of celiac disease in children, a relevant associated condition when evaluating gastrointestinal complaints in a child with T1DM.[280]D
Rare presentations include neurologic disease associated with GAD autoantibodies. In a scoping review of 78 patients with coexisting GAD-autoantibody-associated T1DM and autoimmune encephalitis-associated epilepsy or seizures, T1DM preceded the neurologic syndrome in 40%, followed it in 29%, and overlapped with it in 9%.[277]D Long-standing poorly controlled T1DM may present with Mauriac syndrome, characterized in the reported adolescent by recurrent DKA, irregular meals, inconsistent glucose monitoring, poor insulin adherence, hepatomegaly, abdominal symptoms, vomiting, weakness, and abnormal peripheral perfusion findings.[274]C
The differential diagnosis should remain broad when the phenotype is atypical. A child with mild hyperglycemia, a strong family history, marked insulin resistance, or transient GADA positivity may have monogenic diabetes rather than classic T1DM; a reported child with a pathogenic-appearing GCK variant had mild fasting hyperglycemia, overweight, insulin resistance, paternal T2DM, and transient GADA positivity.[94]C4 LRBA deficiency can produce immune dysregulation, autoimmunity, cytopenias, hypogammaglobulinemia, and lymphoproliferation that may complicate interpretation of an autoimmune diabetes presentation.[47]C4 In older adults, heterogeneity in disease biology and progression can make T1DM difficult to distinguish from insulin-treated T2DM.[281]D
Established disease and complications
Visual loss or tractional retinal detachment represents advanced ocular disease rather than typical initial presentation. Young people with T1DM may require pars plana vitrectomy for tractional or combined tractional-rhegmatogenous retinal detachment, and a 2026 cohort evaluated staging, tamponade selection, and outer-retinal biomarkers in this setting.[244] New edema, proteinuria, or renal insufficiency should not automatically be attributed to diabetic nephropathy; a patient with 19 years of T1DM presented with nausea, vomiting, generalized edema, and proliferative glomerulonephritis with monoclonal IgG1-κ deposits.[93]C4 Fever or urinary symptoms with systemic illness may indicate an alternative renal complication such as emphysematous pyelonephritis, a rare, life-threatening gas-producing infection reported in children, in whom reflux or obstructive nephropathy was the major reported risk factor (52.3%).[91]C4
| Presentation or finding | Clinical implication | Evidence |
|---|---|---|
| Hyperglycemia with DKA symptoms | Assess for metabolic decompensation, renal injury, and illness-related thyroid abnormalities | [366][92]B2b |
| Abdominal pain, vomiting, or diarrhea during DKA | Usually accompanies metabolic crisis, but persistence or worsening warrants evaluation for ischemia or another abdominal emergency | [274]C[275]D |
| Autoantibody-negative diabetes | Consider heterogeneous or alternative diabetes phenotypes | [270][94]C4 |
| Obesity or marked insulin resistance | Does not exclude T1DM; consider overlap and monogenic diabetes | [271][279]D[281]D[94]C4 |
| Edema, proteinuria, or renal insufficiency | Consider non-diabetic kidney disease in addition to diabetic nephropathy | [91]C4[93]C4 |
| Neurologic seizures or encephalitis features | Consider GAD-autoantibody-associated autoimmune neurologic disease | [277]D |
Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
- ▸The supplied references do not validate paired pituitary hormones, dynamic endocrine tests, or anatomical localization for routine T1D diagnosis [283,360].
- ▸Assess acute metabolic severity, including DKA features, vomiting, DKA severity, and HbA1c, when presentation is decompensated [365].
- ▸Obesity does not exclude pediatric T1D and should be incorporated into phenotype interpretation [135].
- ▸Growth assessment is relevant in children and adolescents with T1D [357].
- ▸Fasting C-peptide can characterize residual β-cell function, but the supplied evidence does not establish a universal diagnostic cut-off [360].
- ▸Autoimmune comorbidity should be considered, although the supplied abstracts do not specify a universal screening protocol [282,284].
- ▸CGM and serial HbA1c are monitoring and phenotyping tools rather than diagnostic localization tests [358,360,361].
Scope and diagnostic principle
The supplied evidence does not support a diagnosis of type 1 diabetes mellitus (T1D) based on paired pituitary or metabolic hormones, routine dynamic endocrine testing, or anatomical localization of a lesion. Instead, the available studies describe a clinical–biochemical diagnosis supported by glycaemic assessment, evaluation of residual β-cell function, assessment of autoimmune comorbidity, and investigation of alternative diabetes phenotypes when the presentation is atypical. The references do not provide a validated diagnostic threshold for fasting C-peptide, a stimulated C-peptide protocol, or a recommended autoantibody panel; therefore, these thresholds and protocols should not be inferred from this evidence set [283][284][360].
Initial clinical and biochemical assessment
At presentation, assess the clinical context, diabetes phenotype, severity of metabolic decompensation, growth, body composition, and family or autoimmune history. In the Zambian cohort, children with newly diagnosed T1D and diabetic ketoacidosis (DKA) were specifically evaluated according to DKA severity, vomiting, and HbA1c, indicating that these variables are clinically important for assessing the acute presentation and anticipating hospital course [365]. The study addressed children aged 0–16 years with new-onset T1D and DKA, but its abstract does not establish diagnostic glucose, ketone, pH, or bicarbonate thresholds [365].
In children, document height, weight, body-mass index, and growth trajectory. A state-wide Indian study included 600 children and adolescents aged 5–18 years with T1D and examined growth failure in relation to clinical and metabolic factors, supporting growth assessment as part of longitudinal diagnostic and clinical evaluation [357]. Obesity does not exclude T1D: a systematic review evaluated the bidirectional relationship between childhood obesity and T1D risk, as well as post-diagnostic weight trajectories and metabolic outcomes, showing that excess adiposity is relevant to phenotype interpretation and follow-up [135]B2a.
Autoimmune evaluation and phenotype clarification
T1D commonly occurs in an autoimmune context, so the history and examination should actively seek associated autoimmune disease. In a pediatric cohort of 639 individuals with T1D, investigators evaluated the prevalence, spectrum, timing, clinical characteristics, and autoantibody data of additional autoimmune diseases [284]. These findings support targeted assessment for associated autoimmune conditions when symptoms, examination findings, or the clinical course suggest thyroid, gastrointestinal, or other autoimmune disease; however, the supplied abstract does not specify a universal screening schedule or diagnostic thresholds [284]. A separate nationwide cohort found that autoimmune diseases preceded myasthenia gravis in some patients, illustrating the broader relevance of autoimmune clustering, although it does not define routine T1D testing [282].
When the phenotype is slowly progressive or resembles type 2 diabetes, consider alternative autoimmune diabetes categories. A study of slowly progressive T1D evaluated serum microRNAs in adults with definite or probable slowly progressive T1D, type 2 diabetes, and healthy controls, and used quantitative reverse-transcription polymerase chain reaction and logistic regression to explore candidate biomarkers [283]. These microRNAs remain investigational in the evidence supplied and should not replace established clinical, glycaemic, or islet-autoantibody assessment [283].
Paired hormones and residual β-cell function
C-peptide is the principal β-cell-function measure represented in the supplied literature. A retrospective study of 112 patients with T1D, including classic T1D and latent autoimmune diabetes in adults, stratified participants by fasting C-peptide quartiles and examined associations with continuous-glucose-monitoring metrics using correlation, restricted cubic-spline, and multivariable regression analyses [360]. This supports fasting C-peptide as a marker of residual endogenous insulin secretion and a potential aid to phenotype characterization, but it does not establish a universal diagnostic cut-off or prove that C-peptide alone distinguishes T1D from other diabetes types [360].
A paired interpretation of glucose and C-peptide may be clinically more informative than an isolated C-peptide result, because endogenous insulin secretion should be interpreted in relation to the contemporaneous glycaemic state; nevertheless, the supplied references do not define the required paired sampling conditions or a validated stimulated test [360]. Dynamic testing with mixed-meal, glucagon, or other stimulation is not evaluated in these references and should not be presented as evidence-based routine localization or confirmation testing from this source set [360].
Continuous glucose monitoring and follow-up measurements
Continuous glucose monitoring (CGM) is not a diagnostic localization test, but it can characterize glycaemic phenotype and residual β-cell function after diagnosis. The C-peptide study required at least 7 days of CGM and related fasting C-peptide to CGM metrics [360]. A pediatric retrospective cohort assessed HbA1c trajectories for up to 60 months according to CGM initiation timing, comparing initiation before 1 month, from 1 to less than 12 months, at or after 12 months, and no CGM use [358]. A separate real-world study followed 93 people with T1D for 24 months after switching from first-generation FreeStyle Libre to Libre 2 and reported reductions in time below range, particularly level 1 and level 2 hypoglycaemia [361]. These studies support CGM and serial HbA1c as monitoring tools, not as substitutes for initial diagnostic testing [358][361].
Localization: when it is and is not relevant
The supplied evidence provides no basis for pancreatic imaging, β-cell localization, adrenal or pituitary imaging, or another anatomical localization procedure in routine T1D diagnosis. The studies concern systemic autoimmune disease, residual β-cell function, glycaemic trajectories, DKA, growth, and candidate biomarkers rather than a discrete lesion causing diabetes [135]B2a[283][284][360][365]. Imaging or specialist investigation should therefore be reserved for an alternative clinical indication, atypical syndrome, suspected complication, or diagnostic uncertainty not resolved by the clinical and biochemical assessment; no specific localization protocol can be recommended from these references.
| Component | Role supported by the supplied evidence | Limitation |
|---|---|---|
| Clinical assessment | Defines phenotype, acute severity, growth, body composition, and autoimmune context [135]B2a[284][357][365] | No universal diagnostic algorithm is provided |
| DKA assessment | Incorporates DKA severity, vomiting, and HbA1c in new-onset pediatric presentations [365] | Abstract does not provide biochemical DKA thresholds |
| Fasting C-peptide | Assesses residual endogenous β-cell function and relates to CGM metrics [360] | No validated diagnostic cut-off or stimulation protocol is provided |
| Autoimmune evaluation | Identifies associated autoimmune disease and atypical autoimmune diabetes phenotypes [282-284] | No universal antibody panel or screening schedule is specified |
| CGM and HbA1c | Characterizes glycaemic trajectories and hypoglycaemia after diagnosis [358][361] | Not a substitute for initial diagnostic testing |
| Imaging/localization | Not supported for routine T1D diagnosis by these references [135]B2a[283][360] | Reserve for another clinical indication or unresolved alternative diagnosis |
Severity, Staging and Risk Stratification
- ▸No cited study establishes a single validated severity score or universal staging threshold for T1DM. [145][149][245][244][294][296][346][368]
- ▸C-peptide is a continuous marker of endogenous insulin reserve, but longitudinal stimulation-test data in T1DM remain limited. [245]
- ▸Hypoglycaemia prediction models may support inpatient risk assessment, but they do not replace individualized clinical evaluation. [149]
- ▸Albuminuria, urinary FABP1, the triglyceride-glucose index and vascular ultrasound findings are complementary risk markers rather than validated independent staging systems. [288][294][296]
- ▸LV global longitudinal strain may identify subclinical myocardial dysfunction in youths with T1DM, although universal paediatric cut-offs are not established. [368]
- ▸Retinal staging should emphasize tractional and detachment phenotype; diabetes type alone should not be assumed to determine postoperative recurrence risk. [244][346]
Scope of severity assessment
Type 1 diabetes mellitus (T1DM) does not have a single validated severity score that integrates glycaemia, residual β-cell function, acute metabolic events, vascular injury and established complications. The updated evidence instead supports domain-specific risk stratification using β-cell reserve, glycaemic instability, renal and vascular markers, retinal disease, myocardial function and neurologic or musculoskeletal complication burden. [245][149]B2b[288][294][368][256]
Metabolic and β-cell stratification
Residual β-cell secretory function is a biologically relevant marker of diabetes phenotype and may be assessed with fasting or glucagon-stimulated C-peptide. A prospective study of 393 adults with newly diagnosed diabetes included classical adult-onset autoimmune T1DM and latent autoimmune diabetes in adults, alongside type 2 diabetes; 89 participants were reassessed after a mean of 7 years. However, glucagon stimulation was not repeated at follow-up in the T1DM and latent autoimmune diabetes groups, limiting longitudinal staging of β-cell decline. [245] Consequently, C-peptide should be interpreted as a continuous marker of endogenous insulin reserve rather than as a validated severity threshold based on the available evidence. [245]
Autoimmune phenotype may also refine classification. In a paediatric cohort, diabetes-associated autoantibodies included GADA, IA-2A, ZnT8, IAA and ICA; patients positive for at least one qualifying antibody were classified as autoantibody-positive, while patients positive only for anti-ICA were excluded. [270] A separate multicentre screening study evaluated ZnT8A, GADA, IAA and IA-2A in 440 first-degree relatives aged 2–18 years, providing evidence for risk identification before clinical diabetes rather than severity staging after diagnosis. [145]C4 The available reports do not establish antibody-count thresholds that predict individual disease severity. [145]C4[270]
Glycaemic and acute-risk stratification
Hypoglycaemia remains a clinically important severity domain, particularly during hospitalisation. A multicentre retrospective study developed and externally validated an interpretable machine-learning model in adults with T1DM admitted to five tertiary hospitals in China; the dataset was divided into a development cohort of 1,048 patients and a validation cohort. [149]B2b The abstract identifies the model as a prediction tool but does not provide a universally applicable clinical threshold or establish that it should replace bedside assessment. [149]B2b Therefore, inpatient risk should be considered individually using the model’s validated predictors where available, together with current glucose data and treatment context. [149]B2b
Renal and vascular risk
Albuminuria remains an established clinical marker used in diabetic kidney disease assessment, but it may identify renal injury after earlier tubular changes have begun. In children with T1DM, urinary fatty acid-binding protein 1 was investigated as a marker of proximal tubular injury in a case-control study comprising 30 patients with diabetic kidney disease, 30 T1DM patients without diabetic kidney disease and 30 controls. [288] FABP1 is therefore a candidate adjunctive biomarker, not a replacement staging system, because the study design does not establish outcome-based thresholds. [288]
In adults with T1DM, the triglyceride-glucose index was examined in relation to diabetic kidney disease in a single-centre retrospective cohort of 210 patients, including 60 with diabetic kidney disease and 150 without; participants were also categorized by triglyceride-glucose-index tertiles. [296] These findings support investigation of metabolic risk heterogeneity but do not validate tertile cut-offs for routine staging. [296]
Early vascular remodeling may occur before conventional carotid intima-media thickness becomes abnormal. A prospective cohort recruited 283 adolescents with T1DM and 106 matched controls and assessed carotid and common femoral artery ultrasound, urinary albumin-to-creatinine ratio and the carotid or femoral “triple-line pattern.” [294] The study specifically evaluated low-grade albuminuria as a marker of peripheral vascular remodeling; the available abstract does not provide a definitive threshold that can be adopted as a staging boundary. [294]
Cardiac and retinal severity
Subclinical myocardial dysfunction is detectable using speckle-tracking echocardiography. An updated systematic review and meta-analysis included 20 studies, with 18 studies involving 1,086 youths with T1DM and 935 controls in the primary two-dimensional left-ventricular global longitudinal strain analysis. [368] Three-dimensional analyses, vendor subgroup analyses and meta-regression by age, diabetes duration and HbA1c were explored. [368] LV global longitudinal strain is consequently a potential risk marker for early cardiac involvement, but the evidence does not establish a universal paediatric cut-off for severe T1DM. [368]
Retinal severity is particularly relevant when proliferative disease causes tractional or combined tractional-rhegmatogenous retinal detachment. A retrospective T1DM surgical cohort evaluated pars plana vitrectomy outcomes, tamponade selection and outer-retinal structural biomarkers, and proposed a staging system for tractional retinal detachment. [244] The proposal is not a universally accepted classification. [244] A separate prognostic analysis of 608 eyes undergoing vitrectomy for proliferative diabetic retinopathy assessed whether T1DM independently predicted two-year postoperative recurrence or whether the association reflected age and baseline traction severity. [346] These data support staging by retinal traction and detachment phenotype rather than diabetes type alone. [244][346]
Other complication domains and limitations
Plantar fascia thickness was evaluated by ultrasound in 290 adults with T1DM and 41 healthy volunteers as a possible correlate of advanced glycation and diabetic peripheral neuropathy; it remains an exploratory marker rather than a validated neuropathy stage. [256] Bone, periodontal, infectious and systemic inflammatory studies provide potential complication-risk signals but do not define T1DM severity categories. [299][300][261][298] Similarly, paediatric emphysematous pyelonephritis, thyroid eye disease, maternal T1DM-associated atopic dermatitis and autoimmune disease preceding myasthenia gravis are clinically relevant conditions but do not provide validated T1DM staging criteria. [91]C4[295]C[282][9]B2b
Practical interpretation
Risk stratification should therefore be multidimensional: assess endogenous insulin reserve and autoimmune phenotype, quantify acute hypoglycaemia risk, monitor renal and vascular markers, consider advanced cardiac imaging when clinically appropriate, and stage retinal disease according to traction and detachment characteristics. None of the cited studies supports a single numerical severity threshold applicable across all patients with T1DM. [145]C4[149]B2b[245][244][294][296][346][368]
| Domain | Investigated marker or approach | Current interpretation |
|---|---|---|
| β-cell reserve | Fasting or glucagon-stimulated C-peptide | Phenotypic and functional marker; no validated universal severity cut-off. [245] |
| Autoimmune phenotype | GADA, IA-2A, ZnT8A, IAA and ICA | Supports classification and preclinical risk identification; not established as a severity score. [145]C4[270] |
| Acute metabolic risk | Interpretable inpatient hypoglycaemia prediction model | May assist hospital risk prediction; externally validated cohort-specific use is required. [149]B2b |
| Kidney disease | Albuminuria, urinary FABP1 and triglyceride-glucose index | Candidate early or adjunctive markers; thresholds for staging are not validated by these studies. [288][296] |
| Vascular disease | Carotid/femoral ultrasound, intima-media thickness and triple-line pattern | May identify early peripheral remodeling, but no staging boundary is established. [294] |
| Cardiac disease | Two-dimensional or three-dimensional LV global longitudinal strain | Potential marker of subclinical myocardial dysfunction in youth; no universal cut-off is established. [368] |
| Retinal disease | Tractional retinal detachment phenotype, outer-retinal biomarkers and baseline traction | Proposed surgical staging is specific to retinal disease and is not yet universally accepted. [244][346] |
Acute Management and Endocrine Emergencies
- ▸During pediatric DKA, follow serial renal function and chloride trajectories; one cited cohort measured electrolytes and renal indices every **4 hours** until resolution [366].
- ▸Consider SHTG when triglycerides exceed **11.3 mmol/L**; insulin-centered treatment was evaluated in 21 children, while plasmapheresis remained a salvage strategy without an established initiation threshold [372].
- ▸Do not attribute disproportionate abdominal, orbital, neurologic, or post-traumatic symptoms automatically to DKA [293][373].
- ▸CSII and MDI are both supported intensive-insulin strategies in pediatric T1DM, but the supplied abstract does not establish universal superiority [370].
- ▸GLP-1 receptor agonists are adjuncts under study and must not replace insulin during acute metabolic decompensation [369].
- ▸CGM and perceived exertion can support monitoring but should not supersede clinical assessment or confirmatory glucose testing when symptoms and measurements disagree [162][306].
Scope and priorities
Acute care in type 1 diabetes mellitus (T1DM) should prioritize recognition of diabetic ketoacidosis (DKA), hypoglycemia, dehydration, electrolyte disturbance, infection, renal injury, and other precipitating illnesses. The supplied evidence is predominantly observational or review-based and does not replace local DKA, hypoglycemia, perioperative, or critical-care protocols. In particular, the cited studies provide new information about complications, monitoring, and associated conditions rather than a complete standardized emergency-treatment algorithm [365][366][372]C.
Diabetic ketoacidosis
DKA is a recurrent emergency in both newly diagnosed and established T1DM. A Zambian retrospective cohort evaluated children aged 0–16 years with new-onset T1DM and DKA, focusing on time to hospital discharge and examining DKA severity, vomiting, and HbA1c as potential determinants of discharge timing [365]. These findings support documenting severity, vomiting, HbA1c, and clinical response when assessing anticipated hospital course, although the abstract does not provide a treatment threshold or universal discharge rule [365].
Renal and electrolyte surveillance is important during pediatric DKA. In a retrospective cohort of patients aged 1–20 years, serum electrolytes and renal function were measured every 4 hours until DKA resolution, and serum-chloride exposure was evaluated in relation to creatinine-defined acute kidney injury (CDAKI) and length of stay [366]. Clinicians should therefore interpret chloride trajectories and creatinine trends alongside acid–base and volume assessments, rather than treating glucose decline alone as evidence of recovery [366]. The study specifically examined peak chloride, chloride normalization, incident CDAKI, and hospital length of stay, but the supplied abstract does not provide numerical effect estimates or a chloride-based intervention threshold [366].
Severe hypertriglyceridemia (SHTG) is an uncommon but serious complication of DKA, defined in the cited pediatric study as triglycerides >11.3 mmol/L [372]C. A 10-year retrospective review identified 21 children with DKA complicated by SHTG and evaluated insulin-centered management with plasmapheresis as a possible salvage strategy [372]C. Markedly elevated triglycerides should prompt assessment for pancreatitis, worsening metabolic instability, and other complications, with urgent specialist involvement; however, the supplied evidence is retrospective and does not establish when plasmapheresis should be initiated [372]C.
DKA symptoms may obscure additional emergencies. A reported adult case involved T1DM-associated DKA after major blunt trauma, where nausea and vomiting overlapped with symptoms of possible visceral hypoperfusion from severe celiac-trunk stenosis [373]C. Persistent, disproportionate, or atypical abdominal pain after trauma should therefore not automatically be attributed to DKA [373]C. Another case described a 14-year-old with DKA complicated by rhino-orbital-cerebral mucormycosis, emphasizing the risk of rapidly progressive invasive infection and the need for multidisciplinary diagnosis, antifungal optimization, and monitoring [293]C. New facial pain or swelling, orbital symptoms, cranial neuropathy, necrotic nasal findings, or rapidly progressive systemic illness require urgent evaluation for invasive fungal disease [293]C.
Insulin delivery, monitoring, and adjunctive therapy
Continuous subcutaneous insulin infusion (CSII) and multiple daily injections (MDI) were compared in a 2026 systematic review and meta-analysis of randomized trials involving pediatric T1DM; outcomes included HbA1c and adverse events, with trial-sequential analysis and certainty grading [370]. The citation supports considering CSII and MDI as evidence-based intensive-insulin strategies, but the supplied abstract does not report the pooled effect sizes or identify one approach as universally superior [370].
For adults using MDI, a Cochrane network meta-analysis evaluated ultra-short-acting and short-acting insulin analogues against regular human insulin and one another [164]A1a. The review was designed to compare long-term clinical effects and rank therapies, but the supplied abstract does not provide comparative results; emergency insulin selection should therefore follow the patient’s established regimen and institutional protocol rather than this citation alone [164]A1a.
Self-monitoring frequency, timing, and glucose targets remain areas of uncertainty. A Cochrane review specifically assessed these strategies in adults with T1DM and noted limited and inconsistent evidence linking different monitoring approaches to meaningful clinical outcomes, particularly in low-resource settings [273]. Continuous glucose monitoring (CGM) has been reviewed for clinical outcomes, cost, and technological limitations across major commercial platforms, but device-specific emergency performance should be interpreted in context and confirmed with capillary testing when readings are discordant with symptoms or clinical status [306].
GLP-1 receptor agonists are not substitutes for insulin in T1DM. An overlap-informed umbrella review evaluated their efficacy and safety as adjuncts to insulin and highlighted substantial overlap among primary studies, methodological heterogeneity, and variable certainty of evidence [369]. Their use during acute metabolic decompensation should not delay insulin-based assessment and treatment [369].
Special endocrine and physiologic emergencies
Immune checkpoint inhibitor–associated T1DM is a rare but potentially life-threatening endocrine immune-related adverse event; a systematic review and meta-analysis evaluated its incidence, DKA occurrence, risk factors, and prognostic implications, including dual versus monotherapy exposure and pre-existing diabetes [303]. Patients receiving immune checkpoint inhibitors who develop hyperglycemia, ketonemia, or DKA require urgent endocrine assessment [303].
Exercise can produce acute cardiovascular strain without a predictable glycemic response. In a randomized crossover study of 12 adults with T1DM, perceived exertion was associated with cardiovascular strain but not glycemic response during approximately 30-minute aerobic and resistance sessions [162]A1b. Perceived exertion should therefore complement, not replace, glucose monitoring during exercise [162]A1b. Pregnancy requires individualized glycemic targets and pharmacologic planning; a systematic review synthesized maternal and perinatal outcomes for pre-existing diabetes and gestational diabetes, including T1DM, but the supplied abstract does not provide specific emergency targets [371].
Perioperative glucose management in simultaneous pancreas–kidney transplantation was explored in an 11-patient retrospective case series using a six-phase intraoperative algorithm [305]C. This supports phase-specific institutional planning in highly specialized surgery but cannot establish general perioperative targets [305]C. Finally, recurrent DKA with poor adherence may coexist with severe chronic complications, as illustrated by a case of Mauriac syndrome in an adolescent with hepatomegaly and repeated DKA admissions [274]C.
Practical safety principles
Every acute presentation should include medication and insulin-adherence review, assessment for infection or trauma, serial glucose and ketone evaluation, electrolyte and renal monitoring, and reassessment for atypical complications [293]C[365][366][373]C. School personnel may also encounter hypoglycemia or other diabetes emergencies; a Jordanian survey found that only 15.9% of teachers had received prior diabetes-related training, supporting structured emergency education and access to rescue supplies in schools [374].
| Clinical concern | Evidence-informed action | Evidence |
|---|---|---|
| DKA with possible renal injury or chloride burden | Monitor serial creatinine, electrolytes, and chloride trajectory; do not use glucose decline alone to define recovery | [366] |
| DKA with severe hypertriglyceridemia | Check triglycerides when clinically indicated; involve specialists, with insulin as the central reported therapy and plasmapheresis reserved as possible salvage | [372]C |
| DKA with atypical abdominal pain after trauma | Evaluate for concurrent vascular or surgical pathology | [373]C |
| DKA with facial, orbital, or neurologic findings | Urgently assess for rhino-orbital-cerebral mucormycosis | [293]C |
| Hyperglycemia during immune checkpoint therapy | Evaluate promptly for ICI-associated T1DM and DKA | [303] |
Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
- ▸Insulin replacement remains the foundation of T1DM management; CSII and MDI are evidence-based delivery options requiring individualized selection. [370][379]
- ▸Evidence for optimal self-monitoring frequency and glycaemic target values in adults remains limited and inconsistent. [273]
- ▸Pregnancy requires coordinated, outcome-focused glycaemic target setting and treatment review. [371]
- ▸Renal-risk management in T1DM has historically relied on renin–angiotensin-system inhibition; SGLT2 inhibitors, MRAs, and GLP-1 receptor agonists are being evaluated for kidney outcomes and safety. [375]
- ▸GLP-1 receptor agonists are adjuncts to, not replacements for, insulin, and the certainty of evidence is variable. [369]
- ▸SPKTx, kidney transplantation alone, and islet transplantation are specialist options for selected patients, with comparative evidence limited by observational study designs. [376][380][381]
Treatment framework
Long-term management of type 1 diabetes mellitus (T1DM) is organized around three complementary objectives: replacement of absent endogenous insulin, suppression of diabetes-related risk through individualized glycaemic and complication targets, and definitive or near-definitive interventions for carefully selected patients. Intensive insulin therapy remains central because T1DM is insulin-dependent; treatment may use multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII), with glucose monitoring and education adapted to age, lifestyle, resources, and treatment capability. [370][379]
Replacement: insulin and technology
Insulin replacement should be delivered continuously, with basal insulin and meal- or correction-related doses adjusted to food intake, activity, illness, and glucose trends. The available evidence supports CSII as an established alternative to MDI rather than a universally superior treatment for every patient. A 2026 systematic review and meta-analysis specifically evaluated CSII versus MDI in children and adolescents, assessing HbA1c and safety outcomes and applying trial-sequential analysis to judge evidence sufficiency. [370] A randomized crossover non-inferiority trial in Chinese children and adolescents evaluated a tubeless insulin patch pump against insulin-pen MDI over short treatment periods, including mean blood glucose and safety outcomes. [379] These studies support shared decision-making based on glycaemic performance, hypoglycaemia, usability, cost, device access, and the patient’s ability to manage the technology. [370][379]
In hospitalized adults with T1DM, pump use has also been examined in a nationally representative 2022 U.S. readmissions-database analysis evaluating 30-day readmission and in-hospital mortality. [309] Because this was a retrospective observational study, its associations should not be interpreted as proof that pump therapy causes superior inpatient outcomes. [309]
Suppression: glycaemic and renal targets
Treat-to-target care requires regular review of glucose exposure, hypoglycaemia, treatment burden, and patient-defined goals rather than reliance on a single laboratory measure. A 2026 Cochrane review found that evidence remains limited and inconsistent regarding the optimal timing, frequency, and target values for self-monitoring of blood glucose in adults with T1DM; it also noted uncertainty about links between differing monitoring strategies and meaningful clinical outcomes, particularly in low-resource settings. [273] Monitoring plans should therefore be individualized and integrated with available glucose technology, insulin delivery, hypoglycaemia risk, and access to care. [273]
Pregnancy requires a separate, more intensive target-setting process. A systematic review and meta-analysis evaluated glycaemic targets, treatment initiation, and glucose-lowering pharmacological management in pregnant people with pre-existing diabetes, including T1DM, with maternal and perinatal outcomes prioritized for World Health Organization guideline development. [371] Pregnancy targets and treatment changes should consequently be coordinated between diabetes and obstetric teams, with avoidance of both hyperglycaemia and clinically important hypoglycaemia. [371]
Kidney-risk suppression remains an important long-term objective. Renin–angiotensin-system inhibitors have historically been the principal pharmacological option for chronic kidney disease in T1DM. [375] A 2026 systematic review and meta-analysis assessed sodium-glucose cotransporter-2 inhibitors, mineralocorticoid receptor antagonists, and glucagon-like peptide-1 receptor agonists for kidney function, albuminuria, and safety in T1DM, reflecting interest in expanding kidney-protective therapy beyond renin–angiotensin-system inhibition. [375] These agents should not be treated as interchangeable routine therapy for all people with T1DM; selection must account for the evidence base, kidney status, adverse effects, and patient-specific risk. [375]
GLP-1 receptor agonists have also been evaluated as adjuncts to insulin. An overlap-informed umbrella review assessed randomized-trial meta-analyses and highlighted substantial overlap among primary studies, methodological heterogeneity, and variable certainty of evidence. [369] Thus, GLP-1 receptor agonists should be considered an adjunctive, specialist-directed option rather than a replacement for insulin, with benefits and harms discussed explicitly. [369]
Definitive or near-definitive therapy
For selected individuals with T1DM and end-stage kidney disease, simultaneous pancreas–kidney transplantation (SPKTx) and kidney transplantation alone are established treatment modalities. [376] A systematic review and meta-analysis compared metabolic and macrovascular outcomes after SPKTx versus kidney transplantation alone, although the included evidence was largely retrospective or case-control because randomized English-language trials were lacking. [376] A separate systematic review and exploratory meta-analysis examined survival, kidney-graft outcomes, and cardiovascular benefit, including comparisons with living-donor kidney transplantation, and emphasized that whether pancreas transplantation provides superior outcomes remains debated. [380]
Islet transplantation is an option for selected people with T1DM and hypoglycaemia unawareness. [381] Maintenance immunosuppression is required to prevent allograft rejection; a multicentre phase 2 study evaluated belatacept plus sirolimus as an alternative to calcineurin-inhibitor-based therapy, whose adverse effects motivate investigation of other regimens. [381] Transplantation therefore requires specialist assessment of hypoglycaemia severity, kidney disease, operative and immunosuppressive risks, graft expectations, and lifelong follow-up. [376][380][381]
Practical target review
At each review, reassess insulin adequacy and delivery, glucose-monitoring strategy, hypoglycaemia and ketoacidosis risk, pregnancy status, kidney markers, cardiovascular risk, treatment access, and patient priorities. [273][309][371][375] Definitive therapies should be reserved for appropriately selected patients and discussed using the limitations and certainty of the available comparative evidence. [369][376][380][381]
| Domain | Long-term management focus | Evidence anchor |
|---|---|---|
| Replacement | Basal-bolus insulin delivered by MDI or CSII; consider device capability, safety, access, and preference | [370][379] |
| Glycaemic suppression | Individualized monitoring and targets; evidence for optimal adult SMBG timing and frequency remains uncertain | [273] |
| Pregnancy | Coordinated maternal and perinatal target setting and pharmacological review | [371] |
| Kidney protection | RAS inhibition remains established; newer classes require individualized specialist assessment | [375] |
| Definitive therapy | SPKTx, kidney transplantation alone, or islet transplantation in selected patients | [376][380][381] |
History and Evolution of Treatment
- ▸Contemporary T1DM treatment has evolved from insulin replacement toward integrated CSII, CGM, AID, risk prediction, and individualized adjunctive care. [274] [316] [183] [320]
- ▸Faster insulin aspart is being evaluated within pump-and-CGM therapy using time in the **3.9–10.0 mmol/L** range as a primary outcome and **<8% HbA1c** as an eligibility threshold. [316]
- ▸AID improves consistency of glycemic-target achievement but requires specific strategies for exercise-related glucose fluctuations. [183] [162]
- ▸Medium-chain triglycerides may support brain metabolism and working memory during experimentally induced hypoglycemia, but remain investigational. [383]
- ▸DKA prevention, uninterrupted insulin delivery, and rapid management of severe hypertriglyceridemia remain essential components of care; severe hypertriglyceridemia is defined here as **>11.3 mmol/L** triglycerides. [84] [274] [365] [372]
- ▸Future treatment personalization depends on disease classification, autoantibody and familial-risk screening, immune characterization, microbiome research, and attention to adherence and comorbidity. [145] [186] [259] [270] [317] [318] [321] [363]
From insulin replacement to individualized care
The supplied evidence portrays contemporary type 1 diabetes mellitus (T1DM) treatment as an evolution from insulin replacement alone toward integrated insulin delivery, continuous glucose monitoring (CGM), automated decision support, complication prevention, and individualized adjunctive strategies. Clinical reports continue to demonstrate the consequences of inadequate insulin administration: irregular insulin use, inconsistent glucose monitoring, and recurrent diabetic ketoacidosis (DKA) were associated with Mauriac syndrome in an adolescent, while insulin-based treatment remained central during DKA complicated by severe hypertriglyceridemia. [274]C [372]C These reports reinforce that treatment adherence and uninterrupted insulin delivery remain fundamental, even as technology advances. [274]C [372]C
Intensification of insulin delivery and monitoring
Continuous subcutaneous insulin infusion (CSII) combined with CGM has enabled treatment comparisons based on time in range rather than glycated hemoglobin alone. In a randomized crossover trial of children and adolescents aged 6–17 years whose baseline HbA1c was <8% (64 mmol/mol), faster insulin aspart was compared with standard insulin aspart during pump therapy; the primary outcome was time in the 3.9–10.0 mmol/L glucose range. [316] This represents an evolution toward faster pharmacokinetics and postprandial optimization within established pump-and-CGM care, although the available abstract does not provide the trial’s numerical treatment effect. [316]
Automated insulin delivery (AID) systems represent a further step from patient-directed pump adjustment toward algorithm-assisted insulin dosing. Joint German and Austrian guidance describes increasing AID availability and use, with more consistent achievement of glycemic targets and associated quality-of-life benefits. [183]A1c The same guidance emphasizes that exercise remains a cornerstone of T1DM management but can produce glucose fluctuations that challenge AID algorithms. [183]A1c An exploratory randomized crossover study in 12 adults evaluated perceived exertion, heart rate, and capillary glucose during aerobic and resistance exercise, reflecting continuing efforts to make exercise management practical outside specialized clinical settings. [162]A1b
Prevention of treatment-related hypoglycemia
As intensive insulin therapy improves glycemia, prevention of severe hypoglycemia has become a major treatment objective. The SEHYPAN multicenter case-control study developed predictive models for severe hypoglycemia requiring pre-hospital emergency care among adults treated with multiple daily injections, using clinical characteristics and glucose-monitoring method to identify higher-risk individuals. [320] These models illustrate a shift toward risk-stratified prevention rather than responding only after a severe event has occurred. [320]
An experimental metabolic approach has also explored whether ketone availability can protect the brain during insulin-induced hypoglycemia. In a first-in-human mechanistic study using magnetic resonance spectroscopy, infused β-hydroxybutyrate contributed more directly to brain metabolism during clamped hypoglycemia in participants with T1DM than in healthy participants. [383] In a randomized dietary intervention involving people with T1DM and recurrent hypoglycemia, medium-chain triglycerides, used as a dietary ketone precursor, were associated with better working-memory performance and greater regional brain activation than an isocaloric standard diet during clamped hypoglycemia. [383] This remains an adjunctive investigational strategy rather than a replacement for insulin, CGM, or established hypoglycemia treatment. [383]
Adjunctive metabolic, microbiome, and behavioral approaches
Treatment research is expanding beyond insulin to the gut–metabolic axis. A 12-week double-blind pilot trial randomized 68 Indian children with T1DM aged 8–18 years to 8 g/day oligofructose-enriched inulin or isocaloric maltodextrin and assessed HbA1c and stool microbiome composition. [186]A1b The intervention reflects an emerging attempt to modify short-chain-fatty-acid-producing bacteria, but the pilot design and limited abstract information do not establish a replacement for insulin therapy. [186]A1b A forward-looking analysis similarly calls for gnotobiotic models, targeted metabolomics, and causal studies before gut–brain-axis findings can be translated into routine treatment. [259]
Treatment of acute metabolic complications
DKA remains a major determinant of morbidity and health-service use, particularly where resources are limited. A retrospective cohort of adults with T1DM in Northwest Ethiopia evaluated DKA incidence and predictors using records from 2017–2022, highlighting the continuing need for prevention and access to care. [84]B2b In Zambia, a cohort of children with new-onset T1DM and DKA examined factors associated with time to hospital discharge, including DKA severity, vomiting, and HbA1c. [365] In children with DKA and severe hypertriglyceridemia, defined as triglycerides >11.3 mmol/L, retrospective experience identified insulin as central management and plasmapheresis as a salvage option in selected severe cases. [372]C
Personalization, classification, and prevention
Modern treatment increasingly depends on accurate disease classification and recognition of heterogeneity. A Dutch pediatric cohort found that a small subgroup of children clinically diagnosed with T1DM was autoantibody-negative, supporting consideration of alternative diagnoses or distinct disease biology when autoantibodies are absent. [270] A case report of a child with a glucokinase variant, transient GADA positivity, and severe insulin resistance likewise demonstrates why monogenic diabetes and other forms of diabetes must be distinguished from autoimmune T1DM before committing to a treatment pathway. [94]C4
Immune and comorbidity research may eventually support mechanism-based therapies. ADAM19 upregulation in dendritic cells was investigated in relation to immune features and lower C-peptide levels, while thyroid autoantibodies were studied alongside islet autoantibodies at pediatric T1DM diagnosis. [318] [321] Familial-risk programs are also evolving: Korean multicenter data quantified familial occurrence, and Turkish screening of first-degree relatives measured ZnT8A, GADA, IAA, and IA-2A while assessing anxiety after result disclosure. [317] [145]C4
Finally, effective treatment is influenced by social context and long-term complications. A two-year pediatric cohort evaluated visit adherence, family circumstances, hospitalizations, and HbA1c control, emphasizing that follow-up capacity contributes to outcomes. [363] Studies of brain volumetric changes in young adults with long-duration T1DM and of rare renal disease in a person with 19 years of T1DM illustrate why modern care must address cognitive, neurologic, and renal health in addition to glucose levels. [319] [93]C4
| Treatment direction | Evidence and clinical significance |
|---|---|
| Pump and CGM optimization | Faster versus standard insulin aspart is being tested in children and adolescents using time in range as the primary endpoint. [316] |
| Automated insulin delivery | AID is associated with more consistent glycemic-target achievement and improved quality of life, while exercise remains a management challenge. [183]A1c |
| Hypoglycemia prevention | Predictive models aim to identify adults at high risk for severe hypoglycemia requiring emergency care. [320] |
| Metabolic adjuncts | Medium-chain triglycerides and prebiotic inulin are being investigated as adjunctive strategies, not replacements for insulin. [383] [186]A1b |
| Acute complication care | Insulin remains central in DKA-associated severe hypertriglyceridemia; plasmapheresis may be used as salvage in selected cases. [372]C |
| Personalized medicine | Autoantibody, genetic, familial, immune, behavioral, and comorbidity assessments increasingly inform management. [94]C4 [145]C4 [270] [318] [321] [363] |
Multiglandular Syndromes, Genetic Context and Co-Axis Effects
- ▸T1D may coexist with autoimmune thyroid disease, Graves’ disease with thyroid eye disease, neurological autoimmunity, and broader autoimmune clustering. [217][295][282]
- ▸FOXP3-related IPEX and LRBA deficiency are important genetic immune-dysregulation contexts when diabetes is accompanied by enteropathy, eczema, cytopenias, hypogammaglobulinemia, lymphoproliferation, or multiple autoimmune manifestations. [382][47]
- ▸Autoantibody-negative pediatric diabetes warrants phenotype-aware assessment because it may differ clinically and biochemically from autoantibody-positive T1D. [270]
- ▸Insulin resistance may coexist with T1D; eGDR is a studied surrogate, while dapagliflozin evidence in severe insulin resistance remains limited to case reports and case series. [330][331]
- ▸Interpret thyroid tests during DKA cautiously because euthyroid sick syndrome is common and may recover after DKA resolution. [92]
- ▸Preconception targets include HbA1c <6.5% and CGM time in range 3.9–10 mmol/L for at least 70% of time. [217]
Clinical framework
Type 1 diabetes mellitus (T1D) may coexist with organ-specific autoimmunity, broader immune-dysregulation syndromes, inherited monogenic disease, and metabolic or endocrine co-axes. The available evidence is heterogeneous: it includes retrospective cohorts, case series, case reports, and systematic reviews, and should therefore be used to refine diagnostic suspicion rather than to replace phenotype-directed evaluation. [295]C[270][382]C[47]C4
Autoimmune polyglandular and thyroid associations
Autoimmune thyroid disease is a clinically important co-axis in T1D. A 2025 French expert consensus specifically recommends thyroid-stimulating hormone (TSH) measurement during preconception assessment in women with T1D, alongside evaluation of microangiopathic and macroangiopathic complications and cardiovascular risk factors. [217]A1c Graves’ disease may occur with thyroid eye disease (TED) in isolation or in the context of autoimmune polyglandular syndromes; a 2026 retrospective multicentre study examined patients with moderate-to-severe active TED requiring high-dose intravenous steroids and compared isolated Graves’ disease with autoimmune-associated Graves’ disease. [295]C The study’s stated objective was to define the prevalence and associated autoimmune conditions in this severe TED population; its retrospective design limits causal inference regarding whether coexisting autoimmunity determines TED severity. [295]C
Autoimmune clustering is not confined to thyroid disease. A nationwide Korean cohort found that autoimmune diseases, including autoimmune thyroid disease, occurred in association with myasthenia gravis and investigated their rates during the 10 years preceding myasthenia-gravis diagnosis. [282] This supports attention to neurological and systemic autoimmune symptoms in patients with established autoimmune disease, although the study was not specific to T1D and does not establish a T1D-specific screening protocol. [282] A UK population-based cohort of approximately five million pregnancies evaluated 17 maternal autoimmune diseases against 12 pregnancy outcomes, providing broader evidence that autoimmune comorbidity may influence pregnancy risk assessment; the abstract does not establish a T1D-specific effect for each disease-outcome pair. [83]B2b
Genetic and immune-dysregulation contexts
Early-onset diabetes accompanied by enteropathy, severe eczema, recurrent infection, cytopenias, lymphoproliferation, or multiple autoimmune manifestations should prompt consideration of an inherited immune-dysregulation disorder rather than assuming conventional polygenic T1D. IPEX syndrome, caused by pathogenic FOXP3 variants, is characterized by immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance. [382]C A 2026 case described a four-year-old boy with a confirmed hemizygous FOXP3 missense variant, severe treatment-refractory atopic dermatitis from the neonatal period, failure to thrive, and treatment with dupilumab monotherapy directed at the interleukin-4/interleukin-13 axis. [382]C This is case-level evidence and does not establish dupilumab as standard therapy for IPEX or diabetes-associated immune dysregulation. [382]C
LRBA deficiency is another primary immunodeficiency with immune dysregulation, autoimmunity, and lymphoproliferation. A report of five Moroccan families demonstrated marked phenotypic variability, ranging from isolated autoimmune thrombocytopenia with hypogammaglobulinemia to more extensive multisystem disease. [47]C4 In a patient with atypical diabetes plus cytopenias, hypogammaglobulinemia, lymphoproliferation, or several autoimmune manifestations, immunology referral and genetic evaluation may therefore be appropriate; this inference is based on the reported phenotype spectrum, not on a diabetes-specific diagnostic trial. [47]C4
Autoantibody status may also identify a clinically distinct subgroup. A Dutch pediatric retrospective cohort compared autoantibody-positive and autoantibody-negative T1D using GADA, IA-2A, ZnT8, IAA, and ICA, excluding patients who were solely ICA-positive. [270] The cohort contained 562 children diagnosed before age 18 years; the study was designed to characterize autoantibody-negative disease and its biochemical and clinical differences from antibody-positive T1D. [270]
Metabolic, renal, hepatic, and thyroid co-axes
Insulin resistance can coexist with absolute insulin deficiency. In 263 Iraqi adults with T1D, estimated glucose disposal rate (eGDR) was evaluated as a surrogate of insulin resistance and in relation to microvascular complications and metabolic syndrome. [330] This supports considering insulin resistance when T1D is accompanied by obesity, dyslipidemia, hypertension, or unexpectedly high insulin requirements, although the cross-sectional design cannot prove prediction or causality. [330]
A six-case pediatric report described dapagliflozin use in severe insulin resistance: four patients had Rabson–Mendenhall syndrome, one had insulin-receptor type 1A disease, and one had T1D with severe subcutaneous insulin resistance; all reportedly showed a remarkable response. [331]C These uncontrolled observations do not establish dapagliflozin as routine T1D therapy, particularly because the report does not provide randomized comparative safety data. [331]C A systematic review of randomized trials included five T1D studies evaluating GLP-1 receptor agonists or SGLT2 inhibitors and lean body mass, but the provided abstract does not report a T1D-specific pooled estimate; treatment decisions should therefore not be based on an assumed body-composition benefit. [31]A1a
In acute metabolic illness, co-axis abnormalities may be transient or clinically misleading. Euthyroid sick syndrome was studied in 182 children with T1D-associated diabetic ketoacidosis (DKA), with TSH, free T4, and free T3 measured at presentation and two weeks after DKA resolution. [92]B2b Thyroid tests obtained during DKA should therefore be interpreted in clinical context and, when appropriate, reassessed after recovery rather than automatically diagnosing primary thyroid disease. [92]B2b Polyuria with DKA may also be complicated by acute kidney injury: a systematic review identified 32 pediatric patients, including 19 with DKA, five with new-onset T1D without DKA, and one each with Bartter syndrome and neuroblastoma. [41]C4
Poor insulin adherence and recurrent DKA can produce severe multisystem manifestations. A case of adolescent T1D with recurrent DKA, irregular meals, inconsistent glucose monitoring, and poor insulin adherence was reported as Mauriac syndrome, with hepatomegaly and growth-related clinical features. [274]C Finally, pregnancy planning requires coordinated endocrine and obstetric care: the French consensus recommends preconception HbA1c <6.5% and, for users of continuous glucose monitoring, a glucose target range of 3.9–10 mmol/L (70–180 mg/dL) for at least 70% of time. [217]A1c
| Clinical clue | Relevant context | Evidence-supported response |
|---|---|---|
| T1D with thyroid or other autoimmune disease | Autoimmune polyglandular clustering and Graves’-associated TED [217]A1c[295]C | Measure TSH in preconception care; assess symptoms and organ-specific complications [217]A1c |
| Diabetes with eczema, enteropathy, cytopenias, or lymphoproliferation | IPEX or LRBA-related immune dysregulation [382]C[47]C4 | Refer for immunology and genetic evaluation when phenotype is atypical [382]C[47]C4 |
| High insulin requirement or metabolic-syndrome features | Insulin resistance in T1D [330] | Consider eGDR and assess cardiometabolic risk; do not infer causality from cross-sectional data [330] |
| DKA with abnormal thyroid tests | Euthyroid sick syndrome [92]B2b | Interpret in acute-illness context and consider repeat testing after recovery [92]B2b |
| Polyuria with DKA | Reported pediatric AKI association [41]C4 | Monitor renal function and investigate persistent or disproportionate polyuria [41]C4 |
Complications and Long-term Sequelae
- ▸T1D complications include DKA, hypoglycemia, nephropathy, retinopathy, neuropathy, cardiovascular disease, dyslipidemia, additional autoimmune disease, and psychosocial burden. [303][336][355][368][284][310]
- ▸Cardiovascular risk may manifest early through blood-pressure abnormalities, arterial stiffness, dyslipidemia, and subclinical myocardial dysfunction. [362][368][234][236]
- ▸SPKTx and KTx are treatment options for selected adults with T1D and ESKD; comparative metabolic, cardiovascular, survival, and graft outcomes remain an active evidence area. [376][380]
- ▸Psychological burden is substantial, particularly concern about future complications, diabetes burnout, and fear that diabetes controls daily life. [310][336]
- ▸Evidence for some newer biomarkers and interventions remains limited by cross-sectional, retrospective, exploratory, small-sample, or preclinical designs. [355][236][162][261][305]
Overview
Type 1 diabetes mellitus (T1D) is associated with acute metabolic decompensation, chronic microvascular disease, macrovascular disease, cardiovascular dysfunction, treatment-related complications, psychosocial burden, and additional autoimmune disease. The contemporary evidence base includes systematic reviews, cohort studies, cross-sectional investigations, and exploratory trials, with important limitations related to heterogeneity, retrospective designs, and a lack of randomized evidence for some major interventions. [376][380][334][284]
Acute metabolic and treatment-related complications
Diabetic ketoacidosis (DKA) remains a potentially life-threatening complication of absolute insulin deficiency. In adults receiving immune checkpoint inhibitors, T1D induced by immune checkpoint therapy is rare but potentially life-threatening; a 2026 systematic review and meta-analysis specifically evaluated its incidence, associated DKA frequency, risk factors, and prognostic implications. The analysis also examined whether dual versus single-agent immune checkpoint therapy and pre-existing diabetes were associated with T1D risk or outcomes. [303]
Insulin therapy itself can cause hypoglycemia, and fear of hypoglycemia is a clinically relevant burden. In postmenopausal women with T1D, a cross-sectional BETTER-registry analysis assessed hypoglycemia, fear of hypoglycemia, insulin doses, glycemic control, falls, depressive symptoms, and diabetes complications, highlighting the need to consider treatment burden and safety across the life course. [336] Evidence from a Cochrane review found that the optimal timing, frequency, and glycemic targets for self-monitoring of blood glucose in adults remain uncertain, with limited direct evidence linking specific monitoring strategies to meaningful clinical outcomes. [273]
In children and adolescents, a systematic review and meta-analysis of randomized trials compared continuous subcutaneous insulin infusion (CSII) with multiple daily injections (MDI), evaluating HbA1c and adverse events; trial-sequential analysis was used to assess whether the evidence was sufficiently conclusive. [370] A national inpatient analysis further evaluated whether insulin-pump use was associated with 30-day readmission and in-hospital mortality among adults hospitalized with T1D. [309]
Microvascular complications
Diabetic nephropathy may progress to chronic kidney disease and end-stage kidney disease (ESKD). Urinary cubilin shedding is being investigated as an early biomarker because microalbuminuria may have limited sensitivity; a prospective cohort study measured cubilin in participants with normal kidney function and normoalbuminuria and followed their renal course for more than 20 years. [355]C
For patients with T1D and ESKD, simultaneous pancreas-kidney transplantation (SPKTx) and kidney transplantation alone (KTx) are established treatment modalities. A systematic review and meta-analysis compared metabolic and macrovascular outcomes after these procedures in adults, while another systematic review explored patient survival, kidney-graft outcomes, and cardiovascular benefit, including comparisons with living-donor KTx. [376][380] A small single-center case series also evaluated a six-phase intraoperative glycemic-management algorithm during SPKTx, addressing perioperative glycemic control and immediate outcomes in 11 recipients. [305]C
Retinopathy and neuropathy remain important long-term outcomes assessed in adults with T1D. In the BETTER analysis of women aged 40–60 years, physical outcomes included retinopathy, neuropathy, cardiovascular disease, and falls, allowing comparison between premenopausal and postmenopausal participants. [336]
Cardiovascular and macrovascular complications
Cardiovascular disease is a major long-term complication of T1D. A prospective UK Biobank cohort examined incident cardiovascular disease among participants without established cardiovascular disease at baseline in relation to six lifestyle factors: smoking, alcohol consumption, body mass index, diet quality, physical activity, and sleep duration. [334] A separate U.S. propensity-matched cohort compared long-term major adverse cardiovascular and cerebrovascular events—including stroke, hemorrhage, cardiac arrest, heart failure, myocardial infarction, and peripheral vascular events—in adults with adult-onset T1D versus T2D, with follow-up through 2025. [285]C
Early cardiovascular abnormalities are detectable in childhood. In children with T1D, ambulatory blood-pressure monitoring and pulse-wave analysis assessed hypertension, blood-pressure variability, and arterial stiffness; the study reported higher 24-hour peripheral systolic and diastolic blood-pressure variability measures than in healthy controls. [362] In youths, an updated meta-analysis of 20 studies compared left-ventricular global longitudinal strain (LV GLS) with healthy controls as a marker of subclinical myocardial dysfunction; the primary two-dimensional analysis included 1,086 youths with T1D and 935 controls. [368]
Dyslipidemia is an additional modifiable cardiovascular risk factor. A pediatric audit evaluated adherence to lipid-screening guidance and subsequent management; among 335 identified patients, 263 (78%) underwent initial screening according to the applicable guideline, although the mean testing interval was approximately 17 months, rather than the recommended 5 years. [234]C4 In adolescents, the triglyceride-glucose index and phase angle were investigated as potential markers of glycemic control, body composition, and cardiovascular risk, although the evidence was cross-sectional and derived from 73 participants. [236]C4 Omega-3 polyunsaturated fatty-acid supplementation has also been evaluated in a systematic review and meta-analysis examining total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, fasting plasma glucose, and HbA1c; its efficacy in T1D remains the subject of pooled trial analysis rather than established routine therapy. [333]
Autoimmune, musculoskeletal, and psychosocial sequelae
Children and adolescents with T1D are at increased risk of additional autoimmune disease. A retrospective cohort of 639 young people followed at a tertiary pediatric center evaluated the prevalence, spectrum, timing, clinical characteristics, and associated autoantibodies of these comorbidities. [284]
Diabetes may also influence perioperative and infectious outcomes. Experimental work comparing murine T1D, T2D, and nondiabetic models examined spinal implant-associated infection, wound healing, inflammatory responses, and response to semaglutide; these findings are preclinical and should not be directly extrapolated to clinical treatment. [261]
Psychological and behavioral sequelae are common concerns. In an exploratory analysis of 101 adults using the MyDiaMate platform, frequently reported burdens included concern about future complications (85.1%), guilt or worry when diabetes was poorly controlled (79.2%), diabetes burnout (72.3%), and feeling that diabetes controlled one’s life (72.3%). [310] Exercise is generally considered relevant to cardiovascular risk reduction, but an exploratory randomized crossover trial in 12 adults found that perceived exertion was associated with cardiovascular strain, while not being associated with the acute glycemic response to gym-based aerobic or resistance exercise. [162]A1b
Clinical implications
Long-term surveillance should address renal function and albuminuria, retinopathy, neuropathy, blood pressure, arterial stiffness, lipids, cardiovascular risk, hypoglycemia, autoimmune comorbidity, and psychological well-being. The available evidence supports individualized risk assessment and attention to both traditional complications and emerging markers of subclinical cardiovascular or renal injury, while recognizing that several newer findings arise from observational, cross-sectional, exploratory, or preclinical studies. [355]C[368][362][234]C4[236]C4[284][310][261]
| Domain | Evidence update |
|---|---|
| Acute metabolic complications | Immune checkpoint inhibitor-associated T1D is rare but potentially life-threatening and may present with DKA. [303] |
| Hypoglycemia and monitoring | Hypoglycemia, fear of hypoglycemia, falls, and uncertainty about optimal self-monitoring strategies remain clinically important. [336][273] |
| Kidney disease | Urinary cubilin is being studied as an early nephropathy biomarker before microalbuminuria. [355]C |
| Cardiovascular disease | Lifestyle, dyslipidemia, hypertension, arterial stiffness, LV GLS, and MACCE are evaluated across the life course. [334][285]C[362][368][234]C4 |
| Autoimmune disease | Pediatric T1D is associated with additional autoimmune conditions requiring longitudinal surveillance. [284] |
| Psychosocial complications | Diabetes burnout, worry about complications, guilt, and loss of perceived control are frequent reported burdens. [310] |
Prognosis, Natural History, Special Populations and Prevention
- ▸CSII, patch pumps, MDI, and CGM are the principal technology-based strategies studied for pediatric glycemic control; the supplied evidence includes randomized comparisons and a 5-year observational CGM trajectory study [370,379,358].
- ▸DKA prognosis is linked to renal and electrolyte complications, including chloride burden, creatinine-defined acute kidney injury, and severe hypertriglyceridemia above 11.3 mmol/L [366,372].
- ▸Retinopathy and cardiovascular risk require duration- and HbA1c-aware follow-up, with dynamic DR prediction and long-term MACCE risk evaluated in adult-onset T1D cohorts [388,285].
- ▸Children and adolescents require surveillance for additional autoimmune disease, especially celiac disease and thyroid-related or other autoimmune comorbidity; the supplied studies quantify regional prevalence and timing but do not establish preventive therapy [284,387,345].
- ▸Risk reduction should include structured self-management assessment, screening for disordered eating, lipid monitoring, and attention to adiposity-associated liver disease [384,339,234,386].
Prognosis and long-term disease course
Type 1 diabetes (T1D) is a lifelong disorder requiring intensive insulin replacement. In children, a 2026 systematic review and meta-analysis of randomized trials compared continuous subcutaneous insulin infusion (CSII) with multiple daily injections (MDI), assessing HbA1c and adverse events; trial-sequential analysis and GRADE were used to evaluate the certainty and sufficiency of evidence [370]. A multicenter randomized crossover non-inferiority trial in Chinese children and adolescents aged 3–17 years similarly compared a tubeless patch pump with insulin-pen MDI over 5-day treatment periods, with mean blood glucose as the primary outcome [379]. These studies support technology-assisted insulin delivery as an important component of pediatric glycemic management, although the supplied abstracts do not provide the pooled effect sizes or complete long-term complication outcomes [370][379].
Early access to continuous glucose monitoring (CGM) may influence subsequent glycemic trajectories. In a retrospective Korean cohort of 216 patients diagnosed with T1D at age 18 years or younger, HbA1c was followed for up to 60 months according to whether CGM was initiated within 1 month, after 1 to less than 12 months, after at least 12 months, or not used; adjusted longitudinal trajectories were estimated using mixed-effects models [358]. These data address glycemic evolution rather than definitive microvascular or mortality outcomes, and the supplied abstract does not report the numerical trajectory differences [358].
Complication risk is heterogeneous and is influenced by diabetes duration and glycemic exposure. A longitudinal cohort of 572 adults with adult-onset T1D used time-varying duration and HbA1c in a Cox model to predict diabetic retinopathy (DR), developing and internally validating a dynamic prediction model [388]. The model incorporated discrimination, calibration, Brier score, and decision-curve analyses, but the supplied abstract does not provide its final performance estimates [388]. In adults with adult-onset T1D, a propensity-matched U.S. database study followed patients diagnosed between 2005 and 2015 through 2025 and compared 10-year major adverse cardiovascular and cerebrovascular event (MACCE) risk with type 2 diabetes; outcomes included stroke, cardiac arrest, heart failure, myocardial infarction, and peripheral vascular events [285]C.
Acute prognosis and serious complications
Diabetic ketoacidosis (DKA) remains a major acute threat. In a retrospective cohort of children and young people aged 1–20 years hospitalized with T1D-related DKA, serial chloride and creatinine measurements were examined for chloride burden, creatinine-defined acute kidney injury (CDAKI), and length of stay [366]. The study also evaluated the association between initial beta-hydroxybutyrate and creatinine, emphasizing renal risk assessment during DKA management [366]. Severe hypertriglyceridemia, defined as triglycerides >11.3 mmol/L, was examined in a 10-year retrospective series of 21 children with DKA; the report characterized its clinical spectrum and treatment, with insulin described as central and plasmapheresis as salvage therapy in severe cases [372]C.
Special populations
Pregnancy with pre-existing diabetes requires particularly close glycemic management because maternal and neonatal outcomes are affected by glucose exposure. A systematic review and meta-analysis of randomized trials evaluated glycemic targets, treatment initiation, and glucose-lowering pharmacological strategies in pregnant women with T1D, T2D, or gestational diabetes, prioritizing outcomes used for WHO maternal and perinatal guidance [371]. The supplied abstract does not provide T1D-specific pooled estimates, so treatment decisions should not be inferred from this review alone [371].
People receiving immune checkpoint inhibitors represent a distinct acquired form of insulin-deficient diabetes. A systematic review and meta-analysis evaluated the incidence, risk factors, DKA frequency, and prognostic implications of immune checkpoint inhibitor-induced T1D (ICI-T1D) in adults with cancer [303]. The analysis examined dual versus monotherapy exposure and pre-existing diabetes as potential predictors, highlighting that ICI-T1D is rare but potentially life-threatening and may present with DKA [303].
Autoimmune comorbidity is common in pediatric T1D. A 40-year cohort of 2,954 patients diagnosed from 1981–2024 assessed seasonality, age at onset, sex, birth season, and autoimmune comorbidities; early-onset disease showed no seasonal fluctuation, suggesting stronger genetic or immunologic influence in that subgroup [341]. In a tertiary pediatric cohort of 639 patients, the frequency, spectrum, timing, and associated factors of additional autoimmune diseases were evaluated [284]. Celiac disease is a particularly important comorbidity: a systematic review and meta-analysis estimated its prevalence among children with T1D in the Eastern Mediterranean Region [387], while a retrospective Algerian study of 109 children assessed whether age at T1D diagnosis affected subsequent celiac disease occurrence using serology, histopathology, and clinical data [345]C.
Prevention and risk reduction
No supplied study establishes a population-level intervention that prevents autoimmune T1D. Prevention of adverse outcomes therefore centers on sustained glycemic monitoring, individualized insulin delivery, screening for comorbid autoimmune disease, and cardiovascular-risk management [370][358][284][387]. Behavioral self-management measurement is supported by a systematic review that evaluated the methodological quality and measurement properties of diabetes self-management instruments, providing a basis for selecting assessment tools in clinical care [384]. Disordered eating also warrants active surveillance: a Spanish nationwide cross-sectional study of 451 people aged at least 16 years with T1D used the Diabetes Eating Problems Survey-Revised, with a score ≥20 indicating a positive screen [339].
Cardiovascular prevention includes attention to lipids and adiposity. An Australian pediatric audit evaluated adherence to lipid-screening guidance and subsequent management of dyslipidemia in 335 patients; the observed mean testing interval was 17 months rather than the recommended 5-year interval [234]C4. In adults with T1D, visceral adiposity index was explored as a marker associated with metabolic dysfunction-associated steatotic liver disease using elastography and controlled attenuation parameter assessment in 212 participants [386]. Population-level Asian diabetes trends and attributable risk factors from Global Burden of Disease 2021 data were also assessed, including T1D incidence and disability-adjusted life-year patterns from 1990–2021 [340].
For advanced diabetic kidney disease, simultaneous pancreas-kidney transplantation (SPKT) restores renal function and endogenous insulin secretion in selected adults with T1D and end-stage renal disease. A systematic review and exploratory meta-analysis compared SPKT with kidney transplantation alone for patient survival, kidney-graft outcomes, and cardiovascular benefit, including comparisons involving living-donor transplantation [380]. Cuffless blood-pressure monitoring remains investigational in children: a feasibility study in well-controlled T1D patients with normal office blood pressure compared a wrist-worn optical device with 24-hour ambulatory monitoring and assessed agreement using a prespecified exploratory ±10 mmHg margin [385]C.
| Domain | Updated evidence | Clinical implication |
|---|---|---|
| Glycemic technology | CSII versus MDI meta-analysis; patch-pump randomized crossover trial; CGM timing cohort [370][379][358] | Individualize insulin delivery and consider early glucose monitoring |
| Acute complications | DKA studies of chloride, acute kidney injury, length of stay, and severe hypertriglyceridemia [366][372]C | Monitor renal function, electrolytes, ketones, and triglycerides when clinically indicated |
| Microvascular risk | Adult-onset T1D dynamic DR prediction model using duration and HbA1c [388] | Use duration and glycemic exposure to guide retinopathy surveillance |
| Autoimmunity | Cohort and meta-analysis evidence for autoimmune disease and celiac disease [284][341][387][345]C | Maintain longitudinal screening for associated autoimmune disorders |
| Cardiometabolic prevention | Pediatric dyslipidemia audit, adult visceral adiposity/MASLD study, and MACCE cohort [234]C4[386][285]C | Address lipids, adiposity, blood pressure, and other modifiable risk factors |
| Special populations | Pregnancy, ICI-T1D, and advanced kidney disease/transplantation evidence [371][303][380] | Use specialist multidisciplinary care and population-specific risk assessment |
References
- [1]
Dost A, Bechtold S, Fink K et al.. “2017 American Academy of Pediatrics Clinical Practice Guideline: Impact on Prevalence of Arterial Hypertension in Children and Adolescents With Type 1 Diabetes.” Diabetes care (2020). PMID: 32229598 ↗
L2GUIDELINECited in: Definition, Classification and Axis Nomenclature, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [2]
de Vries M, Westerink J, Kaasjager KHAH et al.. “Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in Patients With Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis.” The Journal of clinical endocrinology and metabolism (2020). PMID: 32827432 ↗
L1SR_OBSCited in: Definition, Classification and Axis Nomenclature, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [3]
Wada E, Onoue T, Kinoshita T et al.. “Adult-onset autoimmune diabetes identified by glutamic acid decarboxylase autoantibodies: a retrospective cohort study.” Diabetologia (2021). PMID: 34268631 ↗
L3COHORTCited in: Definition, Classification and Axis Nomenclature, Clinical Presentation - [4]
Shaka H, Aguilera M, Aucar M et al.. “Rate and Predictors of 30-day Readmission Following Diabetic Ketoacidosis in Type 1 Diabetes Mellitus: A US Analysis.” The Journal of clinical endocrinology and metabolism (2021). PMID: 34043791 ↗
L2OTHERCited in: Definition, Classification and Axis Nomenclature, Severity, Staging and Risk Stratification - [5]
Amato MC, Guarnotta V, Ciresi A et al.. “No phenotypic differences for polycystic ovary syndrome (PCOS) between women with and without type 1 diabetes mellitus.” The Journal of clinical endocrinology and metabolism (2013). PMID: 24243639 ↗
L3OTHERCited in: Definition, Classification and Axis Nomenclature - [6]
Codner E, Soto N, Lopez P et al.. “Diagnostic criteria for polycystic ovary syndrome and ovarian morphology in women with type 1 diabetes mellitus.” The Journal of clinical endocrinology and metabolism (2006). PMID: 16569737 ↗
L3OTHERCited in: Definition, Classification and Axis Nomenclature - [7]
Leslie RD, Palmer J, Schloot NC et al.. “Diabetes at the crossroads: relevance of disease classification to pathophysiology and treatment.” Diabetologia (2016). PMID: 26498592 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Axis Nomenclature, Axis Physiology, Pathophysiology and Biochemical Signature, Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [8]
Marques-Couto P, Afonso J, Coelho-Costa I et al.. “Prevalence and Risk Factors of Diabetic Macular Edema in Type 1 Diabetes: A Systematic Review and Meta-Analysis.” Ophthalmology. Retina (2025). PMID: 41016555 ↗
L1SR_OBSCited in: Definition, Classification and Axis Nomenclature - [9]
Weissmann S, Amitai N, Honig E et al.. “Maternal type 1 diabetes mellitus and atopic dermatitis in offspring: A nationwide cohort study.” JAAD international (2026). PMID: 42100114 ↗
L2COHORTCited in: Definition, Classification and Axis Nomenclature, Epidemiology, Etiology and Risk Factors, Severity, Staging and Risk Stratification, Prognosis, Natural History, Special Populations and Prevention - [10]
Kim KJ, Kim S, Oh R et al.. “High Waist-to-Height Ratio Increases the Risk of Cardiovascular Outcomes in Adults with Type 1 Diabetes Mellitus: A Nationwide Cohort Study.” Diabetes & metabolism journal (2025). PMID: 40904015 ↗
L2COHORTCited in: Definition, Classification and Axis Nomenclature - [11]
Weng SS, Chien LY. “IVF and risk of Type 1 diabetes mellitus: a population-based nested case-control study.” Human reproduction (Oxford, England) (2024). PMID: 38852062 ↗
L3CASE_CONTROLCited in: Definition, Classification and Axis Nomenclature - [12]
Tetik Dinçer B, Urgancı N, Koç A et al.. “Association of endocrine autoantibodies (anti-TPO, anti-GAD, anti-insulin) with histopathological severity in pediatric Celiac disease: a retrospective cohort study.” BMC pediatrics (2025). PMID: 41430660 ↗
L3COHORTCited in: Definition, Classification and Axis Nomenclature, Severity, Staging and Risk Stratification - [13]
Zan Y, Wei Y, Zhang W et al.. “Sintilimab-induced diabetes mellitus and thyroid dysfunction in patient with gastric adenocarcinoma: A case report and literature review.” Medicine (2025). PMID: 40388765 ↗
L4SR_OBSCited in: Definition, Classification and Axis Nomenclature - [14]
Wyckoff JA, Lapolla A, Asias-Dinh BD et al.. “Preexisting Diabetes and Pregnancy: An Endocrine Society and European Society of Endocrinology Joint Clinical Practice Guideline.” The Journal of clinical endocrinology and metabolism (2025). PMID: 40652453 ↗
L1GUIDELINECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Severity, Staging and Risk Stratification, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [15]
Wyckoff JA, Lapolla A, Asias-Dinh BD et al.. “Preexisting Diabetes and Pregnancy: An Endocrine Society and European Society of Endocrinology Joint Clinical Practice Guideline.” European journal of endocrinology (2025). PMID: 40652450 ↗
L1GUIDELINECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Severity, Staging and Risk Stratification, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [16]
Pozzilli P, Bosi E, Cirkel D et al.. “Randomized 52-week Phase 2 Trial of Albiglutide Versus Placebo in Adult Patients With Newly Diagnosed Type 1 Diabetes.” The Journal of clinical endocrinology and metabolism (2020). PMID: 32219329 ↗
L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, History and Evolution of Treatment - [17]
Pescovitz MD, Greenbaum CJ, Bundy B et al.. “B-lymphocyte depletion with rituximab and β-cell function: two-year results.” Diabetes care (2013). PMID: 24026563 ↗
L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment - [18]
Codner E, Escobar-Morreale HF. “Clinical review: Hyperandrogenism and polycystic ovary syndrome in women with type 1 diabetes mellitus.” The Journal of clinical endocrinology and metabolism (2007). PMID: 17284617 ↗
L5SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae - [19]
Du M, Basu A, Fu D et al.. “Serum inflammatory markers and preeclampsia in type 1 diabetes: a prospective study.” Diabetes care (2013). PMID: 23393212 ↗
L2COHORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Prognosis, Natural History, Special Populations and Prevention - [20]
de Filette JMK, Pen JJ, Decoster L et al.. “Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review.” European journal of endocrinology (2019). PMID: 31330498 ↗
L4SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [21]
Geddes J, Deary IJ, Frier BM. “Effects of acute insulin-induced hypoglycaemia on psychomotor function: people with type 1 diabetes are less affected than non-diabetic adults.” Diabetologia (2008). PMID: 18709352 ↗
L1TRIAL_NONRANDOMCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Acute Management and Endocrine Emergencies - [22]
Clotman K, Janssens K, Specenier P et al.. “Programmed Cell Death-1 Inhibitor-Induced Type 1 Diabetes Mellitus.” The Journal of clinical endocrinology and metabolism (2018). PMID: 29955867 ↗
L4CASE_REPORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Clinical Presentation, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [23]
Morkos M, Nensey NK, Bindal A. “Micafungin-Induced Hypoglycemia in a Patient With Type 1 Diabetes: A Case Report and Review of Literature.” The Journal of clinical endocrinology and metabolism (2019). PMID: 30398618 ↗
L4CASE_REPORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment - [24]
Yoneda S, Imagawa A, Fukui K et al.. “A Histological Study of Fulminant Type 1 Diabetes Mellitus Related to Human Cytomegalovirus Reactivation.” The Journal of clinical endocrinology and metabolism (2017). PMID: 28398495 ↗
L4CASE_REPORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [25]
Fazeli PK, Horowitz MC, MacDougald OA et al.. “Marrow fat and bone--new perspectives.” The Journal of clinical endocrinology and metabolism (2013). PMID: 23393168 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature - [26]
Tomar N, Gupta N, Goswami R. “Calcium-sensing receptor autoantibodies and idiopathic hypoparathyroidism.” The Journal of clinical endocrinology and metabolism (2013). PMID: 23873991 ↗
L3OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [27]
Hough FS, Pierroz DD, Cooper C et al.. “MECHANISMS IN ENDOCRINOLOGY: Mechanisms and evaluation of bone fragility in type 1 diabetes mellitus.” European journal of endocrinology (2015). PMID: 26537861 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Complications and Long-term Sequelae - [28]
Verrotti A, Scaparrotta A, Olivieri C et al.. “Seizures and type 1 diabetes mellitus: current state of knowledge.” European journal of endocrinology (2012). PMID: 22956556 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature - [29]
Kratzsch J, Knerr I, Galler A et al.. “Metabolic decompensation in children with type 1 diabetes mellitus associated with increased serum levels of the soluble leptin receptor.” European journal of endocrinology (2006). PMID: 16990661 ↗
L3OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [30]
Assmann TS, Brondani Lde A, Bauer AC et al.. “Polymorphisms in the TLR3 gene are associated with risk for type 1 diabetes mellitus.” European journal of endocrinology (2014). PMID: 24408902 ↗
L3OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [31]
Jobanputra R, Sargeant JA, Plekhanova T et al.. “The Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Co-Transporter-2 Inhibitors on Lean Body Mass in Humans: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.” Diabetes/metabolism research and reviews (2026). PMID: 42319968 ↗
L1SR_MA_RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [32]
Frandsen CS, Dejgaard TF, Madsbad S. “Non-insulin drugs to treat hyperglycaemia in type 1 diabetes mellitus.” The lancet. Diabetes & endocrinology (2016). PMID: 26969516 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [33]
Elliott J, Sloan G, Stevens L et al.. “Female sex is a risk factor for painful diabetic peripheral neuropathy: the EURODIAB prospective diabetes complications study.” Diabetologia (2023). PMID: 37870649 ↗
L2OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [34]
Korczak DJ, Pereira S, Koulajian K et al.. “Type 1 diabetes mellitus and major depressive disorder: evidence for a biological link.” Diabetologia (2011). PMID: 21789690 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Severity, Staging and Risk Stratification - [35]
Pane JA, Coulson BS. “Lessons from the mouse: potential contribution of bystander lymphocyte activation by viruses to human type 1 diabetes.” Diabetologia (2015). PMID: 25794781 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature - [36]
Roca-Rivada A, Marín-Cañas S, Colli ML et al.. “Inhibition of the type 1 diabetes candidate gene PTPN2 aggravates TNF-α-induced human beta cell dysfunction and death.” Diabetologia (2023). PMID: 36988639 ↗
L3OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [37]
Nieuwdorp M, Holleman F, de Groot E et al.. “Perturbation of hyaluronan metabolism predisposes patients with type 1 diabetes mellitus to atherosclerosis.” Diabetologia (2007). PMID: 17415544 ↗
L3OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Complications and Long-term Sequelae - [38]
Segev Y, Eshet R, Yakir O et al.. “Systemic and renal growth hormone-IGF1 axis involvement in a mouse model of type 2 diabetes.” Diabetologia (2007). PMID: 17443310 ↗
L4OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [39]
Kateel R, Parida A, Chogtu B et al.. “Safety of GLP-1 receptor agonists in type 1 diabetes: a systematic review and meta-analysis.” Diabetes research and clinical practice (2026). PMID: 42105869 ↗
L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Acute Management and Endocrine Emergencies - [40]
Abdel-Rahman SM, Al-Shiab R, Shah E et al.. “Efficacy and safety of GLP-1 receptor agonists and SGLT2 inhibitors as adjuncts to insulin in type 1 diabetes: Systematic review and meta-analysis.” Diabetes, obesity & metabolism (2026). PMID: 41605813 ↗
L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [41]
Rivetti G, Braile M, Di Sessa A et al.. “Acute Kidney Injury in Children with Polyuria: A Systematic Review.” Journal of clinical medicine (2026). PMID: 41517599 ↗
L4SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [42]
Jawad M, Afaq S, Hussain S et al.. “Effect of digital interventions on adherence to the management of type 1 diabetes mellitus patients: a systematic review.” BMC endocrine disorders (2025). PMID: 41462455 ↗
L2SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [43]
Chen Y, Tang Y, Yue R et al.. “Effect of Glucagon-Like Peptide-1 Receptor Agonists on Cardiometabolic Risk Factors in Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis.” Diabetes/metabolism research and reviews (2026). PMID: 41331723 ↗
L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [44]
Biondi B, Kahaly GJ, Robertson RP. “Thyroid Dysfunction and Diabetes Mellitus: Two Closely Associated Disorders.” Endocrine reviews (2019). PMID: 30649221 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History, Special Populations and Prevention - [45]
Meijnikman AS, Gerdes VE, Nieuwdorp M et al.. “Evaluating Causality of Gut Microbiota in Obesity and Diabetes in Humans.” Endocrine reviews (2018). PMID: 29309555 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature - [46]
Rotondi M, Chiovato L, Romagnani S et al.. “Role of chemokines in endocrine autoimmune diseases.” Endocrine reviews (2007). PMID: 17475924 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature - [47]
Hbibi M, Elamine A, Benhsaien I et al.. “Case Report: Different faces of LRBA deficiency in five Moroccan families.” Frontiers in immunology (2026). PMID: 42148132 ↗
L4CASE_REPORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [48]
Al Hayek A, Robert AA, Al Burayk AK et al.. “Comparative Clinical and Metabolic Outcomes of GLP-1 Receptor Agonists Versus SGLT2 Inhibitors in Type 1 Diabetes: A Retrospective Cohort Study from Saudi Arabia.” Current diabetes reviews (2026). PMID: 41691684 ↗
L2COHORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [49]
Horton WB, Snell-Bergeon JK. “Hemoglobin A1c Variability Metrics Predict Coronary Artery Calcium and Cardiovascular Events in Type 1 Diabetes: The CACTI Study.” The Journal of clinical endocrinology and metabolism (2023). PMID: 36637994 ↗
L2TRIAL_NONRANDOMCited in: Epidemiology, Etiology and Risk Factors, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [50]
Tsaitlin-Mor L, Cahen-Peretz A, Bentov Y et al.. “Long-term Risk for Type 1 Diabetes and Obesity in Early Term Born Offspring: A Systematic Review and Meta-Analysis.” The Journal of clinical endocrinology and metabolism (2024). PMID: 38079466 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Prognosis, Natural History, Special Populations and Prevention - [51]
Balsells M, García-Patterson A, Gich I et al.. “Maternal and fetal outcome in women with type 2 versus type 1 diabetes mellitus: a systematic review and metaanalysis.” The Journal of clinical endocrinology and metabolism (2009). PMID: 19808847 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [52]
Nicholson WK, Robinson KA, Smallridge RC et al.. “Prevalence of postpartum thyroid dysfunction: a quantitative review.” Thyroid : official journal of the American Thyroid Association (2006). PMID: 16839259 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [53]
Aslam AA, Baksh RA, Pape SE et al.. “Diabetes and Obesity in Down Syndrome Across the Lifespan: A Retrospective Cohort Study Using U.K. Electronic Health Records.” Diabetes care (2022). PMID: 36178378 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History, Special Populations and Prevention - [54]
Zhong VW, Juhaeri J, Cole SR et al.. “Incidence and Trends in Hypoglycemia Hospitalization in Adults With Type 1 and Type 2 Diabetes in England, 1998-2013: A Retrospective Cohort Study.” Diabetes care (2017). PMID: 28716781 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Prognosis, Natural History, Special Populations and Prevention - [55]
Drenthen LCA, Ajie M, Abbink EJ et al.. “No insulin degludec dose adjustment required after aerobic exercise for people with type 1 diabetes: the ADREM study.” Diabetologia (2023). PMID: 36879098 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment - [56]
Bo S, Gentile L, Castiglione A et al.. “C-peptide and the risk for incident complications and mortality in type 2 diabetic patients: a retrospective cohort study after a 14-year follow-up.” European journal of endocrinology (2012). PMID: 22577110 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [57]
Morgan E, Halliday SR, Campbell GR et al.. “Vaccinations and childhood type 1 diabetes mellitus: a meta-analysis of observational studies.” Diabetologia (2015). PMID: 26564178 ↗
L3SR_OBSCited in: Epidemiology, Etiology and Risk Factors - [58]
de Vries SAG, Verheugt CL, Mul D et al.. “Do sex differences in paediatric type 1 diabetes care exist? A systematic review.” Diabetologia (2023). PMID: 36700969 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [59]
Jeitler K, Horvath K, Berghold A et al.. “Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis.” Diabetologia (2008). PMID: 18351320 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [60]
Cardwell CR, Stene LC, Joner G et al.. “Caesarean section is associated with an increased risk of childhood-onset type 1 diabetes mellitus: a meta-analysis of observational studies.” Diabetologia (2008). PMID: 18292986 ↗
L3SR_OBSCited in: Epidemiology, Etiology and Risk Factors - [61]
Stagnaro-Green A. “Approach to the patient with postpartum thyroiditis.” The Journal of clinical endocrinology and metabolism (2012). PMID: 22312089 ↗
L5CASE_REPORTCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [62]
Chou IC, Wang CH, Lin WD et al.. “Risk of epilepsy in type 1 diabetes mellitus: a population-based cohort study.” Diabetologia (2016). PMID: 27030312 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Complications and Long-term Sequelae - [63]
Dafoulas GE, Toulis KA, Mccorry D et al.. “Type 1 diabetes mellitus and risk of incident epilepsy: a population-based, open-cohort study.” Diabetologia (2016). PMID: 27796422 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [64]
Mikłosz A, Chabowski A. “Adipose-derived Mesenchymal Stem Cells Therapy as a new Treatment Option for Diabetes Mellitus.” The Journal of clinical endocrinology and metabolism (2023). PMID: 36916961 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [65]
Li FR, Hukportie DN, Yang J et al.. “Microvascular Burden and Incident Heart Failure Among Middle-Aged and Older Adults With Type 1 or Type 2 Diabetes.” Diabetes care (2022). PMID: 35944243 ↗
L2OTHERCited in: Epidemiology, Etiology and Risk Factors - [66]
Chen X, Affinati AH, Lee Y et al.. “Immune Checkpoint Inhibitors and Risk of Type 1 Diabetes.” Diabetes care (2022). PMID: 35238899 ↗
L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [67]
Jacobson AM, Braffett BH, Erus G et al.. “Brain Structure Among Middle-aged and Older Adults With Long-standing Type 1 Diabetes in the DCCT/EDIC Study.” Diabetes care (2022). PMID: 35699949 ↗
L2OTHERCited in: Epidemiology, Etiology and Risk Factors, History and Evolution of Treatment, Complications and Long-term Sequelae - [68]
Tamer G, Arik S, Tamer I et al.. “Relative vitamin D insufficiency in Hashimoto's thyroiditis.” Thyroid : official journal of the American Thyroid Association (2011). PMID: 21751884 ↗
L3OTHERCited in: Epidemiology, Etiology and Risk Factors - [69]
Denzer C, Karges B, Näke A et al.. “Subclinical hypothyroidism and dyslipidemia in children and adolescents with type 1 diabetes mellitus.” European journal of endocrinology (2013). PMID: 23384709 ↗
L4OTHERCited in: Epidemiology, Etiology and Risk Factors, Complications and Long-term Sequelae - [70]
Sahakyan K, Klein BE, Lee KE et al.. “Inflammatory and endothelial dysfunction markers and proteinuria in persons with type 1 diabetes mellitus.” European journal of endocrinology (2010). PMID: 20332124 ↗
L2OTHERCited in: Epidemiology, Etiology and Risk Factors - [71]
Chantzichristos D, Persson A, Eliasson B et al.. “Incidence, prevalence and seasonal onset variation of Addison's disease among persons with type 1 diabetes mellitus: nationwide, matched cohort studies.” European journal of endocrinology (2017). PMID: 29066573 ↗
L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [72]
Okosieme OE, Wijeyaratne CN, Lazarus JH et al.. “Restricted thyroglobulin antibody epitope specificities in subjects with type 1 diabetes mellitus.” European journal of endocrinology (2009). PMID: 19561043 ↗
L4OTHERCited in: Epidemiology, Etiology and Risk Factors - [73]
Pappa A, Koromantzos P, Seremidi K et al.. “Dental caries and periodontal status in children and adolescents with type 1 diabetes mellitus: an umbrella review.” European archives of paediatric dentistry : official journal of the European Academy of Paediatric Dentistry (2026). PMID: 42270944 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors - [74]
Anesini MB, Pinto M, Bellezza M et al.. “Intentional Insulin Omission (Diabulimia) in Patients with Insulin-Dependent Diabetes: An Eating Disorder? A Systematic Review.” Journal of clinical medicine (2026). PMID: 42123251 ↗
L5SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [75]
Shao MM, Scheideman AF, Zhou AM et al.. “Accuracy of glutamic acid decarboxylase antibodies for the identification of adult-onset type 1 diabetes mellitus: a systematic review and meta-analysis.” Frontiers in endocrinology (2026). PMID: 41987896 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [76]
Di Gialleonardo V, de Vries EF, Di Girolamo M et al.. “Imaging of β-cell mass and insulitis in insulin-dependent (Type 1) diabetes mellitus.” Endocrine reviews (2012). PMID: 22889646 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Prognosis, Natural History, Special Populations and Prevention - [77]
Mackay L, Kilbride L, Adamson KA et al.. “Hormone replacement therapy for women with type 1 diabetes mellitus.” The Cochrane database of systematic reviews (2013). PMID: 23744560 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [78]
Visser J, Snel M, Van Vliet HA. “Hormonal versus non-hormonal contraceptives in women with diabetes mellitus type 1 and 2.” The Cochrane database of systematic reviews (2013). PMID: 23543528 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [79]
Visser J, Snel M, Van Vliet HA. “Hormonal versus non-hormonal contraceptives in women with diabetes mellitus type 1 and 2.” The Cochrane database of systematic reviews (2006). PMID: 17054193 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [80]
Callaghan BC, Little AA, Feldman EL et al.. “Enhanced glucose control for preventing and treating diabetic neuropathy.” The Cochrane database of systematic reviews (2012). PMID: 22696371 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Prognosis, Natural History, Special Populations and Prevention - [81]
Montero N, Webster AC, Royuela A et al.. “Steroid avoidance or withdrawal for pancreas and pancreas with kidney transplant recipients.” The Cochrane database of systematic reviews (2014). PMID: 25220222 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Acute Management and Endocrine Emergencies, Prognosis, Natural History, Special Populations and Prevention - [82]
Ul-Haq I, Alqahtani HS, Shaheen NA et al.. “Incidence and Risk Factors of Diabetic Retinopathy in Patients with Type 1 Diabetes Mellitus: A Retrospective Study in NGHA, Riyadh, Saudi Arabia.” Journal of clinical medicine (2026). PMID: 42194771 ↗
L3COHORTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Prognosis, Natural History, Special Populations and Prevention - [83]
Singh M, Subramanian A, Wambua S et al.. “Autoimmune diseases and risk of adverse pregnancy outcomes: a population-based cohort study of five million pregnancies in the UK.” BMC medicine (2026). PMID: 42169116 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History, Special Populations and Prevention - [84]
Gatira DN, Getnet M, Liyew B et al.. “Incidence and predictors of diabetic ketoacidosis among adults with type 1 diabetes in Northwest, Ethiopia, 2023: a retrospective cohort study.” BMC public health (2026). PMID: 41957727 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Acute Management and Endocrine Emergencies, History and Evolution of Treatment, Complications and Long-term Sequelae - [85]
Halpern B, Nery M, Pereira MAA. “Case Report of Acquired Generalized Lipodystrophy Associated With Common Variable Immunodeficiency.” The Journal of clinical endocrinology and metabolism (2018). PMID: 29846625 ↗
L4CASE_REPORTCited in: Clinical Presentation - [86]
Aly HH, Fouda EM, Kotby AA et al.. “COVID-19-Related Multisystem Inflammatory Syndrome in Children Presenting With New-Onset Type 1 Diabetes in Severe Ketoacidosis: A Case Series.” Diabetes care (2022). PMID: 35113159 ↗
L4CASE_REPORTCited in: Clinical Presentation, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History, Special Populations and Prevention - [87]
Dunn A, Lam A, Hidalgo L et al.. “Autoimmune Thyroid Disease in Islet Transplant Recipients Discontinuing Immunosuppression Late After Lymphodepletion.” The Journal of clinical endocrinology and metabolism (2019). PMID: 30398662 ↗
L4OTHERCited in: Clinical Presentation - [88]
Schreiner F, Plamper M, Dueker G et al.. “Infancy-Onset T1DM, Short Stature, and Severe Immunodysregulation in Two Siblings With a Homozygous LRBA Mutation.” The Journal of clinical endocrinology and metabolism (2016). PMID: 26745254 ↗
L4OTHERCited in: Clinical Presentation - [89]
Johnson SR, Carter HE, Leo P et al.. “Cost-effectiveness Analysis of Routine Screening Using Massively Parallel Sequencing for Maturity-Onset Diabetes of the Young in a Pediatric Diabetes Cohort: Reduced Health System Costs and Improved Patient Quality of Life.” Diabetes care (2018). PMID: 30523035 ↗
L2OTHERCited in: Clinical Presentation, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [90]
Tsai EB, Sherry NA, Palmer JP et al.. “The rise and fall of insulin secretion in type 1 diabetes mellitus.” Diabetologia (2006). PMID: 16404554 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, History and Evolution of Treatment, Prognosis, Natural History, Special Populations and Prevention - [91]
Aparna KV, Darshan M, Kulkarni A et al.. “Emphysematous pyelonephritis in children: Lessons from a case report and systematic review.” Journal of pediatric urology (2026). PMID: 42285016 ↗
L4SR_OBSCited in: Clinical Presentation, Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [92]
Alqahtani YA, Shati AA, Alshaikh AA et al.. “Prevalence and Recovery of Euthyroid Sick Syndrome in Pediatric Diabetic Ketoacidosis: A Retrospective Cohort Study.” Children (Basel, Switzerland) (2026). PMID: 41749652 ↗
L2COHORTCited in: Clinical Presentation, Severity, Staging and Risk Stratification, Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [93]
Li X, Zhang X, Dai X et al.. “Proliferative glomerulonephritis with monoclonal immunoglobulin IgG1-κ deposition in a patient with type 1 diabetes: a case report and literature review.” Frontiers in medicine (2026). PMID: 42375207 ↗
L4CASE_REPORTCited in: Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [94]
Bai H, Yu J, Wang T et al.. “Case Report: A novel likely pathogenic GCK variant in a young Chinese girl with severe insulin resistance.” Frontiers in endocrinology (2026). PMID: 42137361 ↗
L4CASE_REPORTCited in: Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [95]
Liu S, Cao C, Wang X. “Autoimmune polyglandular syndrome type 1 with compound heterozygous AIRE gene pathogenic variants and stage 1 type 1 diabetes mellitus: case report and literature review of Chinese population.” Frontiers in immunology (2026). PMID: 41993177 ↗
L4CASE_REPORTCited in: Clinical Presentation, History and Evolution of Treatment - [96]
Valdivia Camacho OD, Allison T, Wilson LB et al.. “Pediatric Cataracts as a Presenting Sign of Type 1 Diabetes Mellitus.” The Journal of pediatrics (2025). PMID: 40945580 ↗
L4CASE_REPORTCited in: Clinical Presentation - [97]
Maruyama T, Tanaka S, Shimada A et al.. “Insulin intervention in slowly progressive insulin-dependent (type 1) diabetes mellitus.” The Journal of clinical endocrinology and metabolism (2008). PMID: 18397986 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, History and Evolution of Treatment - [98]
Matejko B, Juza A, Kieć-Wilk B et al.. “Transitioning of People With Type 1 Diabetes From Multiple Daily Injections and Self-Monitoring of Blood Glucose Directly to MiniMed 780G Advanced Hybrid Closed-Loop System: A Two-Center, Randomized, Controlled Study.” Diabetes care (2022). PMID: 35972259 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment - [99]
Luijf YM, DeVries JH, Zwinderman K et al.. “Day and night closed-loop control in adults with type 1 diabetes: a comparison of two closed-loop algorithms driving continuous subcutaneous insulin infusion versus patient self-management.” Diabetes care (2013). PMID: 24170747 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment - [100]
Ma X, Xie Z, Qin J et al.. “Association of Vitamin D Pathway Gene CYP27B1 and CYP2R1 Polymorphisms with Autoimmune Endocrine Disorders: A Meta-Analysis.” The Journal of clinical endocrinology and metabolism (2020). PMID: 32915988 ↗
L3SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [101]
Ludvigsson J, Faresjö M, Hjorth M et al.. “GAD treatment and insulin secretion in recent-onset type 1 diabetes.” The New England journal of medicine (2008). PMID: 18843118 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment - [102]
Tamborlane WV, Beck RW, Bode BW et al.. “Continuous glucose monitoring and intensive treatment of type 1 diabetes.” The New England journal of medicine (2008). PMID: 18779236 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment - [103]
Ludvigsson J, Krisky D, Casas R et al.. “GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus.” The New England journal of medicine (2012). PMID: 22296077 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment - [104]
Zhong VW, Juhaeri J, Mayer-Davis EJ. “Trends in Hospital Admission for Diabetic Ketoacidosis in Adults With Type 1 and Type 2 Diabetes in England, 1998-2013: A Retrospective Cohort Study.” Diabetes care (2018). PMID: 29386248 ↗
L2COHORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae - [105]
Szypowska A, Ramotowska A, Dzygalo K et al.. “Beneficial effect of real-time continuous glucose monitoring system on glycemic control in type 1 diabetic patients: systematic review and meta-analysis of randomized trials.” European journal of endocrinology (2011). PMID: 22096111 ↗
L1SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Prognosis, Natural History, Special Populations and Prevention - [106]
Teo E, Hassan N, Tam W et al.. “Effectiveness of continuous glucose monitoring in maintaining glycaemic control among people with type 1 diabetes mellitus: a systematic review of randomised controlled trials and meta-analysis.” Diabetologia (2022). PMID: 35141761 ↗
L1SR_MA_RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Acute Management and Endocrine Emergencies - [107]
Orban T, Bundy B, Becker DJ et al.. “Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial.” Lancet (London, England) (2011). PMID: 21719096 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment - [108]
Schultz ANØ, Christensen R, Bollig G et al.. “Effectiveness of video consultations in type 1 diabetes patients treated with insulin pumps in the outpatient clinic: a randomised controlled trial.” Diabetologia (2025). PMID: 41198916 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment - [109]
Benhalima K, van Nes F, Laenen A et al.. “Risk for ketonaemia in type 1 diabetes pregnancies with sensor-augmented pump therapy with predictive low glucose suspend compared with low glucose suspend: a crossover RCT.” Diabetologia (2021). PMID: 34647140 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Prognosis, Natural History, Special Populations and Prevention - [110]
Gejl M, Gjedde A, Brock B et al.. “Effects of hypoglycaemia on working memory and regional cerebral blood flow in type 1 diabetes: a randomised, crossover trial.” Diabetologia (2017). PMID: 29188338 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, History and Evolution of Treatment - [111]
Golicki DT, Golicka D, Groele L et al.. “Continuous Glucose Monitoring System in children with type 1 diabetes mellitus: a systematic review and meta-analysis.” Diabetologia (2007). PMID: 18060380 ↗
L1SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [112]
Goldacre RR. “Associations between birthweight, gestational age at birth and subsequent type 1 diabetes in children under 12: a retrospective cohort study in England, 1998-2012.” Diabetologia (2017). PMID: 29128935 ↗
L2COHORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [113]
De Meulemeester J, Keymeulen B, De Block C et al.. “One-year real-world benefits of Tandem Control-IQ technology on glucose management and person-reported outcomes in adults with type 1 diabetes: a prospective observational cohort study.” Diabetologia (2025). PMID: 39934368 ↗
L2COHORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment - [114]
Yapanis M, James S, Craig ME et al.. “Complications of Diabetes and Metrics of Glycemic Management Derived From Continuous Glucose Monitoring.” The Journal of clinical endocrinology and metabolism (2022). PMID: 35094087 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [115]
Shalimova A, Graff B, Gąsecki D et al.. “Cognitive Dysfunction in Type 1 Diabetes Mellitus.” The Journal of clinical endocrinology and metabolism (2019). PMID: 30657922 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Complications and Long-term Sequelae - [116]
Prinz N, Tittel SR, Bachran R et al.. “Characteristics of Patients with Type 1 Diabetes and Additional Autoimmune Disease in the DPV Registry.” The Journal of clinical endocrinology and metabolism (2021). PMID: 34061946 ↗
L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [117]
Wang Y, Qin Y, Gu H et al.. “High Residual β-cell Function in Chinese Patients With Autoimmune Type 1 Diabetes.” The Journal of clinical endocrinology and metabolism (2022). PMID: 35218654 ↗
L4OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies - [118]
Menon JC, Singh P, Archana A et al.. “High Frequency of Recessive WFS1 Mutations Among Indian Children With Islet Antibody-negative Type 1 Diabetes.” The Journal of clinical endocrinology and metabolism (2024). PMID: 37931151 ↗
L3OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [119]
Ling P, Yang D, Wang C et al.. “Basal Hyperglycemia Contributes More Than 50% to Time in Range in Pregnant Women With Type 1 Diabetes.” The Journal of clinical endocrinology and metabolism (2024). PMID: 38686666 ↗
L4OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [120]
Demmer RT, Holtfreter B, Desvarieux M et al.. “The influence of type 1 and type 2 diabetes on periodontal disease progression: prospective results from the Study of Health in Pomerania (SHIP).” Diabetes care (2012). PMID: 22855731 ↗
L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [121]
Barrett CE, Park J, Kompaniyets L et al.. “Intensive Care Unit Admission, Mechanical Ventilation, and Mortality Among Patients With Type 1 Diabetes Hospitalized for COVID-19 in the U.S.” Diabetes care (2021). PMID: 34158365 ↗
L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [122]
Epstein EJ, Osman JL, Cohen HW et al.. “Use of the estimated glucose disposal rate as a measure of insulin resistance in an urban multiethnic population with type 1 diabetes.” Diabetes care (2013). PMID: 23596179 ↗
L4OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [123]
Scheuing N, Bartus B, Berger G et al.. “Clinical characteristics and outcome of 467 patients with a clinically recognized eating disorder identified among 52,215 patients with type 1 diabetes: a multicenter german/austrian study.” Diabetes care (2014). PMID: 24623022 ↗
L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies - [124]
van Elderen SG, Brandts A, van der Grond J et al.. “Cerebral perfusion and aortic stiffness are independent predictors of white matter brain atrophy in type 1 diabetic patients assessed with magnetic resonance imaging.” Diabetes care (2011). PMID: 21216862 ↗
L3OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [125]
Lundgaard AT, Westergaard D, Röder T et al.. “Longitudinal metabolite and protein trajectories prior to diabetes mellitus diagnosis in Danish blood donors: a nested case-control study.” Diabetologia (2024). PMID: 39078488 ↗
L3CASE_CONTROLCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [126]
Aleksova J, Ebeling PR, Milat F et al.. “DXA-derived advanced hip analysis and the trabecular bone score in end-stage kidney disease secondary to type 1 diabetes.” European journal of endocrinology (2022). PMID: 36315195 ↗
L3OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [127]
Martos-Moreno GA, Barrios V, Soriano-Guillén L et al.. “Relationship between adiponectin levels, acylated ghrelin levels, and short-term body mass index changes in children with diabetes mellitus type 1 at diagnosis and after insulin therapy.” European journal of endocrinology (2006). PMID: 17062893 ↗
L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [128]
Faccinetti NI, Guerra LL, Penas Steinhardt A et al.. “Characterization of zinc transporter 8 (ZnT8) antibodies in autoimmune diabetic patients from Argentinian population using monomeric, homodimeric, and heterodimeric ZnT8 antigen variants.” European journal of endocrinology (2015). PMID: 26567119 ↗
L3OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [129]
Rogowicz-Frontczak A, Zozuliłska-Ziołkiewicz D, Litwinowicz M et al.. “Are zinc transporter type 8 antibodies a marker of autoimmune thyroiditis in non-obese adults with new-onset diabetes?” European journal of endocrinology (2014). PMID: 24480135 ↗
L3OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Prognosis, Natural History, Special Populations and Prevention - [130]
Krassas GE, Tziomalos K, Pontikides N et al.. “Seasonality of month of birth of patients with Graves' and Hashimoto's diseases differ from that in the general population.” European journal of endocrinology (2007). PMID: 17535862 ↗
L3OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [131]
Lin Q, Zhou Y, Lei M et al.. “Efficacy and safety of automated insulin delivery system in very young children with type 1 diabetes: A systematic review and meta-analysis of randomized controlled trials.” Diabetic medicine : a journal of the British Diabetic Association (2026). PMID: 42108409 ↗
L1SR_MA_RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies - [132]
Murray JA, Husby S. “Celiac Disease.” The New England journal of medicine (2026). PMID: 41950475 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [133]
Langendam M, Luijf YM, Hooft L et al.. “Continuous glucose monitoring systems for type 1 diabetes mellitus.” The Cochrane database of systematic reviews (2012). PMID: 22258980 ↗
L1SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [134]
Clar C, Waugh N, Thomas S. “Routine hospital admission versus out-patient or home care in children at diagnosis of type 1 diabetes mellitus.” The Cochrane database of systematic reviews (2007). PMID: 17443539 ↗
L1SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies - [135]
Mărgineanu C, Usatiuc LO, Sur ML et al.. “The Bidirectional Relationship Between Type 1 Diabetes Mellitus and Obesity in Pediatric Patients: A Systematic Review.” Children (Basel, Switzerland) (2026). PMID: 42353914 ↗
L2SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [136]
Ma IH, Huang WL, Liu YL et al.. “Early Retinal Changes Detected Using Optical Coherence Tomography Angiography in Youth with Type 1 Diabetes Mellitus: A Case-Control Study.” Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde (2026). PMID: 41984745 ↗
L3CASE_CONTROLCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [137]
Harada K, Okazaki Y, Ichiba T. “Prehospital identification of hypoglycemia-induced seizure using a smartphone-linked continuous glucose monitoring application.” The American journal of emergency medicine (2026). PMID: 42119276 ↗
L4CASE_REPORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [138]
Jiang Y, Cui Y, Su D et al.. “Immune checkpoint inhibitor-associated diabetic ketoacidosis induced by cadonilimab: a case report and literature review.” Frontiers in endocrinology (2026). PMID: 42058780 ↗
L4CASE_REPORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, History and Evolution of Treatment - [139]
Wherrett DK, Bundy B, Becker DJ et al.. “Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial.” Lancet (London, England) (2011). PMID: 21714999 ↗
L1RCTCited in: Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment - [140]
Shao W, Yang K, Lu D et al.. “Endocrine Adverse Reactions of Tyrosine Kinase Inhibitors in Combination With Immune Checkpoint Inhibitors.” The Journal of clinical endocrinology and metabolism (2025). PMID: 39986331 ↗
L3OTHERCited in: Severity, Staging and Risk Stratification - [141]
Antonoglou G, Knuuttila M, Niemelä O et al.. “Serum 1,25(OH)D level increases after elimination of periodontal inflammation in T1DM subjects.” The Journal of clinical endocrinology and metabolism (2013). PMID: 23940127 ↗
L2OTHERCited in: Severity, Staging and Risk Stratification - [142]
Mistry S, Gouripeddi R, Raman V et al.. “Stratifying risk for onset of type 1 diabetes using islet autoantibody trajectory clustering.” Diabetologia (2022). PMID: 36446887 ↗
L2OTHERCited in: Severity, Staging and Risk Stratification, Prognosis, Natural History, Special Populations and Prevention - [143]
Liu GC, Fang F, Zhou J et al.. “Deletion of p47phox attenuates the progression of diabetic nephropathy and reduces the severity of diabetes in the Akita mouse.” Diabetologia (2012). PMID: 22653270 ↗
L5OTHERCited in: Severity, Staging and Risk Stratification - [144]
Broe R, Rasmussen ML, Frydkjaer-Olsen U et al.. “Retinal vascular fractals predict long-term microvascular complications in type 1 diabetes mellitus: the Danish Cohort of Pediatric Diabetes 1987 (DCPD1987).” Diabetologia (2014). PMID: 24981770 ↗
L2OTHERCited in: Severity, Staging and Risk Stratification - [145]
Yılmaz UC, Kızılay DÖ, Kurt ÖK et al.. “Autoantibody screening in children who are first-degree relatives of individuals with type 1 diabetes in a sibling-dominant cohort in Turkey: a multicentre study on prevalence, determinants and post-screening parent-child anxiety.” Diabetologia (2026). PMID: 42350669 ↗
L4OTHERCited in: Severity, Staging and Risk Stratification, Acute Management and Endocrine Emergencies - [146]
Idrees H, Memon F, Alam R et al.. “Systematic Review and Meta-Analysis of Insulin Dose and Route of Administration Regimens for Diabetic Ketoacidosis in Children and Adolescents.” Journal of clinical medicine (2025). PMID: 41227190 ↗
L1SR_OBSCited in: Severity, Staging and Risk Stratification - [147]
Fullerton B, Siebenhofer A, Jeitler K et al.. “Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus.” The Cochrane database of systematic reviews (2016). PMID: 27362975 ↗
L1SR_OBSCited in: Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [148]
Fullerton B, Jeitler K, Seitz M et al.. “Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus.” The Cochrane database of systematic reviews (2014). PMID: 24526393 ↗
L1SR_OBSCited in: Severity, Staging and Risk Stratification, Acute Management and Endocrine Emergencies - [149]
Zhang Q, Saad SH, Zhou H et al.. “Development and validation of an interpretable machine learning model for predicting in-hospital hypoglycemia in adults with type 1 diabetes mellitus: a multicenter retrospective study.” Frontiers in endocrinology (2026). PMID: 42095183 ↗
L2COHORTCited in: Severity, Staging and Risk Stratification - [150]
Wang S, Zhang Y, Balati A et al.. “Effect of Sodium-glucose Transporter 2 Inhibitors on Cardiovascular Outcomes in Type 1 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials.” The Journal of clinical endocrinology and metabolism (2025). PMID: 39812177 ↗
L1SR_MA_RCTCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [151]
Cherney DZ, Reich HN, Scholey JW et al.. “The effect of aliskiren on urinary cytokine/chemokine responses to clamped hyperglycaemia in type 1 diabetes.” Diabetologia (2013). PMID: 23893332 ↗
L2TRIAL_NONRANDOMCited in: Acute Management and Endocrine Emergencies - [152]
Marzuillo P, Iafusco D, Zanfardino A et al.. “Acute Kidney Injury and Renal Tubular Damage in Children With Type 1 Diabetes Mellitus Onset.” The Journal of clinical endocrinology and metabolism (2021). PMID: 33595665 ↗
L2OTHERCited in: Acute Management and Endocrine Emergencies - [153]
Dugan CW, Maloney SK, Abramoff KJ et al.. “Effects of Simulated High Altitude on Blood Glucose Levels During Exercise in Individuals With Type 1 Diabetes.” The Journal of clinical endocrinology and metabolism (2022). PMID: 34935935 ↗
L1OTHERCited in: Acute Management and Endocrine Emergencies - [154]
Owens LA, Avalos G, Kirwan B et al.. “ATLANTIC DIP: closing the loop: a change in clinical practice can improve outcomes for women with pregestational diabetes.” Diabetes care (2012). PMID: 22826448 ↗
L2OTHERCited in: Acute Management and Endocrine Emergencies - [155]
Goedendorp MM, Tack CJ, Steggink E et al.. “Chronic fatigue in type 1 diabetes: highly prevalent but not explained by hyperglycemia or glucose variability.” Diabetes care (2013). PMID: 23949561 ↗
L3OTHERCited in: Acute Management and Endocrine Emergencies - [156]
Tsujimoto T, Yamamoto-Honda R, Kajio H et al.. “Vital signs, QT prolongation, and newly diagnosed cardiovascular disease during severe hypoglycemia in type 1 and type 2 diabetic patients.” Diabetes care (2013). PMID: 23939540 ↗
L2OTHERCited in: Acute Management and Endocrine Emergencies - [157]
Chantzichristos D, Eliasson B, Johannsson G. “MANAGEMENT OF ENDOCRINE DISEASE Disease burden and treatment challenges in patients with both Addison's disease and type 1 diabetes mellitus.” European journal of endocrinology (2020). PMID: 32299062 ↗
L5REVIEW_NARRATIVECited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [158]
Barchetta I, Alessandri C, Bertoccini L et al.. “Increased circulating osteopontin levels in adult patients with type 1 diabetes mellitus and association with dysmetabolic profile.” European journal of endocrinology (2015). PMID: 26578639 ↗
L3OTHERCited in: Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [159]
Ishida-Oku M, Iwase M, Sugitani A et al.. “A case of recurrent type 1 diabetes mellitus with insulitis of transplanted pancreas in simultaneous pancreas-kidney transplantation from cardiac death donor.” Diabetologia (2009). PMID: 19911164 ↗
L4CASE_REPORTCited in: Acute Management and Endocrine Emergencies - [160]
Assogba FG, Couchoud C, Hannedouche T et al.. “Trends in the epidemiology and care of diabetes mellitus-related end-stage renal disease in France, 2007-2011.” Diabetologia (2014). PMID: 24496924 ↗
L2OTHERCited in: Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae - [161]
Beulens JW, Kruidhof JS, Grobbee DE et al.. “Alcohol consumption and risk of microvascular complications in type 1 diabetes patients: the EURODIAB Prospective Complications Study.” Diabetologia (2008). PMID: 18626626 ↗
L2OTHERCited in: Acute Management and Endocrine Emergencies - [162]
Gomes JAF, Vasconcelos AR, Nascimento Júnior JRAD et al.. “Perceived Exertion Is Associated with Cardiovascular Strain but Not Glycemic Response to Gym-Based Exercise in Adults with Type 1 Diabetes: An Exploratory Randomized Crossover Trial.” International journal of environmental research and public health (2026). PMID: 42354343 ↗
L1RCTCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae - [163]
Mitchell S, Patwardhan K, Lucocq J et al.. “Metabolic and bariatric surgery for patients with obesity type 1 diabetes mellitus: A comprehensive updated systematic review and meta-analysis.” Diabetic medicine : a journal of the British Diabetic Association (2026). PMID: 41904365 ↗
L1SR_OBSCited in: Acute Management and Endocrine Emergencies - [164]
Guo Y, Mei Y, Bongaerts B et al.. “(Ultra-)short-acting insulin analogues for adults with type 1 diabetes mellitus on multiple daily injections: a network meta-analysis.” The Cochrane database of systematic reviews (2026). PMID: 42318853 ↗
L1SR_OBSCited in: Acute Management and Endocrine Emergencies - [165]
Skott E, Cai W, Stiernborg M et al.. “Associations of prenatal exposure to maternal autoimmune disorders with a wide spectrum of psychiatric and neurodevelopmental disorders in offspring-a nationwide cohort study.” Human reproduction open (2026). PMID: 42077501 ↗
L2COHORTCited in: Acute Management and Endocrine Emergencies, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History, Special Populations and Prevention - [166]
Kim JY, Kim S, Kim JH. “Association between Continuous Glucose Monitoring and Risk of Acute Diabetes-Related Complications in Pediatric Type 1 Diabetes Mellitus: A Nationwide Cohort Study.” Diabetes & metabolism journal (2026). PMID: 42014052 ↗
L2COHORTCited in: Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae - [167]
Kang YM, Giugliano RP, Ran X et al.. “Cardiovascular Outcomes and Efficacy of the PCSK9 Inhibitor Evolocumab in Individuals With Type 1 Diabetes: Insights From the FOURIER Trial.” Diabetes care (2025). PMID: 40544474 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae - [168]
Ruiz de Adana MS, Alhambra-Expósito MR, Muñoz-Garach A et al.. “Randomized Study to Evaluate the Impact of Telemedicine Care in Patients With Type 1 Diabetes With Multiple Doses of Insulin and Suboptimal HbA1c in Andalusia (Spain): PLATEDIAN Study.” Diabetes care (2019). PMID: 31831473 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment - [169]
Porcellati F, Lucidi P, Candeloro P et al.. “Pharmacokinetics, Pharmacodynamics, and Modulation of Hepatic Glucose Production With Insulin Glargine U300 and Glargine U100 at Steady State With Individualized Clinical Doses in Type 1 Diabetes.” Diabetes care (2018). PMID: 30305345 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment - [170]
Rys PM, Ludwig-Slomczynska AH, Cyganek K et al.. “Continuous subcutaneous insulin infusion vs multiple daily injections in pregnant women with type 1 diabetes mellitus: a systematic review and meta-analysis of randomised controlled trials and observational studies.” European journal of endocrinology (2018). PMID: 29545258 ↗
L1SR_MA_RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [171]
Ocheltree SM, Hompesch M, Wondmagegnehu ET et al.. “Comparison of pharmacodynamic intrasubject variability of insulin lispro protamine suspension and insulin glargine in subjects with type 1 diabetes.” European journal of endocrinology (2010). PMID: 20508081 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment - [172]
Del Favero S, Bruttomesso D, Di Palma F et al.. “First use of model predictive control in outpatient wearable artificial pancreas.” Diabetes care (2014). PMID: 24757228 ↗
L4TRIAL_NONRANDOMCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [173]
Park J, Ntelis S, Yunasan E et al.. “Glucagon-Like Peptide 1 Analogues as Adjunctive Therapy for Patients With Type 1 Diabetes: An Updated Systematic Review and Meta-analysis.” The Journal of clinical endocrinology and metabolism (2023). PMID: 37561012 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [174]
Bergenstal RM, Tamborlane WV, Ahmann A et al.. “Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes.” The New England journal of medicine (2010). PMID: 20587585 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment - [175]
Russell SJ, El-Khatib FH, Sinha M et al.. “Outpatient glycemic control with a bionic pancreas in type 1 diabetes.” The New England journal of medicine (2014). PMID: 24931572 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment - [176]
Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H et al.. “Rituximab, B-lymphocyte depletion, and preservation of beta-cell function.” The New England journal of medicine (2009). PMID: 19940299 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment - [177]
Osipova J, Fischer DC, Dangwal S et al.. “Diabetes-associated microRNAs in pediatric patients with type 1 diabetes mellitus: a cross-sectional cohort study.” The Journal of clinical endocrinology and metabolism (2014). PMID: 24937532 ↗
L4COHORTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History, Special Populations and Prevention - [178]
Heller S, Buse J, Fisher M et al.. “Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial.” Lancet (London, England) (2012). PMID: 22521071 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Complications and Long-term Sequelae - [179]
Beam CA, MacCallum C, Herold KC et al.. “GAD vaccine reduces insulin loss in recently diagnosed type 1 diabetes: findings from a Bayesian meta-analysis.” Diabetologia (2016). PMID: 27704166 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [180]
Thorius IH, Husemoen LLN, Nordsborg RB et al.. “Congenital malformations among offspring of women with type 1 diabetes who use insulin pumps: a prospective cohort study.” Diabetologia (2023). PMID: 36640191 ↗
L2COHORTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [181]
Al-Naseem AO, Attia A, Gonnah AR et al.. “Pancreas transplantation today: quo vadis?” European journal of endocrinology (2023). PMID: 36929837 ↗
L5REVIEW_NARRATIVECited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [182]
Wiegand S, Raile K, Reinehr T et al.. “Daily insulin requirement of children and adolescents with type 1 diabetes: effect of age, gender, body mass index and mode of therapy.” European journal of endocrinology (2008). PMID: 18362302 ↗
L2OTHERCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [183]
Moser O, Becker U, van den Boom L et al.. “[Automated insulin delivery (AID) systems, physical activity and sports in type 1 diabetes mellitus: joint guidelines of the DDG and ÖDG].” Wiener klinische Wochenschrift (2026). PMID: 42162485 ↗
L1GUIDELINECited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment, Prognosis, Natural History, Special Populations and Prevention - [184]
Amaral R, Costa B, Penedones A et al.. “Efficacy and Safety of Once-Weekly and Once-Daily Basal Insulins in Type 1 Diabetes Mellitus: A Systematic Review and Network Meta-Analysis of Clinical Trials.” Diabetes, obesity & metabolism (2026). PMID: 42225295 ↗
L1TRIAL_NONRANDOMCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [185]
Bellin MD, Dunn TB. “Transplant strategies for type 1 diabetes: whole pancreas, islet and porcine beta cell therapies.” Diabetologia (2020). PMID: 32894315 ↗
L5REVIEW_NARRATIVECited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [186]
Tamahane V, Shah N, Kajale N et al.. “Effect of prebiotic intervention on glycemic control and gut microbiome profile in Indian children with type 1 diabetes mellitus (T1DM): a pilot randomised control trial.” Endocrine (2026). PMID: 42165942 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), History and Evolution of Treatment - [187]
Campbell F, Biggs K, Aldiss SK et al.. “Transition of care for adolescents from paediatric services to adult health services.” The Cochrane database of systematic reviews (2016). PMID: 27128768 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [188]
Abdelghaffar S, Attia AM. “Metformin added to insulin therapy for type 1 diabetes mellitus in adolescents.” The Cochrane database of systematic reviews (2009). PMID: 19160294 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [189]
Hemmingsen B, Metzendorf MI, Richter B. “(Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.” The Cochrane database of systematic reviews (2021). PMID: 33662147 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [190]
Vardi M, Jacobson E, Nini A et al.. “Intermediate acting versus long acting insulin for type 1 diabetes mellitus.” The Cochrane database of systematic reviews (2008). PMID: 18646147 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [191]
Misso ML, Egberts KJ, Page M et al.. “Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus.” The Cochrane database of systematic reviews (2010). PMID: 20091571 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [192]
Copur S, Mizrak B, Ozbek L et al.. “Once-Weekly Subcutaneous Insulin Efsitora for the Management of Diabetes Mellitus: A Systematic Review and Meta-Analysis Study.” Medeniyet medical journal (2026). PMID: 42383405 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [193]
Toghi-Eshghi SR, Yardley JE. “Morning (Fasting) vs Afternoon Resistance Exercise in Individuals With Type 1 Diabetes: A Randomized Crossover Study.” The Journal of clinical endocrinology and metabolism (2019). PMID: 31211392 ↗
L1RCTCited in: History and Evolution of Treatment - [194]
Parthasarathy G, Kudva YC, Low PA et al.. “Relationship Between Gastric Emptying and Diurnal Glycemic Control in Type 1 Diabetes Mellitus: A Randomized Trial.” The Journal of clinical endocrinology and metabolism (2017). PMID: 27880079 ↗
L1RCTCited in: History and Evolution of Treatment - [195]
Haider DG, Pleiner J, Francesconi M et al.. “Exercise training lowers plasma visfatin concentrations in patients with type 1 diabetes.” The Journal of clinical endocrinology and metabolism (2006). PMID: 16895956 ↗
L4RCTCited in: History and Evolution of Treatment - [196]
Sarem Z, Bumke-Vogt C, Mahmoud AM et al.. “Glucagon Decreases IGF-1 Bioactivity in Humans, Independently of Insulin, by Modulating Its Binding Proteins.” The Journal of clinical endocrinology and metabolism (2017). PMID: 28911141 ↗
L1RCTCited in: History and Evolution of Treatment - [197]
Crowne EC, Samra JS, Cheetham T et al.. “The role of IGF-binding proteins in mediating the effects of recombinant human IGF-I on insulin requirements in type 1 diabetes mellitus.” The Journal of clinical endocrinology and metabolism (2001). PMID: 11502796 ↗
L1RCTCited in: History and Evolution of Treatment - [198]
Griffen SC, Oostema K, Stanhope KL et al.. “Administration of Lispro insulin with meals improves glycemic control, increases circulating leptin, and suppresses ghrelin, compared with regular/NPH insulin in female patients with type 1 diabetes.” The Journal of clinical endocrinology and metabolism (2005). PMID: 16317063 ↗
L1RCTCited in: History and Evolution of Treatment - [199]
Herold KC, Hagopian W, Auger JA et al.. “Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.” The New England journal of medicine (2002). PMID: 12037148 ↗
L1RCTCited in: History and Evolution of Treatment - [200]
. “Effects of insulin in relatives of patients with type 1 diabetes mellitus.” The New England journal of medicine (2002). PMID: 12037147 ↗
L1RCTCited in: History and Evolution of Treatment - [201]
Nathan DM, Lachin J, Cleary P et al.. “Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus.” The New England journal of medicine (2003). PMID: 12788993 ↗
L2RCTCited in: History and Evolution of Treatment - [202]
Keymeulen B, Vandemeulebroucke E, Ziegler AG et al.. “Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.” The New England journal of medicine (2005). PMID: 15972866 ↗
L1RCTCited in: History and Evolution of Treatment - [203]
Skyler JS, Cefalu WT, Kourides IA et al.. “Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study.” Lancet (London, England) (2001). PMID: 11210993 ↗
L1RCTCited in: History and Evolution of Treatment - [204]
Shapiro AM, Lakey JR, Ryan EA et al.. “Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen.” The New England journal of medicine (2000). PMID: 10911004 ↗
L4TRIAL_NONRANDOMCited in: History and Evolution of Treatment - [205]
Bally L, Zueger T, Buehler T et al.. “Metabolic and hormonal response to intermittent high-intensity and continuous moderate intensity exercise in individuals with type 1 diabetes: a randomised crossover study.” Diabetologia (2016). PMID: 26739816 ↗
L1RCTCited in: History and Evolution of Treatment - [206]
Ang M, Meyer C, Brendel MD et al.. “Magnitude and mechanisms of glucose counterregulation following islet transplantation in patients with type 1 diabetes suffering from severe hypoglycaemic episodes.” Diabetologia (2013). PMID: 24305963 ↗
L3RCTCited in: History and Evolution of Treatment - [207]
Garg S, Rosenstock J, Silverman BL et al.. “Efficacy and safety of preprandial human insulin inhalation powder versus injectable insulin in patients with type 1 diabetes.” Diabetologia (2006). PMID: 16506054 ↗
L1RCTCited in: History and Evolution of Treatment - [208]
Davison GW, Ashton T, George L et al.. “Molecular detection of exercise-induced free radicals following ascorbate prophylaxis in type 1 diabetes mellitus: a randomised controlled trial.” Diabetologia (2008). PMID: 18769906 ↗
L1RCTCited in: History and Evolution of Treatment - [209]
Jenni S, Oetliker C, Allemann S et al.. “Fuel metabolism during exercise in euglycaemia and hyperglycaemia in patients with type 1 diabetes mellitus--a prospective single-blinded randomised crossover trial.” Diabetologia (2008). PMID: 18512043 ↗
L1RCTCited in: History and Evolution of Treatment - [210]
Pedersen-Bjergaard U, Agerholm-Larsen B, Pramming S et al.. “Activity of angiotensin-converting enzyme and risk of severe hypoglycaemia in type 1 diabetes mellitus.” Lancet (London, England) (2001). PMID: 11418149 ↗
L2TRIAL_NONRANDOMCited in: History and Evolution of Treatment - [211]
Edwards K, Li X, Lingvay I. “Clinical and Safety Outcomes With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 1 Diabetes: A Real-World Study.” The Journal of clinical endocrinology and metabolism (2023). PMID: 36268825 ↗
L4OTHERCited in: History and Evolution of Treatment - [212]
Galassetti P, Tate D, Neill RA et al.. “Effect of gender on counterregulatory responses to euglycemic exercise in type 1 diabetes.” The Journal of clinical endocrinology and metabolism (2002). PMID: 12414885 ↗
L4OTHERCited in: History and Evolution of Treatment - [213]
Kudva YC, Reynolds C, O'Brien T et al.. “"Diabetic mastopathy," or sclerosing lymphocytic lobulitis, is strongly associated with type 1 diabetes.” Diabetes care (2002). PMID: 11772912 ↗
L3OTHERCited in: History and Evolution of Treatment - [214]
Lu CL, Shen HN, Hu SC et al.. “A Population-Based Study of All-Cause Mortality and Cardiovascular Disease in Association With Prior History of Hypoglycemia Among Patients With Type 1 Diabetes.” Diabetes care (2016). PMID: 27385329 ↗
L3OTHERCited in: History and Evolution of Treatment, Complications and Long-term Sequelae - [215]
Cabrera SM, Chen YG, Hagopian WA et al.. “Blood-based signatures in type 1 diabetes.” Diabetologia (2015). PMID: 26699650 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment, Prognosis, Natural History, Special Populations and Prevention - [216]
Zhang Q, Zhou H, Lin R et al.. “Risk factors for hypoglycaemia in adults with type 1 diabetes: a systematic review and meta-analysis.” BMC endocrine disorders (2025). PMID: 41449374 ↗
L1SR_OBSCited in: History and Evolution of Treatment - [217]
Garabedian C, Sénat MV, Sananès N et al.. “[Preexisting diabetes: Expert consensus from the College of French Gynecologists and Obstetricians and from the French Society of Diabetology].” Gynecologie, obstetrique, fertilite & senologie (2025). PMID: 41365423 ↗
L1GUIDELINECited in: History and Evolution of Treatment, Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [218]
Tang D, Gao X, Zhu M et al.. “Population Pharmacokinetic and Pharmacodynamic Modeling to Support Molar Dose Ratio Determination of Long-Acting Insulin Analogs.” Clinical pharmacokinetics (2026). PMID: 41489799 ↗
L4RCTCited in: History and Evolution of Treatment - [219]
Drai R, Galstyan G, Karonova T et al.. “Immunogenicity, efficacy and safety of a biosimilar insulin glulisine compared with originator in adults with type 1 diabetes mellitus: A phase III randomised clinical trial.” Diabetes, obesity & metabolism (2025). PMID: 41366610 ↗
L1RCTCited in: History and Evolution of Treatment - [220]
Almutairi MNASF. “Neurodevelopmental effects of severe hypoglycemia in children with type 1 diabetes: a systematic review.” Frontiers in pediatrics (2026). PMID: 41660395 ↗
L1SR_OBSCited in: History and Evolution of Treatment - [221]
Aoki TT, Benbarka MM, Okimura MC et al.. “Long-term intermittent intravenous insulin therapy and type 1 diabetes mellitus.” Lancet (London, England) (1993). PMID: 8102666 ↗
L4OTHERCited in: History and Evolution of Treatment - [222]
Kugathasan L, Katz A, Muskiet MHA et al.. “Novel Therapeutic Strategies for Patients With CKD and Diabetes Mellitus.” Kidney international reports (2026). PMID: 42205183 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [223]
Pham-Dobor G, Kaltenecker P, Temesfoi V et al.. “Systematic Analysis and Network Mapping of Disease Associations in Autoimmune Polyglandular Syndrome.” The Journal of clinical endocrinology and metabolism (2025). PMID: 39378147 ↗
L4OTHERCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [224]
Łebkowska A, Adamska A, Krentowska A et al.. “The Influence of Prepubertal Onset of Type 1 Diabetes and Age of Menarche on Polycystic Ovary Syndrome Diagnosis.” The Journal of clinical endocrinology and metabolism (2021). PMID: 33537700 ↗
L4OTHERCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [225]
van Dijk M, Donga E, van Dijk JG et al.. “Disturbed subjective sleep characteristics in adult patients with long-standing type 1 diabetes mellitus.” Diabetologia (2011). PMID: 21573904 ↗
L3OTHERCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [226]
Xiao YL, Jia YQ, Gu LQ et al.. “Prevalence of Celiac Disease in China Among High-Risk Populations: A Systematic Review and Meta-Analysis.” Journal of digestive diseases (2025). PMID: 41183986 ↗
L1SR_OBSCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [227]
Fagerholm E, Ahlqvist E, Forsblom C et al.. “SNP in the genome-wide association study hotspot on chromosome 9p21 confers susceptibility to diabetic nephropathy in type 1 diabetes.” Diabetologia (2012). PMID: 22643932 ↗
L3SR_OBSCited in: Complications and Long-term Sequelae - [228]
González-Clemente JM, Vilardell C, Broch M et al.. “Lower heart rate variability is associated with higher plasma concentrations of IL-6 in type 1 diabetes.” European journal of endocrinology (2007). PMID: 17609399 ↗
L4OTHERCited in: Complications and Long-term Sequelae - [229]
Głowińska-Olszewska B, Moniuszko M, Hryniewicz A et al.. “Relationship between circulating endothelial progenitor cells and endothelial dysfunction in children with type 1 diabetes: a novel paradigm of early atherosclerosis in high-risk young patients.” European journal of endocrinology (2013). PMID: 23111589 ↗
L3OTHERCited in: Complications and Long-term Sequelae - [230]
Nathan DM. “Realising the long-term promise of insulin therapy: the DCCT/EDIC study.” Diabetologia (2021). PMID: 33550441 ↗
L5REVIEW_NARRATIVECited in: Complications and Long-term Sequelae - [231]
Chimen M, Kennedy A, Nirantharakumar K et al.. “What are the health benefits of physical activity in type 1 diabetes mellitus? A literature review.” Diabetologia (2011). PMID: 22189486 ↗
L5REVIEW_NARRATIVECited in: Complications and Long-term Sequelae - [232]
Colombo M, McGurnaghan SJ, Bell S et al.. “Predicting renal disease progression in a large contemporary cohort with type 1 diabetes mellitus.” Diabetologia (2019). PMID: 31807796 ↗
L2OTHERCited in: Complications and Long-term Sequelae - [233]
Cakmak Demir S, Batman A, Yazici D et al.. “Association of High-Risk Obstructive Sleep Apnea with Microvascular Complications in Adults with Type 1 Diabetes Mellitus: A Case-Control Study.” Journal of clinical medicine (2026). PMID: 42074704 ↗
L3CASE_CONTROLCited in: Complications and Long-term Sequelae - [234]
Rodrigues F, White M, O'Connell MA. “Hyperlipidaemia in youth with type 1 diabetes: Are current guidelines clinically useful?” Diabetic medicine : a journal of the British Diabetic Association (2026). PMID: 42387672 ↗
L4OTHERCited in: Complications and Long-term Sequelae - [235]
Tentolouris A, Popovic DS, Liarakos AL et al.. “GLP-1-Based Therapies in Type 1 Diabetes: Emerging Evidence on Cardiovascular, Renal, and Safety Outcomes.” Diabetes, obesity & metabolism (2026). PMID: 42380553 ↗
L5REVIEW_NARRATIVECited in: Complications and Long-term Sequelae - [236]
García-Poblet M, Martínez-Sanz JM, Alberola-Chazarra MA et al.. “Phase angle and triglyceride-glucose index as biomarkers of glycemic control, body composition and cardiovascular risk in adolescents with type 1 diabetes: a cross-sectional study.” Journal of endocrinological investigation (2026). PMID: 42371339 ↗
L4OTHERCited in: Complications and Long-term Sequelae - [237]
Buschur EO, Polsky S. “Type 1 Diabetes: Management in Women From Preconception to Postpartum.” The Journal of clinical endocrinology and metabolism (2021). PMID: 33331893 ↗
L5SR_OBSCited in: Prognosis, Natural History, Special Populations and Prevention - [238]
Basu A, Alaupovic P, Wu M et al.. “Plasma lipoproteins and preeclampsia in women with type 1 diabetes: a prospective study.” The Journal of clinical endocrinology and metabolism (2012). PMID: 22438226 ↗
L2COHORTCited in: Prognosis, Natural History, Special Populations and Prevention - [239]
Kim KM, Kim KJ, Han K et al.. “Associations Between Physical Activity and the Risk of Hip Fracture Depending on Glycemic Status: A Nationwide Cohort Study.” The Journal of clinical endocrinology and metabolism (2024). PMID: 37850407 ↗
L2COHORTCited in: Prognosis, Natural History, Special Populations and Prevention - [240]
Castellaneta S, Piccinno E, Oliva M et al.. “High rate of spontaneous normalization of celiac serology in a cohort of 446 children with type 1 diabetes: a prospective study.” Diabetes care (2015). PMID: 25784659 ↗
L2COHORTCited in: Prognosis, Natural History, Special Populations and Prevention - [241]
Allen LA, Cannings-John RL, Evans A et al.. “Pregnancy in teenagers diagnosed with type 1 diabetes mellitus in childhood: a national population-based e-cohort study.” Diabetologia (2019). PMID: 31863141 ↗
L2COHORTCited in: Prognosis, Natural History, Special Populations and Prevention - [242]
Tosur M, Geyer SM, Rodriguez H et al.. “Ethnic differences in progression of islet autoimmunity and type 1 diabetes in relatives at risk.” Diabetologia (2018). PMID: 29931415 ↗
L2OTHERCited in: Prognosis, Natural History, Special Populations and Prevention - [243]
García-Patterson A, Gich I, Amini SB et al.. “Insulin requirements throughout pregnancy in women with type 1 diabetes mellitus: three changes of direction.” Diabetologia (2009). PMID: 20013109 ↗
L4OTHERCited in: Prognosis, Natural History, Special Populations and Prevention - [244]
Alshehri MS, Alsadoon A, Albazei A et al.. “Pars plana vitrectomy for tractional and combined tractional rhegmatogenous retinal detachment in type 1 diabetes mellitus: outcomes, prognostic factors, and a proposed staging system.” International journal of retina and vitreous (2026). PMID: 42087261 ↗
L2bCited in: Definition, Classification and Axis Nomenclature - [245]
Maciulewski R, Buczyńska-Backiel A, Zielińska-Maciulewska A et al.. “Baseline β-Cell Secretory Reserve and Its Association with Glycaemic Control and Long-Term Outcomes Across Diabetes Phenotypes.” International journal of molecular sciences (2026). PMID: 41752170 ↗
L2bCited in: Definition, Classification and Axis Nomenclature - [246]
İnözü M, Yaşartekin Y, Buluş AD et al.. “Serum uric acid level as a marker associated with microalbuminuria in pediatric patients with type 1 diabetes mellitus.” European journal of pediatrics (2025). PMID: 41329208 ↗
L3bCited in: Definition, Classification and Axis Nomenclature - [247]
Abdulla S, Alemadi B, Bin Shafar L et al.. “Prevalence of hypothyroidism among patients undergoing thyroid function tests in primary healthcare centres in Dubai, UAE.” BMC public health (2025). PMID: 40999380 ↗
L4Cited in: Definition, Classification and Axis Nomenclature - [248]
Tang N, Su N, Zhang Z et al.. “Retinal vessel metric analysis of type 1 diabetes mellitus in OCT angiography.” Frontiers in medicine (2025). PMID: 40584707 ↗
L4Cited in: Definition, Classification and Axis Nomenclature - [249]
Di Giacomo R, Gasparini V, Salvucci G et al.. “Autoimmune polyglandular syndrome and GAD65 related-temporal lobe epilepsy.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2025). PMID: 40571861 ↗
L4Cited in: Definition, Classification and Axis Nomenclature - [250]
Bampton TJ, Chen JW, Brown A et al.. “Epidemiology and burden of adult chronic pancreatitis in South Australia: a 20-year data linkage study.” BMJ open (2025). PMID: 40050052 ↗
L3bCited in: Definition, Classification and Axis Nomenclature - [251]
Xian J, Du R, Yuan H et al.. “The application of predictive value of diabetes autoantibody profile combined with clinical data and routine laboratory indexes in the classification of diabetes mellitus.” Frontiers in endocrinology (2024). PMID: 39247917 ↗
L3bCited in: Definition, Classification and Axis Nomenclature - [252]
Tas N, Mengen E, Alacakır N et al.. “Is there a relationship between hyperchloremia status and the risk of developing acute kidney injury in pediatric patients with diabetic ketoacidosis?” European journal of pediatrics (2024). PMID: 39080001 ↗
L3bCited in: Definition, Classification and Axis Nomenclature - [253]
Eken B, Rawshani A, Rawshani A et al.. “Effects of pre-existing type 1 diabetes mellitus on survival outcome following out-of-hospital cardiac arrest: a registry-based observational study in Sweden.” BMJ open (2024). PMID: 39009457 ↗
L3bCited in: Definition, Classification and Axis Nomenclature - [254]
Huang X, Ouyang D, Xie W et al.. “Development and validation of machine learning-based diagnostic models using blood transcriptomics for early childhood diabetes prediction.” Frontiers in medicine (2025). PMID: 40740938 ↗
L3bCited in: Definition, Classification and Axis Nomenclature - [255]
He X, Wang X, van Heck J et al.. “Blood immune cell profiling in adults with longstanding type 1 diabetes is associated with macrovascular complications.” Frontiers in immunology (2024). PMID: 39011037 ↗
L3bCited in: Definition, Classification and Axis Nomenclature - [256]
Casadei G, Baldari M, Brognara L et al.. “Plantar fascia thickness in type 1 diabetes mellitus patients: Clinical associations and metabolic correlates.” Journal of diabetes investigation (2026). PMID: 42046319 ↗
L3bCited in: Definition, Classification and Axis Nomenclature - [257]
Gómez-Coronado-Martín R, Salinero-Fort MÁ, López-de-Andrés A et al.. “Clinical Validation of Type 1 Diabetes Coding in Hospital Discharge Records Using ADA Criteria: Implications for Spanish and European Health Data Spaces.” Journal of clinical medicine (2026). PMID: 41899210 ↗
L3bCited in: Definition, Classification and Axis Nomenclature - [258]
Bayona Cebada A, Nattero-Chávez L, De la Calle De la Villa E et al.. “Androgen excess disorders remain undiagnosed in one of every four premenopausal women with Type 1 diabetes.” Human reproduction open (2025). PMID: 40747135 ↗
L3bCited in: Definition, Classification and Axis Nomenclature - [259]
Yang D, Yang L, Yang J et al.. “Beyond the known: prospective research directions for the gut-brain axis in obesity and type 1 diabetes mellitus.” Diabetology & metabolic syndrome (2026). PMID: 42050719 ↗
L2bCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [260]
Chen D, Zhang F, Ren T et al.. “Alterations of sphingosine-1-phosphate and its receptors in type 1 diabetes mellitus: an integrated clinical and single-cell transcriptomic study.” Frontiers in immunology (2026). PMID: 42338584 ↗
L3bCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [261]
Olson TE, Lloyd TS, Hamad CD et al.. “Spinal Implant-Associated Infection in Type 2 and Type 1 Diabetes: Phenotype-Specific Inflammatory Features and Therapeutic Response to Semaglutide.” JOR spine (2026). PMID: 42253285 ↗
L3bCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [262]
Min H, Li J, Wang J et al.. “Lipidomic signatures associated with cognitive impairment in type 1 diabetes mellitus: a pilot study integrating clinical serum and mouse hippocampus.” Journal of translational medicine (2026). PMID: 42157048 ↗
L4Cited in: Axis Physiology, Pathophysiology and Biochemical Signature - [263]
Gómez-Barba JM, Cañete-Massé C, Gallardo-Moreno GB et al.. “Machine learning and regional homogeneity reveal early and subtle brain changes in type 1 diabetes.” Journal of neuroradiology = Journal de neuroradiologie (2026). PMID: 42119663 ↗
L3bCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [264]
Golodnikov II, Podshivalova ES, Chechekhin VI et al.. “Single-cell immune transcriptomics reveals an inflammatory-inhibitory set-point spectrum in autoimmune diabetes.” JCI insight (2025). PMID: 41325163 ↗
L3bCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [265]
Mohamed Ali Elbashir R, Elbashir A, Urimuke Basake R et al.. “Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Obese Patients Without Diabetes: A Systematic Review and Meta-Analysis.” Cureus (2025). PMID: 41341350 ↗
L1aCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [266]
Marzban M, Ahmadi N, Sotoodehnejadnematalahi F et al.. “Design and application of a multi-epitope ACE2 antigen for detection of autoantibodies in post-COVID-19 diagnosed type 1 diabetes.” Immunology letters (2025). PMID: 41478466 ↗
L4Cited in: Axis Physiology, Pathophysiology and Biochemical Signature - [267]
Alaei-Shahmiri F, Ghafoury R, Rimaz S et al.. “Attitudes toward Mobile App Use in Individuals with Type 1 Diabetes Mellitus: A Quasi-Experimental Mixed-Methods Investigation of a Digital Support Tool for Diabetes Self-Management Behavior.” Medical journal of the Islamic Republic of Iran (2026). PMID: 42516649 ↗
L2bCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [268]
Fantasia KL, Lanzinger S, Rompicherla S et al.. “Missed opportunities for risk reduction: type 1 diabetes management in older adults in DPV and T1DX-QI registries.” Journal of the Endocrine Society (2026). PMID: 41728214 ↗
L3bCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [269]
Hu Z, Zhu M, Tang L et al.. “Population Pharmacokinetic/Pharmacodynamic Modeling of Volagidemab, a Glucagon Receptor Antagonist, in Healthy Chinese and US Subjects Following Single Subcutaneous Administration.” Pharmaceutical research (2026). PMID: 41714547 ↗
L4Cited in: Axis Physiology, Pathophysiology and Biochemical Signature - [270]
van Rhijn RI, van Trotsenburg ASP, Mentink R. “Autoantibody-Positive versus Autoantibody-Negative Type 1 Diabetes in Children: Clinical and Biochemical Characteristics.” Hormone research in paediatrics (2026). PMID: 41774599 ↗
L3bCited in: Clinical Presentation - [271]
Muzslay E, Herczeg V, Pusztai RI et al.. “Overweight worsens the metabolic presentation of type 1 diabetes mellitus in children.” Frontiers in endocrinology (2026). PMID: 41585812 ↗
L3bCited in: Clinical Presentation - [272]
Linck JA, Michels C, Schwanstecher A et al.. “Current Clinical Features of Diabetic Ketoacidosis in Adults: A German Multicenter Study 2022-2023.” Diabetes technology & therapeutics (2026). PMID: 41005769 ↗
L4Cited in: Clinical Presentation - [273]
Taneri PE, Bongaerts B, Shokraee K et al.. “Timing, frequency, and glycaemic target values for self-monitoring in adults with type 1 diabetes mellitus.” The Cochrane database of systematic reviews (2026). PMID: 42559751 ↗
L1aCited in: Clinical Presentation - [274]
Fu R, Yang M, Guo Y et al.. “Case Report: Case analysis of a juvenile type 1 diabetes mellitus patient with Mauriac syndrome.” Frontiers in endocrinology (2026). PMID: 42528668 ↗
L4Cited in: Clinical Presentation - [275]
Chung JS, Kim JS, Ju JK. “Surgical abdomen masked by metabolic crisis: fulminant ischemic colitis in severe diabetic ketoacidosis - a case report and literature review.” Frontiers in endocrinology (2026). PMID: 42516746 ↗
L5Cited in: Clinical Presentation - [276]
Jin F, Wu W, Yang X et al.. “Dendritic Cells as Immunometabolic Regulatory Nodes in Diabetes: Molecular Mechanisms and Therapeutic Reprogramming.” International journal of molecular sciences (2026). PMID: 42450322 ↗
L5Cited in: Clinical Presentation - [277]
Kouhanjani MF, Plautz A, Melzer N et al.. “Autoimmune encephalitis-associated epilepsy with glutamic acid decarboxylase autoantibodies and type 1 diabetes mellitus: A comprehensive systematic scoping review of a clinical syndrome.” Autoimmunity reviews (2026). PMID: 42173229 ↗
L5Cited in: Clinical Presentation - [278]
Ilmer S, Sohail R, Hyman S. “25-hydroxyvitamin D and the initial presentation of pediatric type 1 diabetes: associations with ketoacidosis severity and beta-cell function.” Frontiers in endocrinology (2026). PMID: 42169725 ↗
L5Cited in: Clinical Presentation - [279]
Shore B. “Editorial Commentary: Outcomes and Complication Risk in Type 1 Diabetic Patients Undergoing Hip Arthroscopy-Diabetes is NOT a Single Disease.” Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association (2026). PMID: 41995260 ↗
L5Cited in: Clinical Presentation - [280]
Almallouhi A, Sadek M, Absah I. “Clinical outcome of constipation as the presenting symptom in children with celiac disease.” Journal of pediatric gastroenterology and nutrition (2025). PMID: 41431920 ↗
L5Cited in: Clinical Presentation - [281]
Kahkoska AR, Neumiller JJ, Alexopoulos AS et al.. “Preparing to Meet the Needs of a Growing Older Adult Population with Type 1 Diabetes: A Narrative Review.” Journal of general internal medicine (2025). PMID: 41361045 ↗
L5Cited in: Clinical Presentation - [282]
Kwon S, Kim BS, Han K et al.. “Rate of Autoimmune Diseases in the 10 Years Preceding Myasthenia Gravis Diagnosis: A Nationwide Cohort Study in South Korea.” Neurology (2026). PMID: 42555884 ↗
L3bCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [283]
Okuma H, Tsutsumi T, Ichijo M et al.. “Serum-derived microribonucleic acids as potential novel biomarkers for slowly progressive type 1 diabetes mellitus.” Journal of diabetes investigation (2026). PMID: 42549632 ↗
L3bCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [284]
Yaman Ortakoylu M, Gonc EN, Ozon A et al.. “Frequency of autoimmune diseases in children and adolescents with type 1 diabetes mellitus.” Frontiers in endocrinology (2026). PMID: 42445886 ↗
L3bCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [285]
Astavans A, Baughman D, Mathioudakis N. “Long-Term Major Adverse Cardiovascular and Cerebrovascular Event Risk in Adult-Onset Type 1 Versus Type 2 Diabetes: A Propensity-Matched Cohort Study.” European journal of preventive cardiology (2026). PMID: 42429688 ↗
L4Cited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [286]
Altıntop SE, Barlas T, Kılıc ACK et al.. “Liver fibrosis risk: a silent threat in type 1 diabetes mellitus.” Journal of endocrinological investigation (2026). PMID: 42566182 ↗
L3bCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [287]
Fang H, Yin J, Tian S et al.. “Thalamic Nuclei Atrophy in Type 1 Diabetes Mellitus Across Disease Duration.” Journal of magnetic resonance imaging : JMRI (2026). PMID: 42312577 ↗
L4Cited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [288]
Aboelenin HM, ElTaher H, Elzehery R et al.. “Evaluation of FABP1 as a biomarker of diabetic kidney disease in children with type 1 diabetes.” European journal of pediatrics (2026). PMID: 42298045 ↗
L3bCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [289]
Styles SE, Haszard JJ, Oravcova-Wheeler Z et al.. “Preliminary Outcomes of a Brief Values-Guided Self-Management Intervention to Improve Glucose Levels Among Emerging Adults With Type 1 Diabetes and Above-Recommended HbA1c: A Pilot Study.” Endocrinology, diabetes & metabolism (2026). PMID: 42234497 ↗
L4Cited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [290]
Mesa Díaz ÁM, Rodríguez de Vera Gómez P, Ruiz Rodríguez M et al.. “Clinical and socioeconomic determinants of glycaemic control derived from continuous glucose monitoring in adults with type 1 diabetes.” Frontiers in endocrinology (2026). PMID: 42109724 ↗
L3bCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [291]
Zheng R, Zhang C, Sun X et al.. “Time in tight range and time in range in relation to diabetic retinopathy and OCTA-derived retinal microvascular parameters in hospitalized adults with type 1 diabetes.” Endocrine (2026). PMID: 42545593 ↗
L3bCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [292]
Boca LO, Ghiga G, Păduraru G et al.. “Pediatric celiac disease and coexisting immune-mediated conditions: a five-year single-center study from North-Eastern Romania.” Frontiers in pediatrics (2026). PMID: 42317660 ↗
L4Cited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [293]
Tang J, Hou Q, Ye J et al.. “Case Report: A diabetic ketoacidosis in adolescents complicated with rhino-orbital-cerebral mucormycosis.” Frontiers in medicine (2026). PMID: 42524461 ↗
L4Cited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [294]
Hsu JC, Lo FS, Jeng JS et al.. “Association of low-grade albuminuria and triple-line pattern as markers of early peripheral vascular remodeling in adolescents with type 1 diabetes.” Journal of diabetes investigation (2026). PMID: 41804023 ↗
L2bCited in: Severity, Staging and Risk Stratification - [295]
Croce L, Gatta E, Gallo M et al.. “Thyroid eye disease in the context of autoimmune polyglandular syndromes: comparative clinical insights from a retrospective study.” Frontiers in endocrinology (2026). PMID: 42568487 ↗
L4Cited in: Severity, Staging and Risk Stratification - [296]
Xiang J, Gao W, Yao Y et al.. “Association between triglyceride-glucose index and diabetic kidney disease in adults with type 1 diabetes.” BMC endocrine disorders (2026). PMID: 41965604 ↗
L3bCited in: Severity, Staging and Risk Stratification - [297]
Bogusz-Górna K, Polańska A, Dańczak-Pazdrowska A et al.. “Selected parameters of epidermal barrier in juveniles with type 1 diabetes correspond with the severity of diabetes - an observational study.” Frontiers in endocrinology (2025). PMID: 41377944 ↗
L3bCited in: Severity, Staging and Risk Stratification - [298]
Abdullah MY, Laaribi AB, Babay W et al.. “Cytokine profiles, genetic polymorphisms, and systemic inflammatory markers in type 1 diabetes patients with COVID-19: IL-18 a predictor of disease severity.” Frontiers in immunology (2026). PMID: 41846929 ↗
L3bCited in: Severity, Staging and Risk Stratification - [299]
Taskin Kursun S, Imre E, Gogas Yavuz D. “Advanced glycation end-products and sclerostin are elevated across diabetes phenotypes and associated with vertebral fractures in type 2 diabetes.” BMC endocrine disorders (2026). PMID: 41963900 ↗
L3bCited in: Severity, Staging and Risk Stratification - [300]
Chakraborty P, Basu M, Mukhopadhyay P et al.. “Study of oral microbiome by next generation sequencing in T1DM adolescents with periodontal disease.” Acta diabetologica (2026). PMID: 41661275 ↗
L3bCited in: Severity, Staging and Risk Stratification - [301]
Ma D, Xu W, Yang Y et al.. “Efficacy and Safety of Open-Source Hybrid Closed-Loop Automated Insulin Delivery in Perioperative Patients.” Biomedicines (2026). PMID: 42193423 ↗
L1bCited in: Acute Management and Endocrine Emergencies - [302]
Chen H, Lin Z, Liu Z et al.. “Effect of sodium-glucose cotransporter-2 inhibitors on fracture risk in patients with type 1 diabetes receiving insulin-based therapy: a meta-analysis.” PeerJ (2026). PMID: 42011364 ↗
L1aCited in: Acute Management and Endocrine Emergencies - [303]
Alharbi TH, Alzahrani HA, Alromaihi RA et al.. “Immune checkpoint inhibitor-induced type 1 diabetes mellitus: incidence, risk factors, and prognostic implications - a systematic review and meta-analysis.” Diabetes research and clinical practice (2026). PMID: 42456777 ↗
L2aCited in: Acute Management and Endocrine Emergencies - [304]
Ramos Cardona JC, Morecroft R, Martinez S et al.. “Glycemic variability associated with gamma secretase inhibitor therapy in a type 1 diabetic patient undergoing treatment for desmoid tumor: a case report.” Frontiers in endocrinology (2026). PMID: 42147100 ↗
L2bCited in: Acute Management and Endocrine Emergencies - [305]
Montes FR, Gutierrez-Navarro JD, Restrepo-Patiño N et al.. “Perioperative outcomes and phase-specific intraoperative glycemic management in simultaneous pancreas-kidney transplantation: A single-center case series.” World journal of transplantation (2026). PMID: 42281876 ↗
L4Cited in: Acute Management and Endocrine Emergencies - [306]
Vayser D, Wang P, Dafesh N et al.. “Outcomes of Diabetes Management with Continuous Glucose Monitoring Technology.” Archives of internal medicine research (2026). PMID: 42306173 ↗
L1bCited in: Acute Management and Endocrine Emergencies - [307]
Juhi A, Kumari R, Mondal H et al.. “Objective Sleep and Circadian Metrics in Adolescents With Type 1 Diabetes Mellitus: A Systematic Review.” Journal of diabetes science and technology (2026). PMID: 42449541 ↗
L1aCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [308]
Yadav J, Kumar J, Kumar R et al.. “Efficacy and safety of stem cell therapy in type 1 diabetes: A systematic review and meta-analysis of randomised controlled trials.” The Indian journal of medical research (2026). PMID: 42397823 ↗
L1aCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [309]
Reguram R, Shah R, Vora T et al.. “Insulin Pump Use and Hospital Outcomes in Adults With Type 1 Diabetes: A 2022 Nationwide Readmissions Database Analysis.” The Journal of clinical endocrinology and metabolism (2026). PMID: 42530032 ↗
L3bCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [310]
Cyranka K, Klupa T, Matejko B et al.. “Exploring key targets for psychodiabetological interventions in adults with type 1 diabetes mellitus: an exploratory network and intervention modeling study using Polish MyDiaMate data.” Diabetes research and clinical practice (2026). PMID: 42480716 ↗
L3bCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [311]
de Lope Quiñones S, Luque-Ramírez M, Quintero Tobar A et al.. “Metabolomic signatures of glycemic control in type 1 diabetes: insights from continuous glucose monitoring.” Journal of endocrinological investigation (2026). PMID: 42474688 ↗
L3bCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [312]
Shamsnia HS, Peyrovinasab A, Niknejad A et al.. “BCG vaccination as an adjunctive strategy in type 1 diabetes: A systematic review of immunometabolic effects and clinical evidence.” Pathology, research and practice (2026). PMID: 42361719 ↗
L1aCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [313]
Lü Y, Li Z, Yang Y et al.. “Insulin pump therapy for T1D: a real-world analysis of a novel two-in-one insulin pump in Chinese adults with type 1 diabetes.” Diabetology & metabolic syndrome (2026). PMID: 42332795 ↗
L4Cited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [314]
Gómez AM, Henao-Carrillo D, Muñoz-Velandia O et al.. “Virtual vs. In-Person Training for MinMed™ 780G Initiation: Comparable Effectiveness and Safety in Adults with Type 1 Diabetes.” Clinical medicine insights. Endocrinology and diabetes (2026). PMID: 42482835 ↗
L3bCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [315]
Cheng Y, Gaborcik JW, Smith RM et al.. “Insulin Glargine Use in Dexamethasone-Induced Hyperglycemia: A Retrospective Cohort Analysis.” The Annals of pharmacotherapy (2026). PMID: 42421396 ↗
L4Cited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [316]
Emilia KK, Magdalena D, Lidia G et al.. “Does faster aspart improve time in range in children with type 1 diabetes with glycaemia close to target on insulin pump therapy?” Diabetic medicine : a journal of the British Diabetic Association (2026). PMID: 41968383 ↗
L1bCited in: History and Evolution of Treatment - [317]
Lee HS, Kim HY, Yang M et al.. “Familial Occurrence of Type 1 Diabetes Mellitus in Korean Children and Adolescents: A Multicenter Study.” Diabetes & metabolism journal (2026). PMID: 41782396 ↗
L3bCited in: History and Evolution of Treatment - [318]
Chen L, Yan C, Huang C et al.. “Upregulation of ADAM19 in dendritic cells is associated with immune features and lower C-peptide levels in type 1 diabetes mellitus.” Diabetology & metabolic syndrome (2026). PMID: 42249412 ↗
L3bCited in: History and Evolution of Treatment - [319]
González-Garrido AA, Gallardo-Moreno GB, Gómez-Barba JM et al.. “Changes in Brain Volumetric Measures Associated With Type 1 Diabetes Depict an Evolutionary Adaptation Process to Developmental Cognitive Demands.” Diabetes/metabolism research and reviews (2026). PMID: 41994900 ↗
L3bCited in: History and Evolution of Treatment - [320]
Rodríguez de Vera Gómez P, Bellido V, Damas Fuentes M et al.. “Development and Validation of Nomogram-Based Predictive Models for Severe Hypoglycemia in Adults With Type 1 Diabetes Treated With Multiple Daily Injections: The SEHYPAN Study.” Diabetes/metabolism research and reviews (2026). PMID: 41791767 ↗
L3bCited in: History and Evolution of Treatment - [321]
Zhu Y, Yang H, Hu C et al.. “Thyroid autoimmunity in relation to islet autoantibodies in newly diagnosed type 1 diabetes mellitus in children and adolescents.” Frontiers in endocrinology (2026). PMID: 42181188 ↗
L3bCited in: History and Evolution of Treatment - [322]
Lipták L, Lipták K, Kempler P et al.. “Early hyperaesthesia and late hypoaesthesia as manifestations of sensory neuropathy in dentistry - two case reports.” Frontiers in endocrinology (2026). PMID: 41685245 ↗
L4Cited in: History and Evolution of Treatment - [323]
Avçin E, Açıkgöz A. “The effect of tele-nursing application on metabolic control, self-efficacy, quality of life and anxiety level in adolescents with Type 1 diabetes: A randomized controlled trial.” Journal of pediatric nursing (2026). PMID: 41653762 ↗
L1bCited in: History and Evolution of Treatment - [324]
Shahim E, Bahrololoom R, Ataollahi M et al.. “Diminished Hepatitis B Antibody Response in Pediatrics With Type 1 Diabetes; the Need for Revaccination Protocol: A Case-Control Study.” Health science reports (2026). PMID: 42528937 ↗
L3bCited in: History and Evolution of Treatment - [325]
Nourbakhsh M, Rouhani F, Razzaghy-Azar M et al.. “Interleukin-6 and Oncostatin M Levels in Patients With Type 1 Diabetes and Its Relationship With Glycemic Indices.” Endocrinology, diabetes & metabolism (2026). PMID: 41917697 ↗
L3bCited in: History and Evolution of Treatment - [326]
Robeva R, Kirilov G, Kalinov K et al.. “Autoimmune diseases in patients with different PCOS phenotypes.” Frontiers in reproductive health (2026). PMID: 42099450 ↗
L3bCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [327]
Girardi KG, Surucu S, Jonnalagadda A et al.. “Type 1 Diabetes Mellitus Correlates With Increased Postoperative Complications and Rates of Conversion to Total Hip Arthroplasty Following Hip Arthroscopy for Femoroacetabular Impingement Syndrome.” Arthroscopy : the journal of arthroscopic & related surgery : official publication of the Arthroscopy Association of North America and the International Arthroscopy Association (2026). PMID: 41995211 ↗
L3bCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [328]
Pellikka I, Ventelä J, Auvinen A et al.. “Association of Childhood Acute Leukemia With Autoimmune Diseases.” International journal of cancer (2026). PMID: 41981796 ↗
L3bCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [329]
Schmolly K, Rudrapatna V, Beaven S. “Recommendations for recognizing and diagnosing Acute Hepatic Porphyria in atypical patient populations.” Orphanet journal of rare diseases (2025). PMID: 41345676 ↗
L4Cited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [330]
Haqi Ismael A, Hameed EK. “Insulin resistance in type 1 diabetes: the silent burden unmasked by eGDR.” Acta diabetologica (2026). PMID: 41619053 ↗
L3bCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [331]
Attia N, Al Noaim K, Mustafa M et al.. “The Use of Dapagliflozin in the Treatment of Children With Severe Insulin Resistance.” Pediatric diabetes (2025). PMID: 41424588 ↗
L4Cited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [332]
Velardi V, Sanson L, Toffoli B et al.. “Under-recognition of autoimmune polyendocrine syndromes in T1DM: results from an extended screening workup.” Endocrine (2026). PMID: 42541639 ↗
L3bCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [333]
Pascual-Morena C, Garrido-Miguel M, Martínez-García I et al.. “Efficacy of Omega-3 Polyunsaturated Fatty Acid Supplementation on the Lipid and Glycemic Profile in Type 1 Diabetes: A Systematic Review and Meta-Analysis.” Nutrition reviews (2026). PMID: 42497400 ↗
L1aCited in: Complications and Long-term Sequelae - [334]
Wang Y, Liu J, Cao F et al.. “Association of healthy lifestyle with incident cardiovascular diseases in individuals with type 1 diabetes mellitus: a prospective cohort study.” Diabetology & metabolic syndrome (2026). PMID: 42443959 ↗
L2bCited in: Complications and Long-term Sequelae - [335]
Chu Y, Zhu J, Liu Z et al.. “Metabolic mediators linking type 1 diabetes mellitus to osteoporosis.” Archives of medical science : AMS (2025). PMID: 42110599 ↗
L2bCited in: Complications and Long-term Sequelae - [336]
Bonhoure A, Yardley JE, Boudreau V et al.. “Physical and psychosocial complications faced by postmenopausal women with type 1 diabetes: a cross-sectional BETTER analysis.” Diabetes research and clinical practice (2026). PMID: 42551704 ↗
L3bCited in: Complications and Long-term Sequelae - [337]
Chausheva G, Shefket S, Bocheva Y et al.. “Platelet Indices and Adipokines in Adults with Long-Standing Type 1 Diabetes.” Journal of clinical medicine (2026). PMID: 42355786 ↗
L3bCited in: Complications and Long-term Sequelae - [338]
Kietaibl AT, Säemann M, Scherr S et al.. “Automated insulin delivery use in a woman living with type 1 diabetes on peritoneal dialysis: a case report.” Therapeutic advances in endocrinology and metabolism (2026). PMID: 42491266 ↗
L4Cited in: Complications and Long-term Sequelae - [339]
Botella-Juan L, Aguilera-Buenosvinos I, Antequera-González M et al.. “Disordered Eating Behaviours and Associated Factors Among People With Type 1 Diabetes: A Cross-Sectional Study in Spain-D1ANAS Project.” Diabetes/metabolism research and reviews (2026). PMID: 42455961 ↗
L3bCited in: Prognosis, Natural History, Special Populations and Prevention - [340]
Zhou X, Yang M, Xue M et al.. “Trends in Diabetes Mellitus Burden and Changes in Attributable Risk Factors in Asia from 1990 to 2021: Results from the Global Burden of Disease Study 2021.” Endocrinology and metabolism (Seoul, Korea) (2026). PMID: 42438067 ↗
L3bCited in: Prognosis, Natural History, Special Populations and Prevention - [341]
Ozen G, Zanfardino A, Ozen Acan G et al.. “Attenuated Seasonality of Childhood Type 1 Diabetes with Increasing Autoimmune Comorbidities: A 40-year Cohort Study.” Irish journal of medical science (2026). PMID: 42484831 ↗
L3bCited in: Prognosis, Natural History, Special Populations and Prevention - [342]
Rao S, Li T, Yan Z et al.. “Association between vitamin A and D levels and the risk of type 1 diabetes mellitus in children.” Frontiers in nutrition (2026). PMID: 42358308 ↗
L3bCited in: Prognosis, Natural History, Special Populations and Prevention - [343]
Li W, Qin L, Gaohui Z et al.. “Incidence and factors associated with hypoglycemia in newly diagnosed hospitalized children and adolescents with type 1 diabetes mellitus in China.” Frontiers in clinical diabetes and healthcare (2026). PMID: 42273407 ↗
L3bCited in: Prognosis, Natural History, Special Populations and Prevention - [344]
Ramani PK, Haynie CM, Beemarajan E et al.. “GAD65 Antibody-Associated Epilepsy and Autoimmune Encephalitis in Children and Young Adults: A Single-Center Case Series and Review of Literature.” Journal of child neurology (2026). PMID: 42227208 ↗
L3bCited in: Prognosis, Natural History, Special Populations and Prevention - [345]
Chellali DA, Benakriche BM, Belbouab R et al.. “Impact of age at diagnosis of type 1 diabetes on the occurrence of celiac disease in children.” Qatar medical journal (2026). PMID: 42534737 ↗
L4Cited in: Prognosis, Natural History, Special Populations and Prevention - [346]
Zhan J, Yang J, Li H et al.. “The Role of Baseline Traction and Diabetes Type in Predicting Recurrence After Vitrectomy for Proliferative Diabetic Retinopathy.” Clinical ophthalmology (Auckland, N.Z.) (2026). PMID: 42577740 ↗
L3bCited in: Definition, Classification and Axis Nomenclature - [347]
Yang X, Zhao L, He Y et al.. “Spatial correspondence between altered brain function and normative neurotransmitter density maps in Type 1 diabetes mellitus.” Journal of endocrinological investigation (2026). PMID: 42667349 ↗
L3bCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [348]
Wu B, He H, Zeng J et al.. “Adipokine patterns in type 1 and type 2 diabetes mellitus: comparative analysis of adiponectin-leptin ratio, visfatin, and TNF-α.” Frontiers in endocrinology (2026). PMID: 42558354 ↗
L3bCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [349]
Khandagale S, Bhor S, Oza C et al.. “Peripheral blood cell counts as correlates of insulin sensitivity in children and youth with type 1 diabetes: A retrospective study from western India.” Endocrine (2026). PMID: 42573870 ↗
L3bCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [350]
Xiao W, Zheng D, Guo Q et al.. “Efficacy of Nurse-Led WIKAP Intervention on Hypoglycemia Coping Confidence and Outcomes in Adolescents with Type 1 Diabetes Mellitus: A Quasi-Experimental Study in Zhijiang, China.” Patient preference and adherence (2026). PMID: 42266228 ↗
L1bCited in: Epidemiology, Etiology and Risk Factors - [351]
Banerjee M, Maisnam I, Mukhopadhyay P et al.. “Female sexual dysfunction in type 1 diabetes: a systematic review and meta-analysis.” Endocrine (2026). PMID: 42209931 ↗
L4Cited in: Epidemiology, Etiology and Risk Factors - [352]
Kasem Ali Sliman R, Shalaby N, Cohen H et al.. “Autoimmune and lymphoproliferative outcomes after Kawasaki disease: a 20-year population-based cohort study.” European journal of pediatrics (2026). PMID: 42690474 ↗
L4Cited in: Epidemiology, Etiology and Risk Factors - [353]
Horsdal HT, Heitmann B, Boelt SG et al.. “Neonatal vitamin D levels and autoimmune disorders: a Danish population-based cohort study.” European journal of epidemiology (2026). PMID: 42418142 ↗
L4Cited in: Epidemiology, Etiology and Risk Factors - [354]
Stalheim AM, Nilsen RM, Vangen S et al.. “Adverse pregnancy outcomes in women with type 1 diabetes: A nationwide, population-based study, 1999-2021.” Acta obstetricia et gynecologica Scandinavica (2026). PMID: 42169457 ↗
L3bCited in: Epidemiology, Etiology and Risk Factors - [355]
Ciccia E, Zhang B, Costacou T et al.. “A Pilot Study of Urinary Cubilin Shedding in Type 1 Diabetes Mellitus: A Potential Biomarker to Predict Nephropathy.” Journal of diabetes research (2026). PMID: 42630017 ↗
L4Cited in: Epidemiology, Etiology and Risk Factors - [356]
Yu MH, Hong N, Jeong SH. “Type 1 diabetes and risk of Parkinson's disease: A nationwide nested case-control study.” Parkinsonism & related disorders (2026). PMID: 42214114 ↗
L3bCited in: Epidemiology, Etiology and Risk Factors - [357]
Varghese SM, Chandy AM, Beegum M B et al.. “Growth failure in 600 children living with type 1 diabetes: evidence from a cross-sectional study in Kerala, India.” BMJ paediatrics open (2026). PMID: 42665331 ↗
L3bCited in: Epidemiology, Etiology and Risk Factors - [358]
Ha DJ, Kim HY, Kim J. “Timing of continuous glucose monitoring initiation and long-term glycemic trajectories in pediatric type 1 diabetes.” Annals of pediatric endocrinology & metabolism (2026). PMID: 42692441 ↗
L3bCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [359]
Hammudıoglu ZE, Kucuk Kurtgoz M, Erol EÇ et al.. “Evaluation of Differential Diagnosis of Odontogenic Lesions in Cone Beam Computed Tomography Images Using Radiomics-Based Machine Learning.” Dento maxillo facial radiology (2026). PMID: 42627344 ↗
L3bCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [360]
Kang J, Huang Q, Jiang Y et al.. “Residual β-cell function is associated with continuous glucose monitoring metrics in patients with type 1 diabetes mellitus.” Frontiers in endocrinology (2026). PMID: 42625605 ↗
L3bCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [361]
Gutiérrez-Pastor A, Pomares-Gómez FJ, Quesada JA. “Long-term glycemic outcomes at 24 months after switching from FreeStyle Libre to FreeStyle Libre 2: A real-world study.” Primary care diabetes (2026). PMID: 42567743 ↗
L3bCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [362]
Baltu D, Çetin YK. “Ambulatory blood pressure abnormalities and arterial stiffness in children with type 1 diabetes: the role of pulse wave velocity.” Pediatric nephrology (Berlin, Germany) (2026). PMID: 42616125 ↗
L3bCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [363]
Arık SD, Çetinkaya SÇ. “Sociodemographic predictors of follow-up adherence and metabolic control in children with type 1 diabetes: a 2-year retrospective cohort study.” Journal of pediatric endocrinology & metabolism : JPEM (2026). PMID: 42730771 ↗
L3bCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [364]
Rodzoń-Norwicz M, Gargasz K, Dąbrowski M et al.. “Mislabeling No More: What Kidney Biopsies Reveal in Diabetes.” Journal of nephrology (2026). PMID: 42634195 ↗
L4Cited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [365]
Mwalungali G, Kaimbo B, Kampamba M et al.. “Clinical Predictors of Time to Hospital Discharge in Children With New-Onset Diabetic Ketoacidosis in Zambia: A Retrospective Cohort Study.” Endocrinology, diabetes & metabolism (2026). PMID: 42584038 ↗
L3bCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [366]
Hasan RA, Agus MS. “Serum Chloride Trajectories and Acute Kidney Injury in Children With Diabetic Ketoacidosis.” Hospital pediatrics (2026). PMID: 42732891 ↗
L2bCited in: Clinical Presentation - [367]
Ma Y, Jiang WN, Zhou T et al.. “Extracellular vesicles at the immune-metabolic crossroads of Hashimoto's thyroiditis and diabetes mellitus.” Frontiers in immunology (2026). PMID: 42688475 ↗
L5Cited in: Clinical Presentation - [368]
Stamati A, Sotiriou G, Emmanoulidou-Fotoulaki E et al.. “Left Ventricular Global Longitudinal Strain as a Marker of Subclinical Myocardial Dysfunction in Youths With Type 1 Diabetes Mellitus: An Updated Systematic Review and Meta-Analysis.” Diabetes/metabolism research and reviews (2026). PMID: 42640083 ↗
L2aCited in: Severity, Staging and Risk Stratification - [369]
Lee O, Son Y, López-Gil JF et al.. “Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists as Adjuncts to Insulin Therapy in Type 1 Diabetes Mellitus: An Overlap-Informed Umbrella Review.” Diabetes, obesity & metabolism (2026). PMID: 42723273 ↗
L1bCited in: Acute Management and Endocrine Emergencies - [370]
Fardan ZH, Mustafa AEM, Ali NMT et al.. “Comparative Effectiveness of Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injections on Glycemic Control in Pediatric Type 1 Diabetes: A Systematic Review, Meta-Analysis, and Trial Sequential Analysis.” Journal of clinical medicine research (2026). PMID: 42730441 ↗
L1aCited in: Acute Management and Endocrine Emergencies - [371]
Villanueva G, Cogo E, Buckley B et al.. “Optimizing diabetes care in pregnancy: A systematic review of glycemic targets, treatment initiation, and glucose-lowering pharmacological management for T1DM, T2DM, and GDM.” Pregnancy (Hoboken, N.J.) (2026). PMID: 42597015 ↗
L1aCited in: Acute Management and Endocrine Emergencies - [372]
Liu M, Wu D, Su C. “Insulin is central, plasmapheresis is salvage: clinical spectrum and management of severe hypertriglyceridemia in 21 children with diabetic ketoacidosis.” Frontiers in endocrinology (2026). PMID: 42718762 ↗
L4Cited in: Acute Management and Endocrine Emergencies - [373]
Huang KE, Zhou QY, Wang L et al.. “Severe celiac trunk stenosis following blunt trauma in a patient with diabetic ketoacidosis: a diagnostic dilemma of traumatic injury versus median arcuate ligament syndrome.” Frontiers in medicine (2026). PMID: 42661822 ↗
L4Cited in: Acute Management and Endocrine Emergencies - [374]
Alqaisi RS, Al-Qerem W, Al Tah BH et al.. “Knowledge, Attitudes, and Practices Regarding Diabetes Mellitus Among Schoolteachers in Jordan: A Cross-Sectional Study.” Healthcare (Basel, Switzerland) (2026). PMID: 42278736 ↗
L3bCited in: Acute Management and Endocrine Emergencies - [375]
Perry F, Leon SJ, Polecina K et al.. “Effects of Renin-Angiotensin Inhibitors, Sodium-Glucose Cotransporter 2 Inhibitors, Mineralocorticoid Receptor Antagonists and Glucagon-Like Peptide 1 Receptor Agonists on Kidney Outcomes in Patients With Type 1 Diabetes: A Systematic Review and Meta-Analysis.” Diabetes, obesity & metabolism (2026). PMID: 42733137 ↗
L1aCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [376]
Choksi H, Klein Nulend R, Cooper T et al.. “Metabolic and macrovascular outcomes following simultaneous pancreas-kidney transplantation and kidney transplantation alone in recipients with type 1 diabetes mellitus: a systematic review and meta-analysis.” Diabetologia (2026). PMID: 42667390 ↗
L1aCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [377]
Muthulingam JA, Lyng AB, Hostrup SN et al.. “Home-Based Transcranial Direct Current Stimulation in Painful Diabetic Peripheral Neuropathy: A Double Blinded, Randomized, Low-Intensity Sham-Controlled Crossover Trial.” Neuromodulation : journal of the International Neuromodulation Society (2026). PMID: 42606402 ↗
L1bCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [378]
Miettinen M, Sirola T, Lähdeoja T et al.. “Surgery Versus Watchful Waiting for First Metatarsophalangeal Joint Osteoarthritis : A Randomized Controlled Trial.” Annals of internal medicine (2026). PMID: 42574728 ↗
L1bCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [379]
Fu J, Wu J, Hui Y et al.. “Efficacy and Safety of an Insulin Patch Pump Compared to Multiple Daily Injections in Pediatric Patients With Diabetes: A Randomized, Open-Label, Crossover, Non-Inferiority Clinical Trial.” Clinical medicine insights. Endocrinology and diabetes (2026). PMID: 42719483 ↗
L1bCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [380]
Bellini MI, De Intinis C, D'Andrea G et al.. “Simultaneous Pancreas-Kidney Transplantation Versus Kidney Transplantation Alone in Type 1 Diabetes: Does Pancreas Transplantation Improve Clinical Outcomes? A Systematic Review and Exploratory Meta-Analysis.” Medical sciences (Basel, Switzerland) (2026). PMID: 42646588 ↗
L2aCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [381]
Rogers NM, Hu M, Jimenez-Vera E et al.. “A multi-centre study of belatacept and sirolimus for islet transplantation.” Diabetologia (2026). PMID: 42608595 ↗
L2bCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [382]
Alshanti M, MacDougall MS, Gokbak MN et al.. “Case Report: Effective IL-4/IL-13 axis suppression and resolution of severe atopic dermatitis by dupilumab monotherapy in a patient with IPEX syndrome.” Frontiers in immunology (2026). PMID: 42676327 ↗
L4Cited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [383]
Tricò D, Jiang L, Spicer D et al.. “Ketone Bodies Derived From Medium-Chain Triglycerides Support Brain Metabolism and Function Under Hypoglycemia in Type 1 Diabetes Mellitus.” Diabetes (2026). PMID: 42384016 ↗
L1bCited in: History and Evolution of Treatment - [384]
Zhou J, Cui Y, Cai X et al.. “Systematic review of behavior-related self-management assessment instruments for patients with diabetes.” Frontiers in public health (2026). PMID: 42729541 ↗
L2aCited in: Prognosis, Natural History, Special Populations and Prevention - [385]
Huml M, Kotková A, Fremuthová T et al.. “Continual cuffless blood pressure monitoring in children: agreement and feasibility compared with ambulatory blood pressure monitoring.” Journal of hypertension (2026). PMID: 42725447 ↗
L4Cited in: Prognosis, Natural History, Special Populations and Prevention - [386]
Mantovani A, Milani I, Morandin R et al.. “Association between visceral adiposity index and metabolic dysfunction-associated steatotic liver disease in adults with type 1 diabetes mellitus: an exploratory cross-sectional study.” Journal of endocrinological investigation (2026). PMID: 42658457 ↗
L3bCited in: Prognosis, Natural History, Special Populations and Prevention - [387]
Fatima F, Ahmed SM. “Prevalence of celiac disease in type 1 diabetes mellitus children in the Eastern Mediterranean Region: A systematic review and meta-analysis.” Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology (2026). PMID: 42669575 ↗
L2aCited in: Prognosis, Natural History, Special Populations and Prevention - [388]
Bao D, Li Y, Mu C et al.. “Construction of a dynamic prediction model for diabetic retinopathy risk in adults with adult-onset type 1 diabetes: a real-world longitudinal cohort study.” Frontiers in clinical diabetes and healthcare (2026). PMID: 42582161 ↗
L3bCited in: Prognosis, Natural History, Special Populations and Prevention - [389]
Patwa N, Bennett A, Shaver N et al.. “Diagnosis and Management of Adult Type 1 Diabetes Mellitus: Systematic Reviews of Biomarkers, Insulin Regimens and Insulin Delivery Devices Highlighting Evidence Gaps in Emergency and Humanitarian Settings.” Diabetes, obesity & metabolism (2026). PMID: 42834837 ↗
L4Cited in: Definition, Classification and Axis Nomenclature - [390]
Lin YK, Ye W, Hepworth E et al.. “Evaluating the impact of severe hypoglycaemia definition wording on severe hypoglycaemia history assessment.” Diabetic medicine : a journal of the British Diabetic Association (2025). PMID: 39797557 ↗
L3bCited in: Definition, Classification and Axis Nomenclature - [391]
Zeng H, Long D, Geng Y et al.. “The association between maternal diabetes and the risk of epilepsy in offspring: a systematic review and meta-analysis.” Frontiers in endocrinology (2026). PMID: 42798566 ↗
L2aCited in: Epidemiology, Etiology and Risk Factors - [392]
Gaweł WS, Fercho JM, Kałużna O et al.. “Progressive Spastic Paraparesis Caused by Thoracic Spinal Epidural Lipomatosis: A Case Report and Systematic Review.” Medical sciences (Basel, Switzerland) (2026). PMID: 42783433 ↗
L4Cited in: Epidemiology, Etiology and Risk Factors - [393]
Zhu K, Gao F, Yue J et al.. “Association between type 1 diabetes mellitus and dental caries in children and adolescents: a meta-analysis and Mendelian randomization study.” Frontiers in endocrinology (2026). PMID: 42769090 ↗
L2aCited in: Epidemiology, Etiology and Risk Factors - [394]
Song US, Lee YJ, Shin CH et al.. “Clinical Characteristics and Temporal Trends of Pediatric Diabetes Subtypes Over 20 Years in a Tertiary Center in Korea.” Annals of pediatric endocrinology & metabolism (2026). PMID: 42834491 ↗
L4Cited in: Epidemiology, Etiology and Risk Factors - [395]
Schnapper M, Guz-Mark A, Matar M et al.. “Celiac disease and celiac serology in children with Type 1 Diabetes: diagnostic timing, serologic patterns, and implications for long-term management.” Pediatric diabetes (2026). PMID: 42812136 ↗
L3bCited in: Epidemiology, Etiology and Risk Factors - [396]
Shegene B, Birhanu A, Tesfaye A et al.. “Incidence and risk factors of hyperglycemic emergencies in adults with diabetes in the public hospitals in Harari region, Eastern Ethiopia.” PLOS global public health (2026). PMID: 42789503 ↗
L3bCited in: Epidemiology, Etiology and Risk Factors - [397]
Şahin MF, Kiyici S, Sigirli D et al.. “Prevalence of food addiction and its association with ghrelin and metabolic parameters in patients with type 1 diabetes mellitus: a cross-sectional study.” BMC endocrine disorders (2026). PMID: 42399864 ↗
L3bCited in: Epidemiology, Etiology and Risk Factors - [398]
Noorwali N, Staltner R, Fedulovs A et al.. “Elevated Markers of Intestinal Barrier Dysfunction and TLR2 Ligands in Individuals with Type 1 Diabetes.” Diabetes, metabolic syndrome and obesity : targets and therapy (2026). PMID: 42708037 ↗
L4Cited in: Axis Physiology, Pathophysiology and Biochemical Signature